TherapeuticsMD (TXMD) POS AM 9 Oct 13 Prospectus update (post-effective amendment) Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2013
Document And Entity Information
Entity Registrant Name	TherapeuticsMD, Inc.
Entity Central Index Key	25743
Document Type	S-1
Document Period End Date	30-Jun-13
Amendment Flag	TRUE
Amendment Description	This Post-Effective Amendment No. 1 to Form S-1 is being filed to update the registration statement on Form S-1 (Registration No. 333-185156), or the Registration Statement, of TherapeuticsMD, Inc., or the Company or Therapeutics, which was initially declared effective by the Securities and Exchange Commission on December 12, 2012, to make certain updating revisions to the information contained herein so that such information is current as of the date of filing. No additional securities are being registered under this Post-Effective Amendment No. 1.
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Current Assets:
Cash	$34,435,468	$1,553,474	$126,421	$422,939
Accounts receivable, net of allowance for doubtful accounts	957,779	606,641	26,720	11,812
Inventory	1,506,059	1,615,210	588,073	618,069
Other current assets	3,607,283	751,938	496,060	6,292
Total current assets	40,506,589	4,527,263	1,237,274	1,059,112
Property and equipment, net	76,494	65,673	26,752	96,192
Other Assets:
Prepaid consulting	1,980,519	953,655	80,515	31,949
Intangible assets	345,238	239,555	62,231	10,000
Security deposit	156,949	31,949	31,949
Total other assets	2,482,706	1,225,159	174,695	41,949
Total assets	43,065,789	5,818,095	1,438,721	1,197,253
Current Liabilities:
Accounts payable	2,045,116	1,641,366	306,511	117,636
Deferred revenue	1,219,072	1,144,752
Other current liabilities	1,334,730	725,870	465,747	115,206
Notes payable			2,150,000
Notes payable, related parties			200,000
Accrued interest			28,321
Total current liabilities	4,598,918	3,511,988	3,150,579	232,842
Long-Term Liabilities:
Notes payable, net of debt discount		3,589,167
Accrued Interest		150,068
Total Long-term liabilities		3,739,235
Total liabilities	4,598,918	7,251,223	3,150,579	232,842
Commitments and Contingencies
Stockholders' Deficit:
Preferred stock
Common stock	131,213	99,785	82,979	55,487
Additional paid in capital	102,834,270	50,580,400	15,198,241	4,988,637
Accumulated deficit	-64,498,612	-52,113,313	-16,993,078	-4,079,713
Total stockholder' deficit	38,466,871	-1,433,128	-1,711,858	964,411
Total liabilities and stockholders' deficit	$43,065,789	$5,818,095	$1,438,721	$1,197,253

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Consolidated Balance Sheets Parenthetical
Allowance for doubtful accounts	$100,385	$42,408	$1,500	$0
Accumulated depreciation of property and equipment	72,684	60,600	33,116	26,655
Debt discount on notes payable		$1,102,680	$0
Preferred stock, par value	$0.00	$0.00	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred stock, shares issued	0	0	0	0
Preferred stock, shares outstanding	0	0	0	0
Common stock, par value	$0.00	$0.00	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000	250,000,000	250,000,000
Common stock, shares issued	131,212,706	99,784,982	82,978,804	55,487,321
Common stock, shares outstanding	131,212,706	99,784,982	82,978,804	55,487,321

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Consolidated Statements Of Operations
Revenues, net	$2,080,885	$819,150	$3,618,080	$1,540,842	$3,818,013	$2,088,177	$1,241,921
Cost of goods sold	463,606	372,370	843,952	708,494	1,348,113	947,112	556,390
Gross profit	1,617,279	446,780	2,774,128	832,348	2,469,900	1,141,065	685,531
Operating expenses:
Sales, general, and administration	5,476,553	3,573,485	10,003,135	6,400,535	14,069,701	6,406,197	3,464,810
Research and development	1,747,084	833,342	3,312,285	1,245,303	4,492,362	107,241	65,402
Depreciation and amortization	10,636	14,535	18,593	29,113	56,260	54,845	22,783
Total operating expense	7,234,273	4,421,362	13,334,013	7,674,951	18,618,323	6,568,283	3,552,995
Operating loss	-5,616,994	-3,974,582	-10,559,885	-6,842,603	-16,148,423	-5,427,218	-2,867,464
Other income and (expense)
Loss on extinguishment of debt				-10,307,864	-10,307,864	-7,390,000
Financing costs	-395,981		-659,968
Beneficial conversion feature		-6,716,504		-6,716,504	-6,716,504
Amortization of debt discount					-1,604,240	-28,719	0
Interest expense	-150	-1,148,761	-1,165,981	-1,250,734	-301,169	-35,661
Loan guaranty costs		-11,745	-2,944	-23,490	-45,036	-38,159
Other income	3,479	1,554	3,479	1,554	3,001	6,392
Total other income (expense)	-392,652	-7,875,456	-1,825,414	-18,297,038	-18,971,812	-7,486,147
Loss before taxes	-6,009,646	-11,850,038	-12,385,299	-25,139,641	-35,120,235	-12,913,365	-2,867,464
Provision for income taxes
Net loss	($6,009,646)	($11,850,038)	($12,385,299)	($25,139,641)	($35,120,235)	($12,913,365)	($2,867,464)
Net loss per share, basic and diluted	($0.05)	($0.14)	($0.11)	($0.29)	($0.38)	($0.21)	($0.07)
Weighted average number of shares outstanding	130,851,978	86,149,419	116,866,764	85,352,818	91,630,693	62,516,461	38,289,463

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Common Stock	Additional Paid in Capital	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2009	$39,516	$1,656,364	($1,212,249)	$483,631
Beginning balance, shares at Dec. 31, 2009	39,516,450
Shares issued in private placement	15,971	3,154,672		3,170,643
Shares issued in private placement, shares	15,970,871
Options issued as compensation		177,601		177,601
Net loss			-2,867,464	-2,867,464
Ending balance at Dec. 31, 2010	55,487	4,988,637	-4,079,713	964,411
Ending balance, shares at Dec. 31, 2010	55,487,321			55,487,321
Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement	166	-255,919		-255,753
Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement, shares	165,879			165,879
Shares issued in private placement	5,552	1,701,448		1,707,000
Shares issued in private placement, shares	5,551,589			5,551,589
Shares issued in exchange for debt	21,682	8,217,455		8,239,137
Shares issued in exchange for debt, shares	21,681,958			21,681,958
Shares issued in exercise of warrants	92	17,158		17,250
Shares issued in exercise of warrants, shares	92,057			92,057
Options issued as compensation		183,355		183,355
Warrants issued for services		190,280		190,280
Warrants issued for loan guaranty costs-related parties		93,969		93,969
Warrants issued for financing costs		45,362		45,362
Warrants issued as financing costs-related parties		9,338		9,338
Warrants issued as compensation-related party		7,158		7,158
Net loss			-12,913,365	-12,913,365
Ending balance at Dec. 31, 2011	82,979	15,198,241	-16,993,078	-1,711,858
Ending balance, shares at Dec. 31, 2011	82,978,804			82,978,804
Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement
Shares issued in private placement	3,954	7,891,531		7,895,485
Shares issued in private placement, shares	3,953,489			3,953,489
Shares issued in exchange for debt	2,775	1,051,882		1,054,657
Shares issued in exchange for debt, shares	2,775,415			2,775,415
Shares issued for exercise of options	1,932	189,068		191,000
Shares issued for exercise of options, shares	1,931,788			1,931,788
Shares issued in exercise of warrants	8,145	3,093,855		3,102,000
Shares issued in exercise of warrants, shares	8,145,486			8,145,486
Options issued as compensation		1,832,061		1,832,061
Warrants issued for services		1,563,620		1,563,620
Warrants issued for financing costs		13,014,784		13,014,784
Warrants issued as compensation-related party		36,284		36,284
Warrants issued for cash		400		400
Cancellation of warrants issued for loan guaranty costs-related parties		-7,830		-7,830
Beneficial conversion feature		6,716,504		6,716,504
Net loss			-35,120,235	-35,120,235
Ending balance at Dec. 31, 2012	$99,785	$50,580,400	($52,113,313)	($1,433,128)
Ending balance, shares at Dec. 31, 2012	99,784,982			99,784,982

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
CASH FLOWS FROM OPERATING ACTIVITIES - CONTINUING OPERATIONS
Net loss	($12,385,299)	($25,139,641)	($35,120,235)	($12,913,365)	($2,867,464)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement				-255,753
Depreciation	12,084	15,141	27,484	25,686	22,783
Amortization of intangible assets	6,509	13,972	28,776	29,159
Provision for doubtful accounts	58,337	15,023	40,548	1,500
Loss on debt extinguishment		10,307,864	10,307,864	7,390,000
Beneficial conversion feature		6,716,504	6,716,504
Amortization of debt discount	1,102,680	1,109,276	1,604,240	28,719
Stock based compensation	1,179,912	529,129	1,868,345	190,513	177,601
Stock based expense for services	637,155	120,120	338,457	22,630
Loan guaranty costs	2,944	23,490	45,036	38,159
Non-cash financing costs	659,938			25,980
Changes in assets and liabilities
Accounts receivable	-409,475	-396,232	-620,469	-16,409	-6,008
Inventory	109,151	-232,168	-1,027,137	29,996	-454,683
Other current assets	-1,696,551	-118,566	42,281	-346,822	152,916
Other assets	-899,000
Accounts payable	403,750	385,620	1,334,855	188,876	95,034
Accrued interest	-150,068	133,702	270,252	33,994
Deferred revenue	74,320	618,877	1,144,752
Accrued expenses and other current liabilities	608,860	248,450	261,121	560,541	36,033
Net cash flows used in operating activities	-10,684,753	-5,649,439	-12,737,326	-4,966,596	-2,843,788
CASH FLOWS FROM INVESTING ACTIVITIES
Payment of security deposit	-125,000
Purchase of property and equipment	-22,905	-66,404	-66,405	-28,766	-27,348
Patent costs, net of abandoned costs	-112,192	-49,184	-206,101	-8,870
Net cash flows used in investing activities	-260,097	-115,588	-272,506	-37,636	-27,348
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock, net of costs	48,512,460		7,895,485	1,000,000
Proceeds from notes and loans payable		6,900,000	8,700,000	2,684,160
Proceeds from exercise of options	6,231	165,999	191,000	17,250
Proceeds from sale of warrants		400	400
Proceeds from notes payable - related parties				300,000
Proceeds from sale of membership units				707,000	3,170,645
Proceeds bank line of credit	500,000			300,000
Repayment of bank line of credit	-500,000		-300,000
Repayment of notes payable - related party		-50,000	-200,000	-100,696
Repayment of notes payable	-4,691,847	-50,780	-1,850,000	-200,000
Net cash flows provided by financing activities	43,826,844	6,965,619	14,436,885	4,707,714	3,170,645
Increase (decrease) in cash	32,881,994	1,200,592	1,427,053	-296,518	299,510
Cash, beginning of period	1,553,474	126,421	126,421	422,939	123,429
Cash, end of period	34,435,468	1,327,013	1,553,474	126,421	422,939
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	212,853	7,756	17,253	696
Cash paid for income taxes
Warrants exercised in exchange for debt and accrued interest		3,102,000	3,102,000
Warrants issued for financing	1,711,956	2,509,537	2,509,537	148,668
Warrants issued for services	462,196	1,532,228	1,563,620	190,280
Shares issued in exchange for debt and accrued interest		1,054,658	1,054,658	849,137
Notes payable issued for accrued interest		$15,123	$15,123

THE_COMPANY

THE COMPANY	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012			Dec. 31, 2011
Company
THE COMPANY	NOTE 1 – THE COMPANY	NOTE 1 – THE COMPANY			NOTE A – THE COMPANY
	TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has two wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company organized on May 13, 2008, or VitaMed, and BocaGreenMD, Inc., a Nevada corporation incorporated on January 10, 2012, or BocaGreen. Unless the context otherwise requires, TherapeuticsMD, VitaMed, and BocaGreen collectively are sometimes referred to as “our company,” “we,” “our,” or “us.”	TherapeuticsMD, Inc., a Nevada corporation (“Therapeutics” or the “Company”) has two wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company organized on May 13, 2008 (“VitaMed”), and BocaGreenMD, Inc., a Nevada corporation, incorporated on January 10, 2012 (“BocaGreen”). Unless the context otherwise requires, the Company, VitaMed, and BocaGreen collectively are sometimes referred to as “our company,” “we,” “our,” or “us.”			Corporate Overview and History of Therapeutics
	Nature of Business	Agreement and Plan of Merger with VitaMed			TherapeuticsMD, Inc., a Nevada corporation (“Therapeutics” or the “Company”) was incorporated in Utah in 1907 under the name Croff Mining Company.  The Company changed its name to Croff Oil Company in 1952 and in 1996 changed its name to Croff Enterprises, Inc.  In the twenty (20) years prior to 2008, Croff’s operations consisted entirely of oil and natural gas leases.  Due to a spin-off of its operations in December 2007, Croff had no business operations or revenue source and had reduced its operations to a minimal level although it continued to file reports required under the Exchange Act.  As a result of the spin-off, Croff was a “shell company” under the rules of the Commission.  In July 2009, the Company (i) closed a transaction to acquire America’s Minority Health Network, Inc. as a wholly owned subsidiary, (ii) ceased being a shell company, and (iii) experienced a change in control in which the former shareholders of America’s Minority Health Network, Inc. acquired control of the Company.  On September 14, 2009, the Company changed its name to AMHN, Inc.  On June 11, 2010, the Company closed a transaction to acquire Spectrum Health Network, Inc. as a wholly owned subsidiary.  On July 20, 2010, the Company filed Articles of Conversion and Articles of Incorporation to redomicile in the State of Nevada and changed the par value of its shares of capital stock to $0.001 per share.  On July 31, 2010, the Company transferred the assets of America’s Minority Health Network, Inc. to a secured noteholder in exchange for the satisfaction of debt associated therewith.  On February 15, 2011, the Company transferred the assets of Spectrum Health Network, Inc. to a secured noteholder in exchange for the satisfaction of debt associated therewith and in exchange for an Exclusive Licensing, Distribution and Advertising Sales Agreement (“Licensing Agreement”) under which the Company could sell subscription services and advertising on the Spectrum Health Network for commissions.  On August 3, 2011 (with an effective date of October 3, 2011), in anticipation of closing the Merger (as defined and described below), the Company filed Amended and Restated Articles of Incorporation to change its name to TherapeuticsMD, Inc. and to increase the shares of Common Stock authorized for issuance to 250,000,000.  On October 4, 2011, the Company closed the Merger with vitaMedMD, LLC, a Delaware limited liability company (“VitaMed”).  As of December 31, 2011, Company management determined that  VitaMed would become the sole focus of the Company and services performed relative to the Licensing Agreement were discontinued.  Unless otherwise stated or unless the context otherwise requires, the description of our business set forth below is provided on a combined basis, taking into account our newly-acquired wholly owned subsidiary, VitaMed.
	We are a women’s healthcare product company focused on creating and commercializing products targeted exclusively for women.  We currently manufacture and distribute branded and generic prescription prenatal vitamins as well as over-the-counter vitamins and cosmetics.	On July 18, 2011, Therapeutics entered into an Agreement and Plan of Merger (“Merger Agreement”) by and among VitaMed and VitaMed Acquisition, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (the “Merger Sub”), pursuant to which the Company would acquire 100% of VitaMed. The proposed acquisition was to be accomplished by the merger of Merger Sub with and into VitaMed with VitaMed being the surviving limited liability company (the “Merger”) in accordance with the Limited Liability Company Act of the State of Delaware. The Merger became effective upon the filing of the Certificate of Merger with the Secretary of State of the State of Delaware on October 4, 2011 (the “Effective Date”). In preparation of and prior to the closing of the Merger Agreement, the Company completed the following required corporate actions:			The Company maintains a website at www.therapeuticsmd.com.
			•	a reverse split of the Company’s 16,575,209 issued and outstanding shares of Common Stock on a ratio of 1 for 100 (the “Reverse Split”). As a result of the Reverse Split, each share of Common Stock outstanding on July 28, 2011 (the “Record Date”), without any action on the part of the holder thereof, became one one-hundredth of a share of Common Stock. The Reverse Split decreased the number of outstanding shares of the Company’s Common Stock by approximately 99% resulting in 165,856 shares outstanding after the Reverse Split. The effectuation of the Reverse Split did not result in a change in the relative equity position or voting power of the shareholders of the Company;	Agreement and Plan of Merger with VitaMed
			•	an increase of our authorized shares of Common Stock to 250,000,000;
			•	a change in the name of the Company to TherapeuticsMD, Inc.; and	On July 18, 2011, Therapeutics entered into an Agreement and Plan of Merger (“Merger Agreement”) by and among VitaMed and VitaMed Acquisition, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (the “Merger Sub”), pursuant to which the Company would acquire 100% of VitaMed.  The proposed acquisition was to be accomplished by the merger of Merger Sub with and into VitaMed with VitaMed being the surviving limited liability company (the “Merger”) in accordance with the Limited Liability Company Act of the State of Delaware.  The Merger became effective upon the filing of the Certificate of Merger with the Secretary of State of the State of Delaware on October 4, 2011 (the “Effective Time”).  In preparation of and prior to the closing of the Merger Agreement, the Company completed the following required corporate actions with an effective date of October 3, 2011:
			•	an amendment to the Company’s Long Term Incentive Compensation Plan to increase the authorized shares for issuance thereunder to 25,000,000.
					·	a reverse split of the Company’s 16,575,209 issued and outstanding shares of Common Stock on a ratio of 1 for 100 (the “Reverse Split”).  As a result of the Reverse Split, each share of Common Stock outstanding on July 28, 2011 (the “Record Date”), without any action on the part of the holder thereof, became one one-hundredth of a share of Common Stock.  The Reverse Split decreased the number of outstanding shares of the Company’s Common Stock by approximately 99% resulting in 165,856 shares outstanding after the Reverse Split.  The effectuation of the Reverse Split did not result in a change in the relative equity position or voting power of the shareholders of the Company,
		On the Effective Date, we acquired 100% of VitaMed in exchange for the issuance of shares of the Company’s Common Stock, as more fully described below (the “Merger”). In accordance with the provisions of this triangulated merger, the Merger Sub was merged with and into VitaMed as of the Effective Date. Upon consummation of the Merger Agreement and all transactions contemplated therein, the separate existence of the Merger Sub ceased and VitaMed became a wholly owned subsidiary of the Company.
					·	an increase of its authorized shares of Common Stock to 250,000,000,
		Exchange of Securities
					Agreement and Plan of Merger with VitaMed (continued)
		On the Effective Date, all outstanding membership units of VitaMed (the “Units”) were exchanged for shares of the Company’s Common Stock. In addition, all outstanding VitaMed options to purchase VitaMed membership units (the “VitaMed Options”) and all outstanding VitaMed warrants to purchase VitaMed membership units (the “VitaMed Warrants”) were exchanged and converted into options and warrants for the purchase of the Company’s Common Stock (“Company Options” and “Company Warrants,” respectively).
					·	a change in the name of the Company to TherapeuticsMD, Inc., and
		All Units, VitaMed Options and VitaMed Warrants were exchanged on a pro-rata basis for shares of the Company’s Common Stock which in the aggregate totaled 70,000,000 shares, resulting in a conversion ratio calculated by the sum of all outstanding Units, VitaMed Options and VitaMed Warrants divided by 70,000,000 (the “Conversion Ratio”). Pursuant to the Conversion Ratio, the Company issued 58,407,331 shares of the Company’s Common Stock in exchange for the outstanding Units, reserved for issuance an aggregate of 10,119,796 shares issuable upon the exercise of the Company Options, and reserved for issuance an aggregate of 1,472,916 shares issuable upon the exercise of the Company Warrants. After giving effect to the Reverse Split, and taking into consideration the 58,407,331 aforementioned shares issued in exchange for the Units, the number of shares of the Company’s Common Stock issued and outstanding as of the Effective Date was 58,573,187, of which the former members of VitaMed owned approximately 99%. All shares of the Company’s Common Stock issued in exchange for the Units, and to be issued upon exercise of the Company Options and Company Warrants, are subject to a lock-up agreement for a period of 18 months from the Effective Date.
					·	an amendment to the Company’s Long Term Incentive Compensation Plan (“LTIP”) to increase the authorized shares for issuance thereunder to 25,000,000.
		Nature of Business
					On October 4, 2011, the Closing Date of the Merger Agreement, the Company acquired 100% of VitaMed in exchange for the issuance of shares of the Company’s Common Stock, as more fully described below (the “Merger”).  In accordance with the provisions of this triangulated merger, the Merger Sub was merged with and into VitaMed as of the Effective Date.  Upon consummation of the Merger Agreement and all transactions contemplated therein, the separate existence of the Merger Sub ceased and VitaMed became a wholly owned subsidiary of the Company.
		We are a women’s healthcare product company focused on creating and commercializing products targeted exclusively for women. We currently manufacture and distribute branded and generic prescription prenatal vitamins as well as over-the-counter, or OTC, vitamins.
					Exchange of Securities
		New Products
					At the Effective Time, all outstanding membership units of VitaMed (the “Units”) were exchanged for shares of the Company’s Common Stock.  In addition, all outstanding VitaMed options to purchase VitaMed membership units (the “VitaMed Options”) and all outstanding VitaMed warrants to purchase VitaMed membership units (the “VitaMed Warrants”) were exchanged and converted into options and warrants for the purchase of the Company’s Common Stock (“Company Options” and “Company Warrants”, respectively).  All Units, VitaMed Options and VitaMed Warrants were exchanged on a pro-rata basis for shares of the Company’s Common Stock which in the aggregate totaled 70,000,000 shares, resulting in a conversion ratio calculated by the sum of all outstanding Units, VitaMed Options and VitaMed Warrants divided by 70,000,000 (the “Conversion Ratio”).  Pursuant to the Conversion Ratio, the Company issued 58,407,331 shares of the Company’s Common Stock in exchange for the outstanding Units, reserved for issuance an aggregate of 10,119,796 shares issuable upon the exercise of the Company Options, and reserved for issuance an aggregate of 1,472,916 shares issuable upon the exercise of the Company Warrants.  After giving effect to the Reverse Split, and taking into consideration the 58,407,331 aforementioned shares issued in exchange for the Units, the number of shares of the Company’s Common Stock issued and outstanding as of the Closing Date was 58,573,187, of which the former members of VitaMed owned approximately 99%.  All shares of the Company’s Common Stock issued in exchange for the Units, and to be issued upon exercise of the Company Options and Company Warrants, are subject to a lock-up agreement for a period of eighteen (18) months from the Closing.
		In March 2012, we launched our first prescription-only prenatal vitamin, vitaMedMD™ Plus Rx, with subsequent launches of our second prescription-only prenatal vitamin, vitaMedMD™ One Rx in April 2012, and our third prescription-only prenatal vitamin, vitaMedMD™ RediChew™ Rx in May 2012. In the fourth quarter 2012, our BocaGreenMD™ brand was launched and our first products include three prescription products Prena1™ Plus, Prena1™ and Prena1™ Chew, which are duplicate, or “generic” formulations of our vitaMedMD-branded prescription prenatals
					Corporate Overview and History of VitaMed
					VitaMed is a specialty pharmaceutical company organized as a limited liability company in the State of Delaware on May 13, 2008.  VitaMed is focused on providing the highest quality products to the women’s health market.  Our direct national sales force that calls on physicians and pharmacies is enhanced by our patent-pending technology and business methodology.  This combination allows us to market both over-the-counter (“OTC”) and prescription nutritional supplements, drugs, medical foods and other medical products through pharmacies and our web-site with the recommendation of physicians by creating  unique value propositions for patients, physician/providers and insurance payors.
					In the early part of 2009, we completed formulation of our first products, a prenatal multivitamin and a vegan docosahexaenoic acid (“DHA”) supplement and introduced the product to the market in June 2009 with sales primarily in South Florida.  In September 2010, we achieved a milestone of $1 million in total sales and had begun to expand our sales force nationally and currently have  product sales into 46 states.  Our product line has been expanded to ten core products and our new product development continues to focus on the women’s health market. As we continue our product development efforts for both new products and refinements to existing products, we are also seeking proprietary ingredients and formulations that can be exclusively licensed or patented for use in women’s healthcare that will further differentiate our products from the competition.
					VitaMed maintains websites at www.vitamedmd.com and www.vitamedmdrx.com.
					Throughout these Notes to Consolidated Financial Statements, the terms “we,” “us,” “our,” “Therapeutics,” or the “Company” refers to TherapeuticsMD, Inc., and unless otherwise specified, includes our wholly owned subsidiary, VitaMed.

BASIS_OF_PRESENTATION_AND_RECE

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Jun. 30, 2013
Basis Of Presentation And Recently Issued Accounting Pronouncements
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	NOTE 2 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
	Interim Financial Statements
	Our accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles, or GAAP, for complete financial statements.  In our opinion, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission, or SEC.  The balance sheet at December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements.  The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period.  Actual results could differ from those estimates. Results of operations for interim periods are not necessarily indicative of results for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2012.
	Fair Value of Financial Instruments
	Our financial instruments consist primarily of receivables, accounts payable, accrued expenses, and short-term debt. The carrying amount of accounts receivable, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such instruments and are considered Level 1 assets under the fair value hierarchy. Interest rates that are currently available to us for issuance of short and long-term debt with similar terms and remaining maturities are used to estimate the fair value of our short and long-term debt and would be considered Level 3 inputs under the fair value hierarchy.
	Fair Value of Financial Instruments
	We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC 820 Fair Value Measurements and Disclosures. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).  Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:
		Level 1	unadjusted quoted prices in active markets for identical assets or liabilities;
		Level 2	quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and
		Level 3	unobservable inputs for the asset or liability.
	At June 30, 2013 and December 31, 2012, we had no assets or liabilities that were valued at fair value on a recurring basis.
	Research and Development
	Research and development, or R&D, expenses include internal R&D activities, external contract research organization, or CRO, services and their clinical research sites, and other activities. Internal R&D activity expenses include laboratory supplies, salaries, benefits, and share-based compensation expenses.  CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting, and regulatory legal counsel.  Internal R&D activities and other activity expenses are charged to operations as incurred.  We make payments to the CRO’s based on agreed upon terms and may include payments in advance of a study starting date.  Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.  We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO.  Accrued CRO costs are subject to revisions as such studies progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.
	Earnings Per Share
	We calculate earnings per share, or EPS, in accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure of two EPS amounts, basic and diluted. We compute basic EPS based on the weighted average number of shares of common stock outstanding during the period. We compute diluted EPS based on the weighted average number of shares of common stock outstanding plus all potentially dilutive common shares outstanding during the period. Such potentially dilutive common shares consist of stock options and warrants. Potentially dilutive common shares totaling 21,773,002 and 18,884,154 at June 30, 2013 and 2012, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to the net loss reported by us.
	Recently Issued and Newly Adopted Accounting Pronouncements
	On July 18, 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU provide guidance on the financial statements presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in this ASU do not require new recurring disclosures. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments in ASU No. 2013-11 are not expected to have an impact on our condensed consolidated financial statements.
	Reclassifications
	Certain 2012 amounts have been reclassified to conform to current year presentation.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2012				Dec. 31, 2011
Summary Of Significant Accounting Policies
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES				NOTE B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation				Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, vitaMed and BocaGreen. All material intercompany balances and transactions have been eliminated in consolidation.				The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary.  All material intercompany balances and transactions have been eliminated in consolidation.
	Cash				Cash and Cash Equivalents
	We maintain cash at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced any losses related to these balances. All of our non-interest bearing cash balances were fully insured at December 31, 2012 and 2011 due to a temporary federal program in effect from December 31, 2010 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts.				Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits.  The Company has never experienced any losses related to these balances.  All of our non-interest bearing cash balances were fully insured at December 31, 2011 and 2010 due to a temporary federal program in effect from December 31, 2010 through December 31, 2012.  Under the program, there is no limit to the amount of insurance for eligible accounts.  Beginning 2013, insurance coverage will revert to $250,000 per depositor at each financial institution, and our non-interest bearing cash balances may again exceed federally insured limits.  The Company had no interest-bearing amounts on deposit excess of federally insured limits at December 31, 2011 and 2010.
					Trade Accounts Receivable and Allowance for Doubtful Accounts
	Beginning 2013, insurance coverage will revert to $250,000 per depositor at each financial institution, at which time our non-interest bearing cash balances may again exceed federally insured limits. We had no interest-bearing amounts on deposit in excess of federally insured limits at December 31, 2012 and 2011.
					Trade accounts receivable are customer obligations due under normal trade terms.  The Company reviews the accounts receivable for uncollectible accounts and credit card charge-backs and provides an allowance for doubtful accounts which is based upon a review of outstanding receivables, historical collection information and existing economic conditions.  Trade accounts receivable past due more than 90 days are considered delinquent.  Delinquent receivables are written off to bad debt expense based on individual credit evaluations, results of collection efforts, and specific circumstances of the customer.  Recoveries of accounts previously written off are recorded as reductions of bad debt expense when received.  Historically, our bad debt expense has been limited because the majority of our trade receivables are paid via credit card.  Data we use to calculate these estimates does not accurately reflect bad debts; adjustments to these reserves may be required.  At December 31, 2011 and 2010, the Company recorded an allowance for doubtful accounts of $1,500 and $0, respectively.
	Trade Accounts Receivable and Allowance for Doubtful Accounts
					Inventories
	Trade accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide an allowance for doubtful accounts which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We consider trade accounts receivable past due more than 90 days to be delinquent. We write-off delinquent receivables to bad debt expense based on individual credit evaluations, results of collection efforts, and specific circumstances of the customer. Recoveries of accounts previously written off are recorded as reductions of bad debt expense when received. Historically, our bad debt expense has been limited because the majority of our trade receivables are paid via credit card. To the extent data we use to calculate these estimates does not accurately reflect bad debts; adjustments to these reserves may be required. At December 31, 2012 and 2011, we recorded an allowance for doubtful accounts of $42,048 and $1,500, respectively.
					Inventories represent packaged nutritional products and supplements which are valued at the lower of cost or market using the average cost method.
	Inventories
					Fixed Assets
	Inventories represent packaged nutritional products and supplements and raw materials which are valued at the lower of cost or market using the average cost method. The costs of manufacturing the prescription products associated with the deferred revenue (as discussed in Revenue Recognition) are recorded as deferred costs, which are included in inventory, until such time as the related deferred revenue is recognized.
					Property and Equipment-Property and equipment is stated at cost, net of accumulated depreciation.  Maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs are charged to operating expense as incurred.  Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from 3 to 7 years.  Depreciation expense totaled $25,686 and $5,105 for the years ended December 31, 2011 and 2010, respectively.
	Fixed Assets
					Website-Costs incurred in the planning stage of a website are expensed, while costs incurred in the development stage are capitalized and amortized over the estimated three-year life of the asset.  Amortization of website development costs totaled $29,159 and $17,678 for the years ended December 31, 2011 and 2010, respectively.
	Equipment-We state equipment at cost, net of accumulated depreciation. Maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs are charged to operating expense as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related assets, which range from three to seven years. Depreciation expense totaled $19,904 and $23,962 for the years ended December 31, 2012 and 2011, respectively.
					Intangible Assets
	Leasehold Improvements-We state improvements at cost, net of accumulated depreciation. We compute depreciation using the straight-line method over the remaining term of the lease. Depreciation expense totaled $7,580 and 1,724 for the years ended December 31, 2012 and 2011, respectively.
					The Company has adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 350 Intangible-Goodwill and Other (“ASC 350”).
	Intangible Assets
					Capitalized patent costs, net of accumulated amortization, include legal costs incurred for a patent application.  In accordance with ASC 350, once the patent is granted, the Company will amortize the capitalized patent costs over the remaining life of the patent using the straight-line method.  If the patent is not granted, the Company will write-off any capitalized patent costs at that time.  Intangible assets are reviewed annually for impairment or when events or circumstances indicate that their carrying amount may not be recoverable.  There was no amortization expense related to patent costs for the years ended December 31, 2011 and 2010 as  patents have not yet been granted.
	Patent and Trademarks-We have adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 350 Intangible-Goodwill and Other (“ASC 350”). Capitalized patent costs, net of accumulated amortization, include legal costs incurred for a patent application. In accordance with ASC 350, once the patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. Intangible assets are reviewed annually for impairment or when events or circumstances indicate that their carrying amount may not be recoverable.
					Impairment of Long-Lived Assets
	There was no amortization expense related to patent costs for the years ended December 31, 2012 and 2011 as patents have not yet been granted.				Carrying values of property and equipment and finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable.  Such events or circumstances include, but are not limited to:
	Website Costs-We expense costs incurred in the planning stage of a website, while costs incurred in the development stage are capitalized and amortized over the estimated three year life of the asset. Amortization of website development costs totaled $28,776 and $29,159 for the years ended December 31, 2012 and 2011, respectively.				·	Significant declines in an asset’s market price;
	Impairment of Long-Lived Assets				·	Significant deterioration in an asset’s physical condition;
	We review the carrying values of property and equipment and finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances include, but are not limited to, the following:				·	Significant changes in the nature or extent of an asset’s use or operation;
		•	significant declines in an asset’s market price;		·	Significant adverse changes in the business climate that could impact an asset’s value, including adverse actions or assessments by regulators;
		•	significant deterioration in an asset’s physical condition;
		•	significant changes in the nature or extent of an asset’s use or operation;		·	Accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;
		•	significant adverse changes in the business climate that could impact an asset’s value, including adverse actions or assessments by regulators;
		•	accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;		·	Current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset’s use; and
		•	current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset’s use; and
		•	expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.		·	Expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.
	If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group’s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. Assessments also consider changes in asset utilization, including the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then a loss is recorded for the difference between the assets’ fair value and respective carrying value. We determine the fair value of the assets using an “income approach” based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate; however, unanticipated events and changes in market conditions could affect such estimates, resulting in the need for an impairment charge in future periods.				If impairment indicators are present, the Company determines whether an impairment loss should be recognized by testing the applicable asset or asset group’s carrying value for recoverability.  This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment.  The Company estimates the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compares that estimate to the respective carrying values in order to determine if such carrying values are recoverable.  This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used.  Assessments also consider changes in asset utilization, including the temporary idling of capacity and the expected timing for placing this capacity back into production.  If the carrying value of the assets is not recoverable, then a loss is recorded for the difference between the assets’ fair value and respective carrying value.  The fair value of the assets is determined using an “income approach” based upon a forecast of all the expected discounted future net cash flows associated with the subject assets.  Some of the more significant estimates and assumptions include: market size and growth, market share, projected selling prices, manufacturing cost and discount rate.  The Company’s estimates are based upon its historical experience, its commercial relationships, market conditions and available external information about future trends.  The Company believes its current assumptions and estimates are reasonable and appropriate; however, unanticipated events and changes in market conditions could affect such estimates, resulting in the need for an impairment charge in future periods.
	Fair Value of Financial Instruments				Fair Value of Financial Instruments
	Our financial instruments consist primarily of receivables, accounts payable, accrued expenses, and short-term debt. The carrying amount of receivables, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such instruments and are considered Level 1 assets under the fair value hierarchy. Interest rates that are currently available to us for issuance of short and long-term debt with similar terms and remaining maturities are used to estimate the fair value of our short and long-term debt and would be considered Level 3 inputs under the fair value hierarchy.				The Company’s financial instruments consist primarily of receivables, accounts payable, accrued expenses and short-term debt.  The carrying amount of receivables, accounts payable and accrued expenses approximates its fair value because of the short-term maturity of such instruments.  Interest rates that are currently available to the Company for issuance of short-term debt with similar terms and remaining maturities are used to estimate the fair value of the Company’s short-term debt.
	We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).				Fair Value of Financial Instruments (continued)
	Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:				The Company categorizes its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).
		Level 1		unadjusted quoted prices in active markets for identical assets or liabilities;	Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:
		Level 2		quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and	Level 1                  Unadjusted quoted prices in active markets for identical assets or liabilities;
		Level 3		unobservable inputs for the asset or liability.		Level 2	Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and
	At December 31, 2012 and 2011, we had no assets or liabilities that were valued at fair value on a recurring basis.				Level 3                  Unobservable inputs for the asset or liability.
	Income Taxes				At December 31, 2011 and 2010, the Company had no assets or liabilities that are valued at fair value on a recurring basis.
	We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. In accordance with ASC 740, Income Taxes, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur. We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. As of December 31, 2012 and 2011, we had no tax positions relating to open tax returns that were considered to be uncertain.				Income Taxes
	Stock Based Compensation				Income taxes are accounted for under the asset and liability method.  Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized when the rate change is enacted.  Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.  In accordance with ASC 740, Income Taxes, the Company recognizes the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position.  Recognized uncertain income tax positions are measured at the largest amount that is greater than 50% likely of being realized.  Changes in recognition or measurement are reflected in the period in which those changes in judgment occur.  The Company recognizes both interest and penalties related to uncertain tax positions as part of the income tax provision.  As of December 31, 2011 and 2010, the Company has no tax positions relating to open tax returns that were considered to be uncertain.
	In December 2004, the FASB issued ASC 718, Compensation – Stock Compensation (“ASC 718”). Under ASC 718 companies are required to measure the compensation costs of unit-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Unit-based compensation arrangements include unit options, restricted share plans, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. We use the Black-Scholes option pricing model that requires the input of highly complex and subjective variables including the expected life of options granted and our expected stock price volatility over a period equal to or greater than the expected life of the options.				In December 2004, the FASB issued ASC 718, Compensation – Stock Compensation (“ASC 718”).  ASC 718 companies are required to measure the compensation costs of unit-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services.  Unit-based compensation arrangements include unit options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans.  As such, compensation cost is measured on the date of grant at their fair value.  Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.  The Company uses the Black-Scholes option pricing model which requires the input of highly complex and subjective variables including the expected life of options granted and the Company’s expected stock price volatility over a period equal to or greater than the expected life of the options.
	Equity instruments (“instruments”) issued to other than employees are recorded on the basis of the fair value of the instruments, as required by ASC 718. FASB ASC 505, Equity Based Payments to Non-Employees defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.				Equity instruments (“instruments”) issued to other than employees are recorded on the basis of the fair value of the instruments, as required by ASC 718.  FASB ASC 505, Equity Based Payments to Non-Employees defines the measurement date and recognition period for such instruments.  In general, the measurement date is when either a (a) performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested.  The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in the ASC.
	We recognize compensation expense for all share-based payments granted based on the grant date fair value estimated in accordance with ASC 718-10, “Share Based Payments.” Compensation expense is generally recognized on a straight-line basis over the employee’s requisite service period.				The Company recognizes compensation expense for all share-based payments granted based on the grant date fair value estimated in accordance with ASC 718-10, “Share Based Payments.”  Compensation expense is generally recognized on a straight-line basis over the employee’s requisite service period.
	Debt Discounts				Debt Discounts
	Costs incurred with parties that are providing long-term financing, which include warrants issued with the underlying debt, are reflected as a debt discount based on the relative fair value of the debt and warrants to the total proceeds. These discounts are generally amortized over the life of the related debt using the effective interest rate method. In connection with debt issued during the years ended December 31, 2012 and 2011, we recorded debt discounts totaling $2,706,920 and $28,719, respectively. The aggregate balance of unamortized debt discount at December 31, 2012 and 2011 was $1,102,680 and $0, respectively. Amortization expense related to debt discounts totaled $1,604,240 and $28,719 for the years ended December 31, 2012 and 2011, respectively, and is included in amortization of debt discount on the accompanying consolidated financial statements.				Costs incurred with parties who are providing long-term financing, which include warrants issued with the underlying debt, are reflected as a debt discount based on the relative fair value of the debt and warrants to the total proceeds.  These discounts are generally amortized over the life of the related debt using the effective interest rate method.  In connection with debt issued during the years ended December 31, 2011 and 2010, the Company recorded debt discounts totaling $28,719 and $0, respectively.  Amortization expense related to debt discounts totaled $28,719 and $0 for the years ended December 31, 2011 and 2010, respectively, and is included in interest expense on the accompanying consolidated financial statements.  Debt discount was fully amortized at December 31, 2011.
	Revenue Recognition				Revenue Recognition
	We recognize revenue on arrangements in accordance with ASC 605, “Revenue Recognition”. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.				The Company recognizes revenue on arrangements in accordance with ASC 605, “Revenue Recognition” (“ASC 605”).  Revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed and collectability is reasonably assured.  The Company generates revenue by sales of products primarily to retail consumers.  The Company’s policy is to recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer.  Outbound shipping and handling fees are included in sales and are billed upon shipment.  Shipping expenses are included in cost of sales.  The majority of the Company’s sales are paid with credit cards and the Company usually receives the cash settlement in two to three banking days.  Credit card sales minimize accounts receivable balances relative to sales.  We provide an unconditional thirty-day money-back return policy whereby we accept product returns from our retail, wholesale and eCommerce customers.  Historically we have experienced returns (monitored on a daily basis) equal to approximately one percent of sales.  Total returns were $20,726 and $13,734 for the years ended December 31, 2011 and 2010, respectively.  We consider the potential returns to be de minimis and have not established an allowance for product returns at this time.
	Over The Counter Products				Shipping and Handling Costs
	We generate OTC revenue by sales of products primarily to retail consumers. Our policy is to recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. Outbound shipping and handling fees are included in sales and are billed upon shipment. Shipping expenses are included in cost of sales. The majority of our sales are paid with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers. We recognize our revenue from OTC sales net of returns, sales discounts, and eCommerce fees.				The Company expenses all shipping and handling costs as incurred.  These costs are included in cost of sales on the accompanying consolidated financial statements.
	For the years ended December 31, 2012 and 2011, we recorded an allowance for returns of $27,168 and $0, respectively. We estimate the allowance for returns based on historical return activity, which is reviewed, and adjusted if necessary, on a quarterly basis.				Advertising Costs
	Prescription Products				The Company expenses advertising costs when incurred.  Advertising expenses totaled $19,408 and $25,698 during the years ended December 31, 2011 and 2010, respectively.
	We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of sales discounts and end-user rebates.				Research and Development Expenses
	We accept returns of unsalable product from customers within a return period of six months prior to and following product expiration. Our prescription products currently have a shelf-life of 24 months from date of manufacture. Given the limited history of prescriptions products, we currently cannot reliably estimate expected returns of the prescription products at the time of shipment. Accordingly, we defer recognition of revenue on prescription products until the right of return no longer exists, which occurs at the earlier of the time the prescription products are dispensed through patient prescriptions or expiration of the right of return. As a result of this policy, we had a deferred revenue balance of $1,144,752 and $0 at December 31, 2012 and 2011, respectively.				Research and development expenditures, which are expensed as incurred, totaled $107,241 and $65,402 during the years ended December 31, 2011 and 2010, respectively.
	We maintain various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The rebate program is designed to enable the end-user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end-user. We estimate the allowance for rebates based on industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. For the years ended December 31, 2012 and 2011, we recorded reduction to income for rebates of $34,255 and $0, respectively.				Earnings Per Share
	Shipping and Handling Costs				The Company calculates earnings per share (“EPS”) in accordance with ASC 260, “Earnings Per Share,” which requires the computation and disclosure of two EPS amounts, basic and diluted.  Basic EPS is computed based on the weighted average number of shares of common stock outstanding during the period.  Diluted EPS is computed based on the weighted average number of common shares outstanding plus all potentially dilutive common shares outstanding during the period.  Such potential dilutive common shares consist of stock options and warrants.  Potential common shares totaling 96,618,626 and 165,752 (Reverse Split shares) at December 31, 2011 and 2010, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to the net loss reported by the Company.
We expense all shipping and handling costs as incurred. These costs are included in cost of sales on the accompanying consolidated financial statements.				Use of Estimates
Advertising Costs				The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.  The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities.  We evaluate our estimates, including those related to contingencies, on an ongoing basis.  We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
We expense advertising costs when incurred. Advertising expenses totaled $65,944 and $19,408 during the years ended December 31, 2012 and 2011, respectively.				Recently Issued Accounting Pronouncements
Research and Development Expenses				In December 2011, FASB issued Accounting Standards Update (“ASU”) 2011-11, Balance Sheet - Offsetting. This guidance requires disclosures about offsetting and related arrangements for recognized financial instruments and derivative instruments.  The standard is effective for us as of January 1, 2013 and will not materially impact our financial statement disclosures.
Research and development expenditures, which are expensed as incurred, totaled $4,492,362 and $107,241 during the years ended December 31, 2012 and 2011, respectively.				In September 2011, the FASB issued ASU 2011-08, “Testing Goodwill for Impairment.”  This guidance provides the option to evaluate prescribed qualitative factors to determine whether a calculated goodwill impairment test is necessary.  The standard is effective for us as of January 1, 2012 and will not materially impact on our financial condition, results of operations, or financial statement disclosures.
Earnings Per Share				In May 2011, FASB issued ASU 2011-05, Comprehensive Income: Presentation of Comprehensive Income, to allow an entity the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements.  In both choices, an entity is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income.  ASU 2011-05 eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders’ equity.  The amendments do not change the guidance regarding the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income.  The amendments should be applied retrospectively and is effective for fiscal years and interim periods within those years beginning after December 15, 2011.  Early adoption is permitted.  The adoption is not expected to have a material impact on the Company’s results of operations, financial position or cash flows.
We calculate earnings per share (“EPS”) in accordance with ASC 260, “Earnings Per Share,” which requires the computation and disclosure of two EPS amounts, basic and diluted. We compute basic EPS based on the weighted average number of shares of Common Stock outstanding during the period. We compute diluted EPS based on the weighted average number of shares of Common Stock outstanding plus all potentially dilutive common shares outstanding during the period. Such potential dilutive common shares consist of stock options and warrants. Potential common shares totaling 25,926,987 and 13,639,845 at December 31, 2012 and 2011, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to the net loss reported by us.				In May 2011, the FASB issued ASU 2011-04, Fair Value Measurement: Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs.  This ASU represents the converged guidance of the FASB and the IASB (the “Boards”) on fair value measurement, and results in common requirements for measuring fair value and for disclosing information about fair value measurements, including a consistent meaning of the term “fair value.”  These amendments change some of the terminology used to describe many of the existing requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements.  The amendments should be applied prospectively, and they are effective during interim and annual periods beginning after December 15, 2011.  Early application by public entities is not permitted.  The adoption is not expected to have a material impact on the Company’s results of operations, financial position or cash flows.
Use of Estimates				Management does not believe there would be a material effect on the accompanying financial statements had any other recently issued but not yet effective accounting standards been adopted in the current period.
Our financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Recently Issued Accounting Pronouncements
In July 2012, FASB issued Accounting Standards Update (“ASU”) No. 2012-02, “Testing Indefinite-Lived Intangible Assets for Impairment” (“ASU 2012-02”). ASU 2012-02 gives entities an option to first assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that the indefinite-lived intangible asset impaired. If based on its qualitative assessment an entity concludes that it is more likely than not that the fair value of an indefinite lived intangible asset is less than its carrying amount, quantitative impairment testing is required. However, if an entity concludes otherwise, quantitative impairment testing is not required. ASU 2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with early adoption permitted. ASU 2012-02 is not expected to have a material impact on our financial position or results of operations.
In December 2011, the FASB issued ASU No. 2011-11, “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities” (“ASU 2011-11”). ASU 2011-11 enhances current disclosures about financial instruments and derivative instruments that are either offset on the statement of financial position or subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset on the statement of financial position. Entities are required to provide both net and gross information for these assets and liabilities in order to facilitate comparability between financial statements prepared in conformity with U.S. GAAP and financial statements prepared on the basis of International Financial Reporting Standards (“IFRS”). ASU 2011-11 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. ASU 2011-11 is not expected to have a material impact on our financial position or results of operations.
In September 2011, the FASB issued ASU No. 2011-08 Intangibles – Goodwill & Other (“ASU 2011-08”), which updates the guidance in Accounting Standards Codification (“ASC”) Topic 350, Intangibles – Goodwill & Other (“ACS Topic 350”). The amendments in ASU 2011-08 permit an entity to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test described in ASC Topic 350. The more-likely-than-not threshold is defined as having a likelihood of more than fifty percent. If, after assessing the totality of events or circumstances, an entity determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. The amendments in ASU 2011-08 include examples of events and circumstances that an entity should consider in evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. However, the examples are not intended to be all-inclusive and an entity may identify other relevant events and circumstances to consider in making the determination. The examples in this ASU 2011-08 supersede the previous examples under ASC Topic 350 of events and circumstances an entity should consider in determining whether it should test for impairment between annual tests, and also supersede the examples of events and circumstances that an entity having a reporting unit with a zero or negative carrying amount should consider in determining whether to perform the second step of the impairment test. Under the amendments in ASU 2011-08, an entity is no longer permitted to carry forward its detailed calculation of a reporting unit’s fair value from a prior year as previously permitted under ASC Topic 350. ASU 2011-08 is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. The adoption of ASU 2011-08 did not have a material impact on our financial position or results of operations.
In May 2011, the FASB issued ASU 2011-04 (“ASU 2011-04”), which updated the guidance in ASC Topic 820, Fair Value Measurement. The amendments in ASU 2011-04 generally represent clarifications of Topic 820, but also include some instances where a particular principle or requirement for measuring fair value or disclosing information about fair value measurements has changed. ASU 2011-04 results in common principles and requirements for measuring fair value and for disclosing information about fair value measurements in accordance with U.S. GAAP and IFRS. The amendments in ASU 2011-04 are to be applied prospectively. For public entities, the amendments are effective for interim and annual periods beginning after December 15, 2011. The adoption of ASU 2011-04 did not have a material impact on our financial position or results of operations.
We do not believe there would have been a material effect on the accompanying financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.
Reclassifications
Certain 2011 amounts have been reclassified to conform to current year presentation.

GOING_CONCERN

GOING CONCERN	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Going Concern
GOING CONCERN	NOTE 3 – GOING CONCERN	NOTE C – GOING CONCERN
	The accompanying financial statements have been prepared assuming that our company will continue as a going concern. For the year ended December 31, 2012, we incurred a loss from operations of approximately $16 million and had negative cash flow from operations of approximately $13 million. Accumulated deficit as of December 31, 2012 was approximately $52 million. These matters raise substantial doubt about our ability to continue as a going concern. Our plans include raising additional proceeds from debt and equity transactions and to continue to increase our sales and marketing activities; however, there are no assurances that we will be successful in these efforts. On March 7, 2013 we filed a Prospectus Supplement for an underwritten public offering of our common stock with anticipated gross proceeds of $50 million. The securities being offered by us are pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the “SEC”) on January 25, 2013, which the SEC declared effective on February 5, 2013. The financial statements do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.	The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  The Company incurred a loss from operations of approximately $5,400,000, had negative cash flow from operations of approximately $5,000,000 and had an accumulated deficit of approximately $17,000,000 at December 31, 2011.  These matters raise substantial doubt about the Company’s ability to continue as a going concern.  Management’s plans include raising additional proceeds from debt and equity transactions and to continue to increase its sales and marketing activities; however, there are no assurances that management will be successful in their efforts.  The financial statements do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should the Company be unable to continue in operation.

INVENTORY

INVENTORY	6 Months Ended					12 Months Ended
	Jun. 30, 2013					Dec. 31, 2012
InventoryAbstract
INVENTORY	NOTE 3 – INVENTORY					NOTE 4 – INVENTORY
	Inventory consists of the following:					Inventory consists of the following:
		June 30,		December 31,
		2013		2012			December 31,
	Finished product	$	1,100,486	$	1,124,739		2012		2011
	Raw material		291,035		380,000	Finished product	$	1,124,739	$	588,073
	Deferred costs		114,538		110,471	Raw material		380,000		-0-
	TOTAL INVENTORY	$	1,506,059	$	1,615,210	Deferred costs		110,471		-0-
						TOTAL INVENTORY	$	1,615,210	$	588,073

OTHER_CURRENT_ASSETS

OTHER CURRENT ASSETS	6 Months Ended					12 Months Ended
	Jun. 30, 2013					Dec. 31, 2012					Dec. 31, 2011
Other Current Assets
OTHER CURRENT ASSETS	NOTE 4 – OTHER CURRENT ASSETS					NOTE 5 – OTHER CURRENT ASSETS					NOTE F – OTHER CURRENT ASSETS
	Other current assets consist of the following:					Other current assets consist of the following:					Other current assets consist of the following:
		June 30,		December 31,
		2013		2012			December 31,
	Prepaid research and development costs	$	1,686,254	$	189,375		2012		2011			December 31,
	Deferred financing costs		1,051,988		-0-	Prepaid consulting	$	432,216	$	95,962		2011		2010
	Prepaid consulting		541,936		432,216	Deposits with vendors		189,375		300,503	Deposits with vendors	$	300,503	$	-0-
	Other receivables-related party (Note 12)		171,261		-0-	Prepaid insurance		127,403		52,611	Prepaid consulting		95,962		-0-
	Prepaid insurance		125,266		127,403	Prepaid guaranty costs		2,944		46,984	Prepaid insurance		52,611		6,292
	Other prepaid costs		30,578		-0-	TOTAL OTHER CURRENT ASSETS	$	751,938	$	496,060	Prepaid guaranty costs		46,984		-0-
	Prepaid guaranty costs		-0-		2,944						TOTAL OTHER CURRENT ASSETS	$	496,060	$	6,292
	TOTAL OTHER CURRENT ASSETS	$	3,607,283	$	751,938

FIXED_ASSETS

FIXED ASSETS	6 Months Ended							12 Months Ended
	Jun. 30, 2013							Dec. 31, 2012							Dec. 31, 2011
Fixed Assets
FIXED ASSETS	NOTE 5 – FIXED ASSETS							NOTE 6 – FIXED ASSETS							NOTE G – FIXED ASSETS
	Fixed assets consist of the following:							Fixed assets consist of the following:							Fixed assets consist of the following:
		June 30,			December 31,
		2013			2012				December 31,							December 31,
	Equipment	$	90,573		$	67,668			2012			2011				2011			2010
	Furniture and fixtures		46,625			46,625		Equipment	$	67,668		$	33,650		Website	$	91,743		$	65,791
	Leasehold improvements		11,980			11,980		Furniture and fixtures		46,625			22,169		Equipment		33,651			30,837
			149,178			126,273		Leasehold improvements		11,980			4,049		Furniture and fixtures		26,219			26,219
	Accumulated depreciation		(72,684	)		(60,600	)			126,273			59,868				151,613			122,847
	TOTAL FIXED ASSETS	$	76,494		$	65,673		Accumulated depreciation		(60,600	)		(33,116	)	Accumulated depreciation		(81,500	)		(26,655	)
								TOTAL FIXED ASSETS	$	65,673		$	26,752		TOTAL FIXED ASSETS	$	70,113		$	96,192
	Depreciation expense for the six months ended June 30, 2013 and 2012 was $12,084 and $15,141, respectively.
								Depreciation expense for the years ended December 31, 2012 and 2011 was $27,484 and $25,686, respectively.							Depreciation expense for the years ended December 31, 2011 and 2010 was $54,845 and $22,783, respectively.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2012
Intangible Assets
INTANGIBLE ASSETS	NOTE 7 –INTANGIBLE ASSETS
	Other assets consist of the following:
		December 31,
		2012		2011
	Patent costs	$	224,971	$	18,870
	Website costs, net of amortization of $77,159 and $48,383 for the years ended December 31, 2012 and 2011, respectively		14,584		43,361
	TOTAL INTANGIBLE ASSETS	$	239,555	$	62,231
	Amortization expense for the years ended December 31, 2012 and 2011 was $28,776 and $29,159, respectively

OTHER_ASSETS

OTHER ASSETS	6 Months Ended					12 Months Ended
	Jun. 30, 2013					Dec. 31, 2011
Other Assets:
OTHER ASSETS	NOTE 6 – OTHER ASSETS					NOTE H – OTHER ASSETS
	Prepaid expense consists of the following:					Other assets consist of the following:
		June 30,		December 31,
		2013		2012			December 31,
	Prepaid manufacturing costs	$	899,000	$	-0-		2011		2010
	Prepaid consulting expense		1,081,519		953,655	Prepaid consulting	$	71,689	$	-0-
	TOTAL PREPAID EXPENSE	$	1,980,519	$	953,655	Prepaid guaranty costs		8,826		-0-
						TOTAL OTHER ASSETS	$	80,515	$	-0-
	Intangible assets consist of the following:
		June 30,		December 31,
		2013		2012
	Patent costs	$	337,163	$	224,971
	Website costs, net of amortization of $83,668 and $77,159, respectively		8,075		14,584
	TOTAL INTANGIBLE ASSETS	$	345,238	$	239,555
	Amortization expense for the six months ended June 30, 2013 and 2012 was $6,509 and $13,972, respectively.

OTHER_CURRENT_LIABILITIES

OTHER CURRENT LIABILITIES	6 Months Ended					12 Months Ended
	Jun. 30, 2013					Dec. 31, 2012					Dec. 31, 2011
Other Current Liabilities
OTHER CURRENT LIABILITIES	NOTE 7 – OTHER CURRENT LIABILITIES					NOTE 8 – OTHER CURRENT LIABILITIES					NOTE J – OTHER CURRENT LIABILITIES
	Other current liabilities consist of the following:					Other current liabilities consist of the following:					Other current liabilities consist of the following:
		June 30,		December 31,
		2013		2012			December 31,						December 31,
	Accrued offering costs	$	500,000	$	-0-		2012		2011				2011		2010
	Accrued payroll and commission costs		228,877		397,210	Accrued payroll	$	285,210	$	295,915	Accrued payroll		$	227,477	$	-0-
	Accrued vacation costs		263,851		114,899	Accrued vacation		114,899		68,438	Accrued vacation			68,438		24,208
	Accrued professional fees		120,250		90,000	Accrued commission		112,000		-0-	Other accrued expenses			128,473		90,998
	Allowance for coupons and returns		86,540		53,002	Accrued legal and accounting expense		90,000		15,010	Dividends payable(1)			41,359		-0-
	Other accrued expenses		93,853		29,400	Allowance for coupons and returns		53,002		-0-	TOTAL OTHER CURRENT LIABILITIES		$	465,747	$	115,206
	Dividends payable(1)		41,359		41,359	Dividends payable(1)		41,359		41,359	____________________
	TOTAL OTHER CURRENT LIABILITIES	$	1,334,730	$	725,870	Other accrued expenses		29,400		45,025	-1	In June 2008, the Company declared and paid a special dividend of $0.40 per share of common stock to all shareholders of record as of June 10, 2008.  This amount reflects moneys remaining unclaimed by the certain shareholders.
	______________					TOTAL OTHER CURRENT LIABILITIES	$	725,870	$	465,747
	(1) In June 2008, the Company declared and paid a special dividend of $0.40 per share of common stock to all stockholders of record as of June 10, 2008.  This amount reflects unclaimed dividends by certain stockholders.
						(1) In June 2008, we declared and paid a special dividend of $0.40 per share of common stock to all shareholders of record as of June 10, 2008. This amount reflects moneys remaining unclaimed by certain shareholders.

NOTES_PAYABLE

NOTES PAYABLE	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Notes Payable [Abstract]
NOTES PAYABLE	NOTE 8 – NOTES PAYABLE	NOTE 9 – NOTES PAYABLE	NOTE I – NOTES PAYABLE
	Issuance and Payment of Multiple Advance Revolving Credit Note	Issuance of Promissory Notes	During 2009, a non-affiliate business consultant (the “Consultant”) provided consulting services to the Company in the amount of $210,000 (the “Debt”).  The Company issued the Consultant a demand promissory note for $210,000 dated November 9, 2010 (the “November 2010 Note”) which was subsequently assigned to non-affiliate entities (the “Noteholders”).  On April 18, 2011, the Company and the Noteholders agreed that in exchange for the forbearance of the Noteholders not to make demand for repayment of the November 2010 Note for a minimum of sixty (60) days, the Company would (i) cancel the November 2010 Note and (ii) issue two convertible promissory notes to the Noteholders in the principal amount of $105,000 each bearing interest at the rate of six percent (6%) per annum (the “Convertible Notes”).  The Convertible Notes were due on demand any time after sixty (60) days from the date of issuance (the “Maturity Date”).  At the option of the Noteholders, the Convertible Notes could be converted into shares of the Company’s Common Stock at any time after the Maturity Date at a fixed conversion price of $0.0105 per share.  The Conversion Price was not subject to adjustment at any time for any future stock split, stock combination, dividend or distribution of any kind.  On October 18, 2011, the Company and the Noteholders entered into Debt Conversion Agreements and converted the principal of the Convertible Notes into 20,000,000 shares of the Company’s Common Stock valued at $7,600,000.  The transaction was recorded as debt settlement expense on the accompanying financial statements.
	On January 31, 2013, we entered into a business loan agreement with Plato and Associates, LLC, a Florida limited liability company, or Plato, for a Multiple Advance Revolving Credit Note, or the Plato Note.  The Plato Note allows us to draw down funding up to the $10 million maximum principal amount, at a stated interest rate of 6% per annum.  Plato may make advances to us from time to time under the Plato Note at our request, which advances will be of a revolving nature and may be made, repaid, and made from time to time.  Interest payments shall be due and payable on the tenth day following the end of each calendar quarter in which any interest is accrued and unpaid, commencing on April 10, 2013, and the principal balance outstanding under the Plato Note, together with all accrued interest and other amounts payable under the Plato Note, if any, will be due and payable on February 24, 2014.  The Plato Note is secured by substantially all of our assets.  On each of February 25 and March 13, 2013, $200,000 was drawn against the Plato Note. On March 21, 2013, we repaid $401,085, including accrued interest, and as of June 30, 2013, there was no balance outstanding under the Plato Note.	In January and February 2012, we issued 6% promissory notes for an aggregate of $900,000 with due dates of March 1, 2012. As discussed below, these promissory notes were modified on February 24, 2012 through the issuance of secured promissory notes (the “February 2012 Notes”).	On March 1, 2011, the Company entered into a Demand Promissory Note with the Company’s then majority shareholder wherein the Company could periodically borrow funds to satisfy its operational requirements.  Interest accrued at 20% per annum.  On October 4, 2011, this Demand Promissory Note plus accrued interest totaling $170,152 was forgiven.  The forgiveness of this related party debt was included in additional paid in capital on the accompanying financial statements.
	As additional consideration for the Plato Note, we issued Plato a warrant to purchase 1,250,000 shares of our common stock at an exercise price $3.20 per share (see NOTE 9 – STOCKHOLDERS’ EQUITY for more details).	In August and September 2012, we issued 6% promissory notes for an aggregate of $1,600,000 due on October 1, 2012, which due date was subsequently extended. The notes were paid in full in October 2012.	On March 7, 2011, VitaMed entered into a Business Loan Agreement and Promissory Note  for a $300,000 bank line of credit (the “Bank LOC”) for which the bank required a personal guarantee and cash collateral.  Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers of VitaMed, and by Reich Family Limited Partnership, an entity controlled by Mitchell Krassan, also an officer of VitaMed.  The Bank LOC accrued interest at the rate of 3.020% per annum based on a year of 360 days and was due on March 1, 2012.  The bank and VitaMed negotiated a one-year extension to the Bank LOC which was executed on March 19, 2012 (the “Bank LOC Extension”).  The Bank LOC Extension accrues interest at the rate of 2.35% and is due on March 1, 2013.  At December 31, 2011, the outstanding principle balance of the Bank LOC was $300,000.  In consideration for the personal guarantees and cash collateral, VitaMed issued VitaMed Warrants for an aggregate of 499,998 Units (or Company Warrants for an aggregate of 613,713 shares pursuant to the Conversion Ratio).  The ten-year Company Warrants vest at the rate of an aggregate of 76,714 shares per calendar quarter end and have an exercise price of $0.2444 per share.  In the event that the Bank LOC is repaid prior to being fully vested, the Company Warrants will be reissued only for the number of shares vested through the date of repayment.  At March 31, 2012, an aggregate of 306,867 shares will be vested thereunder.
	Borrowing Under Amended Bank LOC	In September 2012, we issued a 6% promissory note for $200,000 due on October 15, 2012. The note was paid in full in October 2012.	On June 1, 2011, VitaMed sold Promissory Notes (the “VitaMed Promissory Notes”) in the aggregate of $500,000 with accompanying VitaMed Warrants to purchase an aggregate of 500,000 Units (or Company Warrants to purchase an aggregate of 613,718 shares pursuant to the Conversion Ratio).  The VitaMed Promissory Notes earn interest at the rate of four percent (4%) per annum and were due at the earlier of (i) the six (6) month anniversary of the date of issuance and (ii) such time as VitaMed received the proceeds of a promissory note(s) issued in an amount of not less than $1,000,000 (the “Funding”).  Upon the closing of the Funding on July 18, 2011, as more fully described in the following paragraph, two of the VitaMed Promissory Notes in the aggregate of $200,000 were paid in full.  By mutual agreement, the remaining VitaMed Promissory Notes in the aggregate of $300,000 were extended until the Closing of the Merger.  On October 6, 2011, one of the VitaMed Promissory Notes for $50,000 was paid in full.  By mutual agreement, VitaMed Promissory Notes in the aggregate of $100,000 were converted into 266,822 shares of the Company’s Common Stock at $0.38 per share, which represents fair value of the shares on the date of conversion.  Other VitaMed Promissory Notes in the aggregate of $150,000 were extended to March 1, 2012.  At December 31, 2011, the outstanding principle balance of the VitaMed Promissory Notes was an aggregate of $150,000.  As mentioned hereinafter in FOOTNOTE O – SUBSEQUENT EVENTS, two VitaMed Promissory Notes in the aggregate of $100,000 were further extended to April 14, 2012 and one for $50,000 was further extended to June 1, 1012.  The ten-year Company Warrants have an exercise price of $0.4074 per share and none have been exercised.
	In February 2013, we borrowed $100,000 from First United Bank under the Amended Bank LOC. The Amended Bank LOC required a personal guarantee and cash collateral limited to $100,000 which was provided by Reich Family Limited Partnership, or Reich Family LP, an entity controlled by Mitchell Krassan, an officer of the Company.  On April 25, 2013, we paid the principal and interest due under the Amended Bank LOC of $100,735.  On May 1, 2013, the Amended Bank LOC expired and was not renewed.  Accordingly, the personal guarantee was canceled and the cash collateral was refunded to Reich Family LP.	Issuance of February 2012 Notes	On July 18, 2011, VitaMed sold two Senior Secured Promissory Notes (the “Secured Notes”) in the amount of $500,000 each and also entered into a Security Agreement under which VitaMed pledged all of its assets to secure the obligation.  The Secured Notes bear interest at the rate of six percent (6%) per annum and are due on the one (1) year anniversary thereof.  The Senior Secured Notes bear interest at the rate of six percent (6%) per annum and are due on the one (1) year anniversary of the date thereof.  The Company may pay the Senior Secured Notes by delivering such number of shares of the Company’s Common Stock as shall be determined by dividing the outstanding principal then due and owing by the Company’s Share Price.  For purposes of the Senior Secured Notes, the “Share Price” shall mean the lower of the most recent price at which the Company offered and sold shares of its Common Stock (not including any shares issued upon the exercise of options and/or warrants or upon the conversion of any convertible securities) or the five-day average closing bid price immediately preceding the date of conversion.  At December 31, 2011, the outstanding principle balance of the Secured Notes was $500,000 each.
	Issuance of Promissory Notes	On February 24, 2012, we issued and sold the February 2012 Notes to an individual and an entity (the “Parties”), both of which are stockholders of our company, in the principal amount of $1,358,014 and $1,357,110 respectively (the “Principal Base Amount(s)”) and granted Warrants for the purchase in the aggregate of 9,000,000 shares of our Common Stock (4,500,000 to each Party) (the “February 2012 Warrants”) pursuant to the terms of a Note Purchase Agreement (the “Note Purchase Agreement”) also dated February 24, 2012. As consideration for the February 2012 Notes and the February 2012 Warrants, we received an aggregate of $1,000,000 of new funding from the Parties (the “February Funding”), and the Parties surrendered certain promissory notes previously issued by us in the amount of $1,700,000 plus accrued interest of $15,124 (collectively known as the “Prior Notes”).	In September and October 2011, VitaMed sold Convertible Promissory Notes (the “VitaMed Convertible Notes”) in the aggregate of $534,160.  The VitaMed Convertible Notes earned interest at the rate of four percent (4%) per annum and were due December 1, 2011.  On November 18, 2011, the Company and the VitaMed Convertible Noteholders entered into Debt Conversion Agreements and converted the principal and accrued interest of the VitaMed Convertible Notes into 1,415,136 shares of the Company’s Common Stock at $0.38 per share which represents the fair value of the shares on the date of conversion.
			In November and December, 2011, the Company sold six-percent Promissory Notes for an aggregate of $800,000 with due dates of March 1, 2012.  At December 31, 2011, the outstanding principle balance of the Promissory Notes was $800,000.  As mentioned hereinafter in FOOTNOTE O – SUBSEQUENT EVENTS, these Notes were paid in full on February 24, 2012 through the issuance of Secured Promissory Notes.
	In January and February 2012, we sold 6% promissory notes for an aggregate of $900,000 with due dates of March 1, 2012.  As discussed below in Issuance and Settlement of February 2012 Notes, these promissory notes were modified on February 24, 2012 through the issuance of secured promissory notes, or the February 2012 Notes.	We granted 5,685,300 Warrants in consideration of the modification of the Prior Notes and 3,314,700 Warrants with the February Funding. We determined that the resulting modification of the Prior Notes was substantial in accordance with ASC 470-50, “Modifications and Extinguishments.” As such the modification was accounted for as an extinguishment and restructuring of the debt, and the 5,685,300 warrants issued in consideration of the modification were expensed. The fair value of the Prior Notes was estimated by calculating the present value of the future cash flows discounted at a market rate of return for comparable debt instruments to be $1,517,741, resulting in a debt discount of $197,383 and recognized a loss on extinguishment of debt of $10,307,864, which represented the fair value of the 5,685,300 warrants net of the difference between the carrying amount of the Prior Notes and their fair value as of the date of the modification on the accompanying consolidated financial statements.
			In December 2011, the Company sold four-percent Promissory Notes for an aggregate of $100,000 with due dates of March 1, 2012.  At December 31, 2011, the outstanding principle balance of the Promissory Notes was $100,000.  As mentioned hereinafter in FOOTNOTE O – SUBSEQUENT EVENTS, these Notes were further extended by mutual agreement to April 14, 2012.
	Issuance and Settlement of February 2012 Notes	We determined the relative fair value of the 3,314,700 Warrants granted with the February Funding to be $859,647 and recorded the amount as debt discount to be amortized over the term of the February 2012 Notes. As a result of the surrender of the February 2012 Notes on June 19, 2012 (see Issuance of June 2012 Notes below), we expensed the remaining unamortized debt discount. As of December 31, 2012, we recorded amortization of debt discount totaling $859,647 related to the February 2012 Notes on the accompanying consolidated financial statements.
	On February 24, 2012, we issued the February 2012 Notes to an individual and an entity, or the Parties, both of which are our stockholders, in the principal base amount of $1,358,014 and $1,357,110, respectively, and granted warrants for the purchase in the aggregate of 9,000,000 shares of our common stock, or the February 2012 Warrants, pursuant to the terms of a Note Purchase Agreement, also dated February 24, 2012.  As consideration for the February 2012 Notes and the February 2012 Warrants, we received an aggregate of $1,000,000 of new funding from the Parties and the Parties surrendered certain promissory notes previously issued by us in the aggregate amount of $1,700,000 plus accrued interest of $15,124. Under the February 2012 Notes, the Parties loaned us an additional $3,000,000 during March, April, and May 2012.	Under the February 2012 Notes, the Parties loaned us an additional $3,000,000 during March, April, and May 2012.
	On June 19, 2012, we settled $3,102,000 in principle and interest of the February 2012 Notes in exchange for the exercise of 8,145,486 warrants. As discussed below in Issuance and Payment of June 2012 Notes, the remaining balance of $2,691,847 of the February 2012 Notes was modified on June 19, 2012 through the issuance of secured promissory notes, or the June 2012 Notes, (see NOTE 9 – STOCKHOLDERS’ EQUITY, Warrants Issued in Connection with Debt, for more details).	On June 19, 2012, we settled $3,102,000 in principal and interest of the February 2012 Notes in exchange for the exercise of 8,145,486 Common Stock purchase warrants. As discussed below, the remaining balance of $2,691,847 of the February 2012 Notes was modified on June 19, 2012 through the issuance of secured promissory notes (the “June 2012 Notes”).
	Issuance and Payment of June 2012 Notes	Issuance of June 2012 Notes
	On June 19, 2012, we issued the June 2012 Notes to the Parties in the principal base amounts of $2,347,128 and $2,344,719, respectively, pursuant to the terms of a note purchase agreement, or the June 2012 Note Purchase Agreement.  As consideration for the June 2012 Notes, the Parties surrendered the remaining balance of the February 2012 Notes in the aggregate amount of $1,347,128 and $1,344,719, respectively (which sums included principle and interest through June 19, 2012), and we received an aggregate of $2,000,000 of new funding from the Parties (the “June Funding”).  The principal base amount of each of the June 2012 Notes, plus any additional advance made to us thereafter, together with accrued interest at the annual rate of 6%, was due in one lump sum payment on February 24, 2014. As security for our obligations under the June 2012 Note Purchase Agreement and the June 2012 Notes, we entered into a security agreement and pledged all of our assets, tangible and intangible, as further described therein. We also granted warrants to purchase an aggregate of 7,000,000 shares of our common stock in connection with the June Funding.  On March 21, 2013, we repaid $4,882,019 including accrued interest, leaving a balance of $21,595 in accrued interest as of March 31, 2013 related to the June 2012 Notes.  On April 25, 2013, the balance of accrued interest was paid in full.	On June 19, 2012, we issued and sold secured promissory notes (the “June 2012 Notes”) to the Parties in the principal base amounts of $2,347,128 and $2,344,719, respectively pursuant to the terms of a note purchase agreement (the “June 2012 Note Purchase Agreement”). As consideration for the June 2012 Notes, the Parties surrendered the remaining balance of the February 2012 Notes in the aggregate amount of $1,347,128 and $1,344,719, respectively (which sums included principal and interest through June 19, 2012), and we received an aggregate of $2,000,000 of new funding from the Parties (the “June Funding”). The principal amount of each of the June 2012 Notes, plus any additional advance made to us thereafter, together with accrued interest at the annual rate of 6%, is due in one lump sum payment on February 24, 2014. As security for our obligations under the June 2012 Note Purchase Agreement and the June 2012 Notes, we entered into a Security Agreement and pledged all of our assets, tangible and intangible, as further described therein. We granted 7,000,000 Common Stock purchase warrants in connection with the June Funding.
		We determined the relative fair value of the 7,000,000 Common Stock purchase warrants to be $1,649,890 and recorded this amount as a debt discount to be amortized over the term of the June 2012 Notes. In conjunction with the February 2012 Notes and June 2012 Notes, as of December 31, 2012, we recorded an aggregate of $547,210, as amortization of debt discount on the accompanying consolidated financial statements. At December 31, 2012, we reported a notes payable balance of $3,589,167, net of debt discount of $1,102,680 in long-term liabilities on the accompanying consolidated financial statements.
		Issuance of Other Promissory Notes During 2011
		On March 1, 2011, we entered into a Demand Promissory Note with our then majority stockholder wherein we could periodically borrow funds to satisfy our operational requirements. Interest accrued at 20% per annum. On October 4, 2011, this Demand Promissory Note plus accrued interest totaling $170,152 was forgiven. The forgiveness of this related party debt was included in additional paid in capital on the accompanying financial statements.
		In November and December, 2011, we sold 6% Promissory Notes for an aggregate of $800,000 with due dates of March 1, 2012. At December 31, 2011, the outstanding principle balance of the Promissory Notes was $800,000. As discussed above (See Issuance of February 2012 Notes, included in this Note 9) these Notes were paid in full on February 24, 2012 through the issuance of the February 2012 Notes.
		Conversion of July 2011 Secured Notes
		In July 2011, VitaMed sold two senior secured promissory notes (the “Secured Notes”) in the amount of $500,000 each and also entered into a security agreement under which VitaMed pledged all of its assets to secure the obligation. The Secured Notes bear interest at the rate of 6% per annum, are due on the one year anniversary thereof, and are convertible into shares of our Common Stock at our option. We may pay the Secured Notes by delivering such number of shares of our Common Stock as shall be determined by dividing the outstanding principal then due and owing by our Share Price. For purposes of the Secured Notes, the “Share Price” shall mean the lower of the most recent price at which we offered and sold shares of our Common Stock (not including any shares issued upon the exercise of options and/or warrants or upon the conversion of any convertible securities) or the five-day average closing bid price immediately preceding the date of conversion. On June 19, 2012, we and the Parties agreed to convert the Secured Notes, and according to the terms thereof, aggregated principal and interest through June 19, 2012 of $1,054,647 was converted at $0.38 per share into an aggregate of 2,775,415 shares of our Common Stock. This resulted in a beneficial conversion feature of $6,716,504 as recorded in other income and expense on the accompanying condensed consolidated financial statements. For the years ended December 31, 2012 and 2011, we recorded an aggregate of $33,204 and $21,453, respectively, as interest expense on the accompanying consolidated financial statements.
		March 2011 Bank Line of Credit
		In March 2011, VitaMed entered into a Business Loan Agreement and Promissory Note with First United Bank (“1st United”) for a $300,000 bank line of credit (the “Bank LOC”) for which personal guarantees and cash collateral were required. Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers of VitaMed, and by Reich Family Limited Partnership,
		an entity controlled by Mitchell Krassan, also an officer of VitaMed. In consideration for the personal guarantees and cash collateral, Common Stock purchase warrants for an aggregate of 613,713 shares were granted (see NOTE 10 for more details). The Bank LOC accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012. We and 1st negotiated a one-year extension to the Bank LOC which was executed on March 19, 2012 (the “Bank LOC Extension”). The Bank LOC Extension accrues interest at the rate of 2.35% and is due on March 1, 2013. On November 13, 2012, the then outstanding balance of $299,220 was repaid in full and we and 1st United amended the Business Loan Agreement and Promissory Note to reflect a $100,000 bank line of credit (the “Amended Bank LOC”). In accordance with the Amended Bank LOC, the personal guarantees and cash collateral were removed for Mr. Finizio and Mr. Milligan. During the years ended December 31, 2012 and 2011, interest expense of $7,366 and $5,650, respectively, was paid and is included in interest expense on the accompanying consolidated financial statements. We have made no withdrawals against the Amended Bank LOC as of December 31, 2012.
		Issuance of VitaMed Promissory Notes
		In June 2011, VitaMed sold Promissory Notes (the “VitaMed Promissory Notes”) in the aggregate principal amount of $500,000. In consideration for the VitaMed Promissory Notes, Warrants for an aggregate of 613,718 shares were granted. The VitaMed Promissory Notes earn interest at the rate of 4% per annum and were due at the earlier of (i) the six month anniversary of the date of issuance and (ii) such time as VitaMed received the proceeds of a promissory note(s) issued in an amount of not less than $1,000,000 (the “Funding”). Upon the closing of the Funding in July 2011, as more fully described above in Conversion of July 2011 Secured Notes, two of the VitaMed Promissory Notes in the aggregate of $200,000 were paid in full. By mutual agreement, the remaining VitaMed Promissory Notes in the aggregate of $300,000 were extended. In October 2011, one of the VitaMed Promissory Notes for $50,000 was paid in full. Also in October 2011, by mutual agreement, VitaMed Promissory Notes in the aggregate of $100,000 were converted into 266,822 shares of our Common Stock at $0.38 per share, which represents the fair value of the shares on the date of conversion. In June 2012, a VitaMed Promissory Note held by an unaffiliated individual was paid in full including $2,160 in accrued interest. The remaining VitaMed Promissory Notes in the aggregate of $100,000 were extended to October 15, 2012 (one held by Mr. Milligan for $50,000 and one for $50,000 held by BF Investments, LLC (owned by Brian Bernick, a member of the board of directors of the Company). On October 4, 2012 these VitaMed Promissory Notes were paid in full including $5,341 in accrued interest.
		In September and October 2011, VitaMed sold Convertible Promissory Notes (the “VitaMed Convertible Notes”) in the aggregate of $534,160. The VitaMed Convertible Notes earned interest at the rate of 4% per annum and were due December 1, 2011. On November 18, 2011, we and the VitaMed Convertible Noteholders entered into Debt Conversion Agreements and converted the principal and accrued interest of the VitaMed Convertible Notes into 1,415,136 shares of our Common Stock at $0.38 per share which represents the fair value of the shares on the date of conversion.
		In December 2011, we issued 4% promissory notes to Mr. Finizio and Mr. Milligan and for an aggregate of $100,000 ($50,000 each) with original due dates of March 1, 2012. These promissory notes were extended by mutual agreement to June 1, 2012. In June 2012, the VitaMed Promissory Note held by Mr. Finizio was paid in full, including $888 in accrued interest. Mr. Milligan’s VitaMed Promissory Note was extended to October 15, 2012. On October 4, 2012 this VitaMed Promissory Notes was paid in full including $1,519 in accrued interest.
		For the years ended December 31, 2012 and 2011, we recorded an aggregate of $6,344 and $2,390, respectively, as interest expense on the accompanying consolidated financial statements.
		Conversion of 2010 Demand Promissory Note
		During 2009, a non-affiliate business consultant (the “Consultant”) provided consulting services to us for $210,000. We issued the Consultant a demand promissory note for $210,000 dated November 9, 2010 (the “November 2010 Note”), which was subsequently assigned to non-affiliate entities (the “Noteholders”). On April 18, 2011, we and the Noteholders agreed that in exchange for the forbearance of the Noteholders not to make demand for repayment of the November 2010 Note for a minimum of 60 days, we would (i) cancel the November 2010 Note and (ii) issue two convertible promissory notes to the Noteholders in the principal amount of $105,000, each bearing interest at the rate of 6% per annum (the “Convertible Notes”). The Convertible Notes were due on demand any time after 60 days from the date of issuance (the “Maturity Date”). At the option of the Noteholders, the Convertible Notes could be converted into shares of our Common Stock at any time after the Maturity Date at a fixed conversion price of $0.0105 per share. The Conversion Price was not subject to adjustment at any time for any future stock split, stock combination, dividend or distribution of any kind. On October 18, 2011, we and the Noteholders entered into Debt Conversion Agreements and converted the principal of the Convertible Notes into 20,000,000 shares of our Common Stock valued at $7,600,000. The transaction was recorded as debt settlement expense on the accompanying financial statements.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended												12 Months Ended
	Jun. 30, 2013												Dec. 31, 2012												Dec. 31, 2011
Stockholders' Deficit:
STOCKHOLDERS' EQUITY	NOTE 9 – STOCKHOLDERS’ EQUITY												NOTE 10 – STOCKHOLDERS’ EQUITY												NOTE D – STOCKHOLDERS’ EQUITY
	Common Stock												As discussed in NOTE 1, on October 4, 2011, all Units were exchanged for shares of our Common Stock. In addition, all VitaMed Options and VitaMed Warrants were exchanged and converted into Company Options and Company Warrants. All Units VitaMed Options and VitaMed Warrants were exchanged on a pro-rata basis for shares of our Common Stock, which in the aggregate totaled 70,000,000 shares, resulting in a conversion ratio calculated by the sum of all Units, VitaMed Options and VitaMed Warrants divided by 70,000,000 (the “Conversion Ratio”). Pursuant to the Conversion Ratio, we issued 58,407,331 shares of our Common Stock in exchange for the Units, reserved for issuance an aggregate of 10,119,796 shares issuable upon the exercise of the Company Options, and reserved for issuance an aggregate of 1,472,916 shares issued upon the exercise of the Company Warrants.												As previously mentioned herein, on October 4, 2011, all Units were exchanged for shares of the Company’s Common Stock.  In addition, all VitaMed Options and VitaMed Warrants were exchanged and converted into Company Options and Company Warrants.  All Units , VitaMed Options and VitaMed Warrants were exchanged on a pro-rata basis for shares of the Company’s Common Stock which in the aggregate totaled 70,000,000 shares, resulting in a conversion ratio calculated by the sum of all Units,  VitaMed Options and VitaMed Warrants divided by 70,000,000 (the “Conversion Ratio”).  Pursuant to the Conversion Ratio, the Company issued 58,407,331 shares of the Company’s Common Stock in exchange for the Units, reserved for issuance an aggregate of 10,119,796 shares issuable upon the exercise of the Company Options and reserved for issuance an aggregate of 1,472,916 shares issued upon the exercise of the Company Warrants.
	At June 30, 2013, we had 250,000,000 shares of common stock, $0.001 par value per share, authorized with 131,212,706 shares issued and outstanding.												Preferred Stock												Preferred Stock
	Public Offering												At December 31, 2012, we had 10,000,000 shares of Preferred Stock, par value $0.001 authorized and none outstanding, which shares can be designated by our Board of Directors.												At December 31, 2011, the Company had 10,000,000 shares of Preferred Stock, par value $0.001 authorized and none outstanding, which shares can be designated by the Company’s Board of Directors.
	On March 14, 2013, we entered into an underwriting agreement, or the Underwriting Agreement, with Jefferies LLC, as representative of the underwriters named therein, or the Underwriters, relating to the issuance and sale of 29,411,765 shares of our common stock. The price to the public in the offering was $1.70 per share and the Underwriters agreed to purchase the shares from us pursuant to the Underwriting Agreement at a price of $1.581 per share. The net proceeds to us from this offering was  approximately $45.4 million, after deducting underwriting discounts and commissions and other offering expenses payable by us.  In addition, under the terms of the Underwriting Agreement, we granted the Underwriters a 30-day option to purchase up to an additional 4,411,765 shares of common stock. The offering closed on March 20, 2013.												Common Stock												Common Stock
	Additional Shares Purchased under Offering												At December 31, 2012, we had 250,000,000 shares of Common Stock, $0.001 par value authorized, with 99,784,982 shares of Common Stock issued and outstanding.												At December 31, 2011, the Company had 250,000,000 shares of Common Stock, $0.001 par value authorized, with 82,978,781 shares of Common Stock issued and outstanding.
	As part of the public offering of our common stock described in Public Offering above, on April 12, 2013, the Underwriters exercised their option to purchase an additional 1,954,587 shares of our common stock to cover over-allotments.  We issued these shares to the Underwriters on April 18, 2013 and received proceeds of approximately $3.1 million, net of expenses.												During 2012 certain individuals exercised their right to purchase shares of our Common Stock. The shares were issued in reliance upon an exemption from the registration provisions of the Securities Act of 1933 provided by Section 4(1) of the Act and Rule 144 and are covered by a Lock-Up Agreement.												Between February and May 2011, VitaMed sold 2,892,630 Units for an aggregate purchase price of $707,000.
	Warrants to Purchase Common Stock of the Company													•	Options to purchase an aggregate of 1,691,393 shares of our Common Stock were exercised for $191,000.										On October 3, 2011, the Company effected a reverse split of its 16,575,209 issued and outstanding shares of Common Stock on a ratio of 1 for 100 resulting in 165,856 shares issued and outstanding thereafter.
	As of June 30, 2013, we had common stock purchase warrants outstanding for an aggregate of 14,293,499 shares of our common stock with a weighted average contractual remaining life of 4.8 years and exercise prices ranging from $0.24 to $3.20 per share, resulting in a weighted average exercise price of $1.86 per share.													•	Using the cashless exercise feature an aggregate of 240,395 Options were exercised, with 26,428 Options surrendered, resulting in the issuance of 240,395 shares of the Company’s Common Stock.										On October 5, 2011, the Company closed a Stock Purchase Agreement with Pernix Therapeutics, LLC, a Louisiana limited liability company (“Pernix”).  Pursuant to the terms of the Stock Purchase Agreement dated September 8, 2011, Pernix agreed to purchase 2,631,579 shares of the Company’s Common Stock (the “Shares”) at a purchase price of $0.38 per share for a total purchase price of $1,000,000 (“Purchase Price”).  In connection with the Stock Purchase Agreement, the Company and Pernix entered into a Lock-Up Agreement which, among other things, restricts the sale, assignment, transfer, encumbrance and other disposition of the Shares issued to Pernix.  Pursuant to the terms of the Lock-Up Agreement, Pernix agreed that for a period of twelve (12) months from the date of the Lock-Up Agreement, it would not make or cause any sale of the Shares (the “Lock-Up Period”).  After the completion of the Lock-Up Period, Pernix agreed not to sell or dispose of more than five percent (5%) of the Shares per quarter for the following twelve (12) month period.
	The valuation methodology used to determine the fair value of our Warrants is the Black-Scholes-Merton option-pricing model, or Black-Scholes Model, an acceptable model in accordance with ASC 718-10, Compensation – Stock Compensation. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the Warrant.												During June 2012, we settled $3,102,000 in principal and interest of the February 2012 Notes in exchange for the Parties’ exercise of a portion of the February 2012 Warrants for an aggregate of 8,145,486 shares of our Common Stock. The shares were issued in reliance upon an exemption from the registration provisions of the Securities Act of 1933 provided by Section 4(1) of the Securities Act of 1933 and Rule 144. During June 2012, we and the Parties also agreed to convert a portion of the February 2012 Notes, and according to the terms thereof, principal and interest through June 19, 2012 of totaling $1,054,647 was converted at $0.38 per share into 2,775,415 shares of our Common Stock. The shares were issued in reliance upon an exemption from the registration provisions of the Securities Act of 1933 provide by Section 4(1) of the Act and Rule 144.												In October and November 2011, the Company converted principle and accrued interest in the aggregate of $849,137 into shares of Common Stock of the Company totaling 20,000,000 and 1,681,958, respectively, as more fully described in NOTE I – NOTES PAYABLE.
	Warrants Issued in Connection with Debt												In September 2012, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with multiple investors (collectively, the “Investors”) relating to the issuance and sale of our Common Stock in a private placement. The Purchase Agreement was closed on October 2, 2012 (the “Closing Date”) through which we sold an aggregate of 3,953,489 shares of our Common Stock (the “Shares”) at $2.15 per share for an aggregate purchase price of $8,500,001. In connection with the private placement, Jefferies LLC (“Jefferies”) served as our exclusive placement agent. Jefferies compensation for the transaction was a cash fee of $552,500, which is included in accounts payable in the accompanying consolidated financial statements. We also paid legal fees and expenses for the Investors in the aggregate of $52,016, resulting in net proceeds to us of $7,895,485. The Shares were issued in reliance upon the exemptions from registration under the Securities Act of 1933 provided by Section 4(2) and Rule 506 of Regulation D promulgated thereunder. The Shares were issued directly by us and did not involve a public offering or general solicitation. The Investors in the private placement are “Accredited Investors” as that term is defined in Rule 501 of Regulation D and acquired the Shares for investment only and not with a present view toward, or for resale in connection with, the public sale or distribution thereof. As part of the Purchase Agreement, we agreed to file a registration statement, which was filed November 27, 2012.												In December 2011, a former director of VitaMed  exercised Company Options to purchase 92,057 shares of the Company’s Common Stock at an aggregate exercise price of $17,250.
	On January 31, 2013, we granted a warrant for the purchase of 1,250,000 shares of our common stock in connection with the issuance of the Plato Note, or the Plato Warrant, (see NOTE 8 – NOTES PAYABLE, Issuance of Multiple Advance Revolving Credit Note).  The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant will vest and become exercisable on October 31, 2013 and may be exercised any time after that date prior to the January 31, 2019 expiration date of the Plato Warrant.  This Warrant, with a fair value of approximately $1,711,956, was valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%.  At June 30, 2013, $1,051,988 was reported as deferred financing costs included in other current assets in the accompanying condensed consolidated balance sheet and is being amortized over the life of the Plato Note. For the six months ended June 30, 2013, $659,938 was recorded as financing costs on the accompanying condensed consolidated financial statements.												On October 3, 2011, we effected a reverse split of our 16,575,209 issued and outstanding shares of Common Stock on a ratio of 1- for -100 resulting in 165,856 shares issued and outstanding thereafter.												Warrants
	On June 19, 2012, we granted warrants for the purchase of an aggregate of 7,000,000 shares of our common stock in connection with the issuance of the June 2012 Notes, or the June 2012 Warrants, (see NOTE 8 – NOTES PAYABLE, Issuance of June 2012 Notes). Of the June 2012 Warrants issued, 6,000,000 are exercisable at $2.00 per share and 1,000,000 are exercisable at $3.00 per share.  The fair value of the June 2012 Warrants of $9,424,982 was determined by using the Black-Scholes Model on the date of the grant using a term of 5 years; a volatility of 44.64%; risk free rate of 0.75%; and a dividend yield of 0%.  The relative fair value of the June 2012 Warrants of $1,649,890 was determined by using the relative fair value calculation method on the date of the grant.  As a result of the repayment of the associated debt on March 21, 2013, we expensed the remaining unamortized debt discount of $885,709 at the time of the repayment.												On October 5, 2011, we closed a Stock Purchase Agreement with Pernix Therapeutics, LLC, a Louisiana limited liability company (“Pernix”). Pursuant to the terms of the Stock Purchase Agreement dated September 8, 2011, Pernix agreed to purchase 2,631,579 shares of our Common Stock (the “Shares”) at a purchase price of $0.38 per share for a total purchase price of $1,000,000 (“Purchase Price”). In connection with the Stock Purchase Agreement, we and Pernix entered into a Lock-Up Agreement that, among other things, restricts the sale, assignment, transfer, encumbrance and other disposition of the Shares issued to Pernix. Pursuant to the terms of the Lock-Up Agreement, Pernix agreed that for a period of 12 months from the date of the Lock-Up Agreement, it would not make or cause any sale of the Shares (the “Lock-Up Period”). After the completion of the Lock-Up Period, Pernix agreed not to sell or dispose of more than 5% of the Shares per quarter for the following 12 month period. Pernix is a related party (for further details see Note 12).												The valuation methodology used to determine the fair value of Common Stock purchase warrants is the Black-Scholes-Merton option-pricing model (“Black-Scholes Model”), an acceptable model in accordance with ASC 718-10.  The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate and the term of the Common Stock purchase warrant.
	On February 24, 2012, we issued warrants for the purchase of an aggregate of 5,685,300 shares of our common stock in connection with the modification of certain existing promissory notes, or the Modification Warrants, and warrants for the purchase of an aggregate of 3,314,700 shares of our common stock in connection with the issuance of the February 2012 Notes (the “February 2012 Warrants”) (see NOTE 8 – NOTES PAYABLE, Issuance of February 2012 Notes). Both the Modification Warrants and the February 2012 Warrants are exercisable at $0.38 per share. The Modification Warrants’ fair value of $10,505,247 and the February 2012 Warrants’ fair value of $6,124,873 was determined by using the Black-Scholes Model on the date of the grant using a term of 5 years; a volatility of 44.5%; risk free rate of 0.89%; and a dividend yield of 0%. We recorded the fair value of the Modification Warrants as part of the loss on extinguishment of debt in the accompanying condensed consolidated financial statements.  The relative fair value of the February 2012 Warrants of $859,647 was recorded as debt discount. As a result of the surrender of the February 2012 Notes on June 19, 2012, we expensed the remaining unamortized debt discount.												In October and November 2011, we converted principal and accrued interest in the aggregate of $849,137 into shares of Common Stock of our totaling 20,266,822 and 1,415,136, respectively, as more fully described in NOTE 9.												As of December 31, 2011, the Company had Company Warrants outstanding for an aggregate of 3,057,627 shares of the Company’s Common Stock (including the conversion of VitaMed Warrants as described above) with a weighted average contractual life of 8.0 years and exercise prices ranging from $0.24 to $1.50 per share resulting in a weighted average exercise price of $0.39 per share.
	Warrants Issued for Services												In December 2011, Alan Wurtzel, a former director of VitaMed, exercised Company Options to purchase 92,057 shares of our Common Stock for an aggregate exercise price of $17,250.												As of December 31, 2011, unamortized costs associated with Company Warrants totaled approximately $349,000.
	On May 7, 2013, we entered into a consulting agreement, or the Agreement, with Sancilio & Company, Inc., or SCI, to develop drug platforms to be used in hormone replacement drug products, or the Drug Products.  These services include support of our efforts to successfully obtain U.S. Federal Drug Administration, or FDA, approval for the Drug Products, including a vaginal capsule for the treatment of vulvar and vaginal atrophy, or VVA.  In connection with the Agreement, SCI agreed to forfeit its rights to receive warrants for the purchase of an aggregate of 833,000 shares of our common stock that were to be issued pursuant to the terms of a prior consulting agreement dated May 17, 2012.  As consideration under the Agreement, we agreed to issue SCI a warrant to purchase 850,000 shares of our common stock that vest as follows:												Warrants
													The valuation methodology used to determine the fair value of Common Stock purchase warrants is the Black-Scholes-Merton option-pricing model (“Black-Scholes Model”), an acceptable model in accordance with ASC 718-10. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the Common Stock purchase warrant.												During the year ended December 31, 2011, the Company issued the following:
		1	283,333 shares were earned on May 11, 2013 upon successful filing of the IND application with the FDA for the Drug Product for an estradiol-based product in a softgel vaginal capsule for the treatment of VVA.  The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of the vesting using a term of 5 years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as consulting expense in the accompanying condensed consolidated financial statements,
		2	283,333 shares vested on June 30, 2013.  The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of 5 years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. We recorded $154,068 as prepaid expense-short term and $308,128 as prepaid expense-long term in the accompanying condensed consolidated financial statements.  We will begin amortizing this expense monthly over 3 years beginning in July 2013, and										As of December 31, 2012, we had Company Warrants outstanding for an aggregate of 12,193,499 shares of our Common Stock (including the conversion of VitaMed Warrants as described above) with a weighted average contractual remaining life of 4.8 years and exercise prices ranging from $0.24 to $3.00, per share resulting in a weighted average exercise price of $1.63 per share. Unamortized costs associated with Company Warrants totaled approximately $93,000 at December 31, 2012.												Purpose		Number of Shares Under Company Warrants			Exercise			Exercise Term in Years		Fair Value
		3	283,334 shares will vest upon the receipt by us of any final FDA approval of a Drug Product that SCI helped us design.  It is anticipated that this event will not occur before December 2015.																											Price
													During the year ended December 31, 2012, we issued the following:												Loan guaranty			613,713		$	0.24			10	$	93,969
	In March 2012, we issued a warrant for the purchase of an aggregate of 31,000 shares of our common stock to five unaffiliated individuals for services rendered. These warrants were valued on the date of the grant using a term of 5 years; a volatility of 44.81%; risk free rate of 1.04%; and a dividend yield of 0%; $29,736 was recorded as consulting expense in the accompanying condensed consolidated financial statements.																								Loan consideration			613,718		$	0.41			5		30,993
															Number of Shares Under Company Warrants			Exercise Price			Exercise Term in Years		Fair Value		Product consulting			1,045,485		$	0.38-$0.41			10-May		189,942
	A summary of our warrant activity and related information for 2013 follows:												Debt modification			5,685,300			$0.38			5	$	10,505,247	Services			784,711		$	0.38-$1.50			10-May		159,363
													Issued with debt			10,314,700			$0.38-$3.00			5		15,549,855				3,057,627							$	474,267
			Number of			Weighted Average			Weighted				Services			1,332,500			$2.40-$2.80			5		1,563,620
			Shares			Exercise			Average		Aggregate					17,332,500							$	27,618,722	On March 7, 2011, VitaMed entered into a Business Loan Agreement and Promissory Note for a $300,000 bank line of credit (the “Bank LOC”) for which the bank required a personal guarantee and cash collateral.  Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers of VitaMed, and by Reich Family Limited Partnership, an entity controlled by Mitchell Krassan, also an officer of VitaMed.  The Bank LOC accrued interest at the rate of 3.020% per annum based on a year of 360 days and was due on March 1, 2012.  The bank and VitaMed negotiated a one-year extension to the Bank LOC which was executed on March 19, 2012 (the “Bank LOC Extension”).  The Bank LOC Extension accrues interest at the rate of 2.35% and is due on March 1, 2013.  In consideration for the personal guarantees and cash collateral, VitaMed issued VitaMed Warrants for an aggregate of 499,998 Units (or Company Warrants for an aggregate of 613,713 shares pursuant to the Conversion Ratio).  The ten-year Warrants vest at the rate of an aggregate of 76,714 shares per calendar quarter end and have an exercise price of $0.2444 per share.  In the event that the bank loan is repaid prior to being fully vested, the Company Warrants will be reissued only for the number of shares vested through the date of repayment.  At March 31, 2012, an aggregate of 306,867 shares will be vested thereunder.  The VitaMed Warrants were valued on the date of the grant using a term of 10 years; a volatility of 47.89%; risk free rate of 3.48%; and a dividend yield of 0%.  Of the $93,969 fair value, $38,159 was recorded as loan guaranty costs in other income and expense and $55,810 was recorded as prepaid expense on the accompanying consolidated financial statements.
			Under Company Warrants			Price			Remaining		Intrinsic
									Contractual		Value														In June 2011, VitaMed sold Promissory Notes (the “VitaMed Promissory Notes”) in the aggregate of $500,000 with accompanying VitaMed Warrants for an aggregate of  500,000 shares (or Company Warrants for an aggregate of 613,718 shares pursuant to the Conversion Ratio).  The VitaMed Warrants were valued on the date of the grant using a term of five (5) years; a range of volatility from 39.13% to 39.15%; risk free rate ranging from 1.38-1.65%; and a dividend yield of 0%.  The Company Warrants vested immediately.  Although the fair value was $30,993, using the appropriate accounting treatment, $28,719 was recorded as debt discount and fully amortized during 2011 with the amortized amount recorded as interest expense on the accompanying consolidated financial statements.
									Life in Years				Warrants Issued in Conjunction with Debt
	Balance at December 31, 2012			12,193,499		$	1.63			4.8	$	17,971,994													On July 21, 2011,VitaMed entered into a one-year consulting agreement with Lang Naturals, Inc. (“Lang”), wherein Lang would assist in the design, development and distribution efforts of VitaMed’s initial product offering.  As compensation, Lang received a VitaMed Warrant for 200,000 shares (or a Company Warrant for 245,485 shares pursuant to the Conversion Ratio).  The VitaMed Warrant was valued on the date of the grant using a term of five (5) years; a volatility of 39.44%; risk free rate of 1.56%; and a dividend yield of 0%.  The Company Warrant vested immediately.  Of the $12,548 fair value, $5,612 was recorded as non-cash compensation and $6,936 was recorded as prepaid expense on the accompanying consolidated financial statements.
	Granted			2,100,000		$	2.72			7.3	$	867,000	On February 24, 2012, we issued an aggregate of 5,685,300 Warrants in connection with the modification of certain existing promissory notes (the “Modification Warrants”), and 3,314,700 Warrants with the issuance of secured promissory notes (the “February 2012 Warrants”) (see NOTE 9). Both the Modification Warrants and the February 2012 Warrants are exercisable at $0.38. The Modification Warrants’ fair value of $10,505,247 and the February 2012 Warrants’ fair value of $6,124,873 were determined by using the Black-Scholes Model on the date of the grant. Both valuations used a term of five years; a volatility of 44.5%; risk free rate of 0.89%; and a dividend yield of 0%. We recorded the fair value of the Modification Warrants as part of the loss on extinguishment of debt in the accompanying consolidated financial statements. The relative fair value of the February 2012 Warrants of $859,647 was recorded as debt discount. As a result of the surrender of the February 2012 Notes on June 19, 2012, we expensed the remaining unamortized debt discount. As of December 31, 2012, we recorded amortization of debt discount totaling $859,647 related to the February 2012 Notes.
	Exercised			-0-																					On October 21, 2011, the Company granted a Company Warrant to Daniel A. Cartwright, the Company’s Chief Financial Officer, for 600,000 shares with a fair value of $133,045 for services performed.  The Company Warrant was valued on the date of the grant using a term of 10 years; volatility of 45.94%; risk free rate of 2.23%; and a dividend yield of 0%.  The Company Warrant vests over a 44-month period beginning on November 21, 2011 (or 13,636 shares for months 1-43 and 13,652 shares for month 44).  Of the $133,045 fair value, $7,158 was recorded as non-cash compensation on the accompanying consolidated financial statements.  The remaining $125,887 will be expense to non-cash compensation equitably over the remaining 42 months.
	Expired			-0-									On June 19, 2012, we issued an aggregate of 7,000,000 Warrants in connection with the issuance of secured promissory notes (the “June 2012 Warrants”) (see NOTE 9). Of the 7,000,000 June 2012 Warrants, 6,000,000 are exercisable at $2.00 and 1,000,000 are exercisable at $3.00. The fair value of the June 2012 Warrants of $9,424,982 was determined by using the Black-Scholes Model on the date of the grant. The Warrants were valued on the date of the grant using a term of five years; a volatility of 44.64%; risk free rate of 0.75%; and a dividend yield of 0%. The relative fair value of the June 2012 Warrants of $1,649,890 was determined by using the relative fair value calculation method on the date of the grant. At December 31, 2012, $1,102,680 was reported as debt discount and $547,210 was recorded as amortization of debt discount on the accompanying consolidated financial statements.
	Cancelled			-0-																					Also on October 21, 2011, the Company granted a Company Warrant for 184,211 shares with a fair value of $25,980 to an unrelated entity for consulting services covered under a two (2) month agreement.  The Company Warrant was valued on the date of the grant using a term of five (5) years; volatility of 41.04%; risk free rate of 1.08%; and a dividend yield of 0%.  The $25,980 fair value was recorded as financing expense on the accompanying consolidated financial statements.
	Balance at June 30, 2013			14,293,499		$	1.79			4.8	$	17,985,449	Warrants Issued for Services
	Vested and Exercisable at June 30, 2013			12,149,559		$	1.67			4.3	$	16,540,175													On October 23, 2011, VitaMed entered into a two-year consulting agreement with Lang wherein a Lang representative will help evaluate improvements to existing products and new products as well as services including but not limited to research, design, compliance, scientific and regulatory affairs and commercialization of products.  As compensation, Lang received a Company Warrant for 800,000 shares.  The Company Warrant was valued on the date of the grant using a term of 10 years; a volatility of 45.94%; risk free rate of 2.23%; and a dividend yield of 0%.  The Company Warrant vested immediately.  Of the $177,394 fair value, $17,010 was recorded as non-cash compensation and $160,384 was recorded as prepaid expense on the accompanying consolidated financial statements.
													In March 2012, we issued an aggregate of 31,000 Warrants to five unaffiliated individuals for services rendered. These Warrants were valued on the date of the grant using a term of five years; a volatility of 44.81%; risk free rate of 1.04%; and a dividend yield of 0%; $29,736 was recorded as consulting expense in the accompanying consolidated financial statements.
	As of June 30, 2013, we had warrants outstanding with exercise prices ranging from $0.24 to $3.20 per share. As of June 30, 2013, unamortized costs associated with warrants totaled approximately $3,995,000.																								On December 28, 2011, the Company granted a Company Warrant for 500 shares with a fair value of $338 to an unrelated individual for consulting services covered under a three (3) month agreement.  The Company Warrant was valued on the date of the grant using a term of 10 years; volatility of 51.83%; risk free rate of 0.91%; and a dividend yield of 0%.  The Company Warrant vested immediately.  Of the $338 fair value, $15 was recorded as non-cash compensation and $323 was recorded as prepaid expense on the accompanying consolidated financial statements.
													In May 2012, we issued an aggregate of 1,300,000 Warrants to an unaffiliated entity for services to be rendered over approximately five years beginning in May 2012. Services provided are to include (a) services in support of our drug development efforts including, but not limited to, services in support our ongoing and future drug development and commercialization efforts, regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing and controls efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated therewith; (b) services in support of our efforts to successfully obtain New Drug Approval; and (c) other consulting services as mutually agreed upon from time to time in relation to new drug development opportunities. The Warrants were valued at $1,532,228 on the date of the grant using a term of five years; a volatility of 44.71%; risk free rate of 0.74%; and a dividend yield of 0%. At December 31, 2012 we reported $360,528 as prepaid expense-short term, $953,655 as prepaid expense-long term, and recorded $218,045 as consulting expense in the accompanying consolidated financial statements. The contract will expire upon the commercial manufacture of a drug product. Based on the review, we have determined that the process will take approximately five years. As a result, we are amortizing the $1,532,228 over five years.
	Stock Options																								The weighted average fair value per share of Company Warrants granted and the assumptions used in the Black-Scholes Model during the years ended December 31, 2011 are set forth in the table below.
													In June 2012, we issued an aggregate of 1,500 Warrants to three unaffiliated individuals for services rendered. The Warrants were valued on the date of the grant using a term of five years; a volatility of 44.78%; risk free rate of 0.72%; and a dividend yield of 0%. A total of $1,656 was recorded as consulting expense in the accompanying consolidated financial statements.
	In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or LTIP, to provide financial incentives to our employees, members of our Board, and our advisers and consultants who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the LTIP consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, EVA awards, and other stock or cash awards as described in the LTIP. There are 25,000,000 shares authorized for issuance under the LTIP. Under this LTIP, non-qualified stock options for the purchase of an aggregate of 12,934,725 shares of our common stock were outstanding at June 30, 2013.																										2011
													During the year ended December 31, 2011, we issued the following:												Weighted average fair value		$	0.36
	On February 23, 2012, the Board adopted the 2012 Stock Incentive Plan, a non-qualified plan not requiring approval by our stockholders, or the 2012 SOP.  The 2012 SOP was designed to serve as an incentive for retaining qualified and competent key employees, officers and directors, and certain consultants and advisors.  There are 10,000,000 shares authorized for issuance under the 2012 SOP and non-qualified stock options for the purchase of an aggregate of 1,625,000 shares of our common stock were outstanding at June 30, 2013.																								Risk-free interest rate			0.91-3.48	%
															Number of Shares Under Company Warrants			Exercise Price			Exercise Term in Years		Fair Value		Volatility			39.13-51.83	%
	The valuation methodology used to determine the fair value of the stock options is the Black-Scholes Model.  The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model during the six months ended June 30, 2013 are set forth in the table below.												Loan guarantee			613,713		$	0.24			10	$	93,969	Term (in years)			10-May
													Loan consideration			613,718		$	0.41			5		30,993	Dividend yield			0	%
			Six Months			Year Ended December 31, 2012							Product consulting			1,045,485			$0.38-$0.41			10-May		189,942
			Ended										Services			784,711			$0.38-$1.50			10-May		159,363	The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term.  Estimated volatility is a measure of the amount by which the Company’s stock price is expected to fluctuate each year during the term of the award.  The Company’s estimated volatility is an average of the historical volatility of the stock prices of its peer entities whose stock prices were publicly available.  The Company’s calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards.  The Company used the historical volatility of peer entities due to the lack of sufficient historical data of its stock price during 2001-2011.
			30-Jun-13													3,057,627							$	474,267
	Risk-free interest rate			0.65-1.42	%		0.61-2.23	%																	The Company issued no Common Stock purchase warrants during the year ended December 31, 2010.  A summary of the Company’s Common Stock purchase warrant activity and related information for 2011 follows:
	Volatility			33.35-45.76	%		40.77-46.01	%					In March 2011, VitaMed entered into a Business Loan Agreement and Promissory Note for a $300,000 bank line of credit (the “Bank LOC”) for which the bank required personal guarantees and cash collateral. Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers of VitaMed, and by Reich Family Limited Partnership, an entity controlled by Mitchell Krassan, also an officer of VitaMed. The Bank LOC accrued interest at the rate of 3.020% per annum based on a year of 360 days and was due on March 1, 2012. The bank and VitaMed negotiated a one-year extension to the Bank LOC, which was executed on March 19, 2012 (the “Bank LOC Extension”). The Bank LOC Extension accrues interest at the rate of 2.35% and is due on March 1, 2013. In consideration for the personal guarantees and cash collateral, VitaMed issued VitaMed Warrants for an aggregate of 499,998 Units (or Company Warrants for an aggregate of 613,713 shares pursuant to the Conversion Ratio). The ten-year Company Warrants vest at the rate of an aggregate of 76,714 shares per calendar quarter end and have an exercise price of $0.2444 per share. In the event that the bank loan is repaid prior to being fully vested, the Company Warrants will be reissued only for the number of shares vested through the date of repayment. On November 13, 2012, the then outstanding balance of $299,220 was repaid in full and we and the bank amended the Business Loan Agreement and Promissory Note to reflect a $100,000 bank line of credit (the “Amended Bank LOC”). As part of the Amended Bank LOC, the personal guarantees and cash collateral were removed for Mr. Finizio and Mr. Milligan. In accordance with the terms of the Company Warrants, the Company Warrants previously granted to Mr. Finizio and Mr. Milligan have been amended to reflect the amount vested prior to the date of the Amended Bank LOC (179,000 each). At December 31, 2012, an aggregate of 562,571 Company Warrants were vested.
	Term (in years)			5-6.25			5-6.25																				Number of Shares Under Company Warrant			Weighted Average Exercise Price			Weighted
	Dividend yield			0	%		0	%					The Company Warrants, with a fair value of $93,969 ($86,139 after adjusting for the effect of the Amended Bank LOC), were valued on the date of the grant using a term of 10 years; a volatility of 47.89%; risk free rate of 3.48%; and a dividend yield of 0%. As of December 31, 2012 and 2011, $45,036 and $38,159, respectively, was recorded as loan guaranty costs in other income and expense on the accompanying consolidated financial statements.																				Average		Aggregate
																																	Remaining		Intrinsic Value
	The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected life.  Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards.  We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price.  The average expected life is based on the contractual term of the option using the simplified method.												In June 2011, VitaMed issued Promissory Notes (the “VitaMed Promissory Notes”) in the aggregate of $500,000 with accompanying VitaMed Warrants for an aggregate of 500,000 shares (or Company Warrants for an aggregate of 613,718 shares pursuant to the Conversion Ratio). The VitaMed Warrants were valued on the date of the grant using a term of five years; a range of volatility from 39.13% to 39.15%; risk free rate ranging from 1.38-1.65%; and a dividend yield of 0%. The Company Warrants vested immediately. Although the fair value was $30,993, using the appropriate accounting treatment, $28,719 was recorded as debt discount and fully amortized during 2011 with the amortized amount recorded as interest expense on the accompanying consolidated financial statements.																				Contractual
																																	Life
	On June 28, 2013, an individual exercised his stock option to purchase an aggregate of 61,372 shares of our common stock for an aggregate purchase price of $6,251.												In July 2011, VitaMed entered into a one-year consulting agreement with Lang Naturals, Inc. (“Lang”), providing for Lang to assist in the design, development, and distribution efforts of VitaMed’s initial product offering. As compensation, Lang received a VitaMed Warrant for 200,000 shares (or a Company Warrant for 245,485 shares pursuant to the Conversion Ratio). The VitaMed Warrant was valued on the date of the grant at $12,548 using a term of five years; a volatility of 39.44%; risk free rate of 1.56%; and a dividend yield of 0%. The Company Warrant vested immediately. As of December 31, 2012 and 2011, $6,936 and $5,612, respectively was recorded as non-cash compensation on the accompanying consolidated financial statements.												Balance at December 31, 2010			-0-
																									Granted			3,057,627		$	0.36			8.7	$	3,483,691
	On June 21, 2013, we issued 10-year stock options to employees and consultants for the purchase of an aggregate of 632,500 shares with an exercise price of $2.98.  An aggregate of 232,500 shares available under the stock options vest over a 3-year period on the anniversary of issuance, an aggregate of 100,000 shares vest monthly over an 18 month period, and an aggregate of 300,000 shares vest monthly over a 3-year period.												In October 2011, we (i) issued a Company Warrant for 600,000 shares with a fair value of $133,045 to an officer of the Company for services performed. The Company Warrant was valued on the date of the grant using a term of 10 years; volatility of 45.94%; risk free rate of 2.23%; and a dividend yield of 0%. The Company Warrant vests over a 44-month period beginning on November 21, 2011 (or 13,636 shares for months 1-43 and 13,652 shares for month 44). As of December 31, 2012 and 2011, of the $133,045 fair value, $36,284 and $7,158, respectively, was recorded as non-cash compensation on the accompanying consolidated financial statements. The remaining $89,603 will be expensed to non-cash compensation equitably over the remaining 30 months; (ii) issued a Company Warrant for 184,211 shares with a fair value of $25,980 to an unrelated entity for consulting services covered under a two month agreement. The Company Warrant was valued on the date of the grant using a term of five years; volatility of 41.04%; risk free rate of 1.08%; and a dividend yield of 0%. As of December 31, 2011, the $25,980 fair value was recorded as financing expense on the accompanying consolidated financial statements; and (iii), VitaMed entered into a two-year consulting agreement with Lang providing for a Lang representative to help evaluate improvements to existing products and new products as well as services, including but not limited to, research, design, compliance, scientific and regulatory affairs and commercialization of products.												Exercised			-0-
																									Expired			-0-
	On May 10, 2013, we issued 10-year stock options to employees for the purchase of an aggregate of 100,000 shares with an exercise price of $2.71.  An aggregate of 50,000 shares available under the stock options vest over a 4-year period on the anniversary of issuance and an aggregate of 50,000 shares vested immediately.												As compensation, Lang received a Company Warrant for 800,000 shares. The Company Warrant was valued on the date of the grant using a term of 10 years; a volatility of 45.94%; risk free rate of 2.23%; and a dividend yield of 0%. The Company Warrant vested immediately. Of the $177,394 fair value, $88,696 and $17,010 was recorded as non-cash compensation and $71,688 and $160,384 was recorded as prepaid expense as of December 31, 2012 and 2011, respectively, on the accompanying consolidated financial statements.												Cancelled			-0-
																									Balance at December 31, 2011			3,057,627		$	0.36			8.7	$	3,483,691
On May 6, 2013, we issued a 10-year stock option to a consultant for the purchase of an aggregate of 96,068 shares with an exercise price of $2.96.  The shares available under the stock options vest monthly over a 12-month period.												In December 2011, we issued a Company Warrant for 500 shares with a fair value of $338 to an unrelated individual for consulting services covered under a three month agreement. The Company Warrant was valued on the date of the grant using a term of 10 years; volatility of 51.83%; risk free rate of 0.91%; and a dividend yield of 0%. The Company Warrant vested immediately. As of December 31, 2011, of the $338 fair value, $15 was recorded as non-cash compensation and $323 was recorded as prepaid expense on the accompanying consolidated financial statements.												Vested and Exercisable at December 31, 2011			2,254,758		$	0.37			5.6	$	2,361,339
On May 2, 2013, the Compensation Committee of the Board recommended the granting of stock options to our directors.  The Board approved the recommendation and we issued 10-year stock options for the purchase of an aggregate of 575,000 shares of our common stock with an exercise price of $2.80, as follows: (i) a stock option for the purchase of 225,000 shares of our common stock to the Chairman of the Board; (ii) a stock option for the purchase of 75,000 shares of our common stock to the chair of each committee of the board; and (ii) an Option for the purchase of 50,000 shares of our common stock to each of the remaining directors.  All of these stock options vest on December 31, 2013.												The weighted average fair value per share of Company Warrants granted and the assumptions used in the Black-Scholes Model during the years ended December 31, 2012 and 2011 are set forth in the table below.												Stock Options
On May 8, 2013, Robert Finizio, our Chief Executive Officer, forfeited his contractual right to receive 600,000 shares upon exercise of a stock option granted in connection with his employment agreement as well as his right to receive any future stock options. Mr. Finizio gave up these rights with the understanding that these stock options would be returned to the pool of stock options available for issuance to attract future employees.														2012			2011							In 2009, the Company  adopted the 2009 Long Term Incentive Compensation Plan (the “LTIP”) to provide financial incentives to employees, members of the Board, and advisers and consultants of the Company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives (the “Awards”).  The Awards available under the LTIP consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, EVA awards, and other stock or cash awards as described in the LTIP.  There are 25,000,000 shares authorized for issuance thereunder.  Prior to the Merger, no awards had been issued under the LTIP.
												Weighted average fair value		$	2.05		$	0.16
On March 29, 2013, we issued 10-year stock options to employees and consultants for the purchase of an aggregate of 180,109 shares with exercise prices ranging from $1.70 to $2.70.  An aggregate of 500 shares available under the stock options vest over a 4-year period on the anniversary of issuance, an aggregate of 12,500 shares vest monthly over a 1-year period, 92,109 shares vest monthly over a 13-month period from the date of issuance, and an aggregate of 75,000 shares vest as follows: an aggregate of 31,250 vest immediately and an aggregate of 43,750 vest monthly over the subsequent seven months.												Risk-free interest rate			0.72-1.04%			0.91-3.48%						A summary of activity under the LTIP and related information follows:
												Volatility			44.64-44.81%			39.13-51.83%
On June 29, 2012, we issued 10-year stock options to employees, consultants, and a director for the purchase of an aggregate of 250,000 shares with an exercise price of $2.80.  An aggregate of 7,500 shares available under the stock options vest over a 4-year period on the anniversary of issuance, an aggregate of 115,000 shares vest over a 2-year period on the anniversary of issuance, 2,500 shares vest over a 1-year period on the anniversary of issuance, 75,000 shares vest monthly from December 31, 2012, and 50,000 vest immediately.												Term (in years)			5			10-May								Number of Shares Under Company Option			Weighted Average Exercise Price			Weighted
												Dividend yield			0	%		0	%													Average		Aggregate Intrinsic Value
On April 16, 2012, the Board approved the issuance of 10-year stock options for our directors for the purchase of: (i) an aggregate of 350,000 shares (50,000 shares each) to our directors for services to be rendered during calendar year 2012 and (ii) an aggregate of 75,000 shares (25,000 shares each) to the chairs of the Audit, Compensation and Nominating and Corporate Governance Committees for services to be rendered during calendar year 2012.  The stock options have an exercise price of $2.55 per share vested in full on December 31, 2012.  In addition, Dr. Brian Bernick, a director and employee, was issued a stock option for 150,000 shares for services rendered as an employee, having an exercise price of $2.55, which vested in full on April 16, 2013.																																Remaining
												The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term.																				Contractual
On March 30, 2012, we issued 10-year stock options to employees and consultants for the purchase of an aggregate of 480,000 shares with an exercise price of $2.40.  An aggregate of 405,000 shares available under the stock options vest over a 4-year period on the anniversary of issuance, an aggregate of 60,000 shares vest over a 2-year period on the anniversary of issuance, and 15,000 shares vest monthly over a 12-month period from the date of issuance.																																Life
												Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is an average of the historical volatility of the stock prices of its peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of peer entities due to the lack of sufficient historical data of its stock price during 2001-2012.												Balance at December 31, 2010			-0-
On March 30, 2012, the Board approved a cashless exercise provision for use by holders of stock options.  Also on March 30, 2012, an individual exercised his option to purchase 245,485 shares of our common stock. The aggregate purchase price of approximately $60,000 was paid pursuant to a cashless exercise provision wherein the individual surrendered his right to receive 25,000 shares thereunder.																								Granted (1)			10,682,218		$	0.16			7.6	$	14,188,484
												A summary of our Common Stock purchase warrant activity and related information for the years ended December 31, 2012 and 2011 follows:												Exercised			(92,057	)	$	0.19
On February 27, 2012, we issued stock options to our officers and directors for the purchase of an aggregate of 600,000 shares with an exercise price of $2.20 per share.  The stock options vested in full on February 27, 2013.																								Expired			-0-
														Number of Shares Under Company Warrants			Weighted Average Exercise Price			Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value		Cancelled			-0-
In January 2012, certain individuals exercised their stock options to purchase an aggregate of 1,630,022 shares of our common stock for an aggregate purchase price of $166,000.																								Balance at December 31, 2011			10,590,161		$	0.16			7.6	$	14,067,649
												Balance at December 31, 2010			-0-									Vested and Exercisable at  December 31, 2011			6,581,049		$	0.13			7.5	$	9,038,719
A summary of activity under the LTIP and 2012 SOP and related information follows:												Granted			3,057,627		$	0.36			7.9	$	3,483,691	____________________
												Exercised			-0-									-1	This includes:  (i) VitaMed Options granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units of which 16,000 were canceled prior to conversion (or Company Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and October 3, 2011 for an aggregate of 621,000 Units (or Company Options for 762,235 shares per the Conversion Ratio) and (iii) Company Options granted between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares.  The terms and conditions of the VitaMed Options were reflected in the replacement Company Options including the number of shares vested.
		Number of			Weighted			Weighted		Aggregate		Expired			-0-
		Shares			Average			Average		Intrinsic		Cancelled			-0-									The weighted-average grant date fair value of Company Options granted during the years ended December 31, 2011 and 2010 was $0.19 and $0.09, respectively.
		Under			Exercise			Remaining		Value		Balance at December 31, 2011			3,057,627		$	0.36			7.9	$	3,483,691
		Company			Price			Contractual				Granted			17,332,500		$	1.26			4.3	$	31,891,150	As of December 31, 2011, Company Options outstanding covered an aggregate of 10,590,161 shares with a weighted average contractual life of 7.6 years and exercise prices ranging from $0.10 to $1.22 per share resulting in a weighted average exercise price of $0.16 per share.
		Option						Life in Years				Exercised			(8,145,486	)	$	0.38
Balance at December 31, 2012			13,733,488		$	1.16			7.7	$	26,804,117	Expired			-0-									The valuation methodology used to determine the fair value of Company Options is the Black-Scholes-Merton option-pricing model (“Black-Scholes Model”), an acceptable model in accordance with ASC 718-10.  The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life.
Granted			1,583,677		$	2.79			9.9	$	365,845	Cancelled			(51,142	)	$	0.24
Exercised			(61,372	)								Balance at December 31, 2012			12,193,499		$	1.63			4.8	$	17,971,994	The assumptions used in the Black-Scholes Model during the years ended December 31, 2011 and 2010 and are set forth in the table below.
Expired			-0-									Vested and Exercisable at
Cancelled			(600,000	)								31-Dec-12			11,784,408		$	1.69			4.7	$	16,859,266			2011			2010
Balance at June 30, 2013			14,655,793		$	1.08			7.8	$	26,038,328													Risk-free interest rate			0.91-2.54	%		1.27-3.12	%
Vested and Exercisable at June 30, 2013			9,623,443		$	0.6			6.5	$	23,208,051	Stock Options												Volatility			37.92-40.48	%		36.34-42.46	%
																								Expected life (in years)			5.5-6.25			5-6.25
												In 2009, we adopted the 2009 Long Term Incentive Compensation Plan (the “2009 Plan”) to provide financial incentives to employees, members of the Board, advisers , and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives (the “Awards”). The Awards available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. Prior to the Merger, no awards had been issued under the 2009 Plan. As of December 31, 2012 there were 11,508,488 shares issued under the 2009 Plan.												Dividend yield			0	%		0	%
The weighted-average issue date fair value of stock options issued during the six months ended June 30, 2013 was $1.01.
												On February 23, 2012, our Board of Directors adopted the 2012 Stock Incentive Plan, a non-qualified plan not requiring approval by our stockholders (the “2012 Plan”). The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. There are 10,000,000 shares of our Common Stock authorized for issuance thereunder. As of December 31, 2012 there were 2,225,000 shares issued under the 2012 Plan.												The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected life.  Estimated volatility is a measure of the amount by which the Company’s stock price is expected to fluctuate each year during the term of the award.  The Company’s estimated volatility is an average of the historical volatility of the stock prices of its peer entities whose stock prices were publicly available.  The Company’s calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards.  The Company used the historical volatility of peer entities due to the lack of sufficient historical data of its stock price during 2001-2011.  The average expected life is based on the contractual term of the option using the simplified method.
At June 30, 2013, we had stock options outstanding with exercise prices ranging from $0.10 to $3.40 per share.
												A summary of activity under the 2009 and 2012 Plans and related information follows:												Share-based compensation expense for Company Options recognized in our results for the years ended December 31, 2011 and 2010 ($180,087 and $177,601 respectively) is based on awards vested and we estimated no forfeitures.  ASC 718-10 requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates.
Share-based compensation expense for stock options recognized in our results for the six months ended June 30, 2013 and 2012 ($1,161,770 and $510,987, respectively) is based on awards vested and was estimated without forfeitures.  ASC 718-10, requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates.
														Number of Shares Under Company Options			Weighted Average Exercise Price			Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value		At December 31, 2011 and 2010, total unrecognized estimated compensation expense related to non-vested Company Options granted prior to that date was approximately $244,000 and $206,000, respectively, which is expected to be recognized over a weighted-average period of 3.3 years.  No tax benefit was realized due to a continued pattern of operating losses.
At June 30, 2013, total unrecognized estimated compensation expense related to non-vested stock options issued prior to that date was approximately $3,695,420 which is expected to be recognized over a weighted-average period of 1.49 years. No tax benefit was realized due to a continued pattern of operating losses.
												Balance at December 31, 2010			-0-
												Granted(1)			10,682,218		$	0.16			7.6	$	14,188,484
												Exercised			(92,057	)	$	0.19
												Expired			-0-
												Cancelled			-0-
												Balance at December 31, 2011			10,590,161		$	0.16			7.6	$	14,067,649
												Granted			5,121,250		$	2.8			9.7	$	1,737,530
												Exercised			(1,931,788	)	$	0.13
												Expired			-0-
												Cancelled			(46,135	)
												Balance at December 31, 2012			13,733,488		$	1.16			7.7	$	26,804,117
												Vested and Exercisable at December 31, 2012			8,370,408		$	0.38			6.7	$	22,811,422
												(1) This includes: (i) VitaMed Options granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units of which 16,000 were canceled prior to conversion (or Company Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and October 3, 2011 for an aggregate of 621,000 Units (or Company Options for 762,235 shares per the Conversion Ratio) and (iii) Company Options granted between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options were reflected in the replacement Company Options including the number of shares vested.
												The weighted-average grant date fair value of Company Options granted during the years ended December 31, 2012 and 2011 was $1.16 and $0.16, respectively.
												As of December 31, 2012 and 2011, Company Options outstanding covered an aggregate of 13,733,488 and 10,590,161 shares, respectively, with a weighted average contractual life of 7.7 and 7.6 years, respectively, and exercise prices ranging from $2.20 to $3.40 per share in 2012 and $0.10 to $1.22 per share in 2011 resulting in a weighted average exercise price of $1.16 and $0.16 per share, respectively.
												The valuation methodology used to determine the fair value of Company Options is the Black-Scholes-Merton option-pricing model (“Black-Scholes Model”), an acceptable model in accordance with ASC 718-10. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life.
												The assumptions used in the Black-Scholes Model during the years ended December 31, 2012 and 2011 and are set forth in the table below.
														2012			2011
												Risk-free interest rate			0.61-2.23%			0.91-2.54%
												Volatility			40.77-46.01%			37.92-40.48%
												Expected life (in years)			5-6.25			5.5-6.25
												Dividend yield			0	%		0	%
												The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected life.
												Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is an average of the historical volatility of the stock prices of its peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of peer entities due to the lack of sufficient historical data of its stock price during 2001-2011. The average expected life is based on the contractual term of the option using the simplified method.
												Share-based compensation expense for Company Options recognized in our results for the years ended December 31, 2012 and 2011 ($1,832,062 and $183,355 respectively) is based on awards vested and we estimated no forfeitures. ASC 718-10 requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates.
												At December 31, 2012 and 2011, total unrecognized estimated compensation expense related to non-vested Company Options granted prior to that date was approximately $4,391,000 and $244,000, respectively, which is expected to be recognized over a weighted-average period of 1.8 years. No tax benefit was realized due to a continued pattern of operating losses.

INCOME_TAXES

INCOME TAXES	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012							Dec. 31, 2011
Income Taxes
INCOME TAXES	NOTE 10 – INCOME TAXES	NOTE 11– INCOME TAXES							NOTE E – INCOME TAXES
	Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2013 as a result of (i) the losses recorded during the six months ended June 30, 2013, (ii) additional losses expected for the remainder of 2013, and/or (iii) net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not" that some component or all of the benefits of deferred tax assets will not be realized. As of June 30, 2013, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.	With the advent of the Merger, we determined that VitaMed would become the sole focus of our company and previous business performed by our predecessor was discontinued. Because of these events, deferred income taxes are determined by calculating the loss from operations of our company starting October 4, 2011. Deferred income taxes are determined using the liability method for the temporary differences between the financial reporting basis and income tax basis of our assets and liabilities. Deferred income taxes are measured based on the tax rates expected to be in effect when the temporary differences are included in our tax return. Deferred tax assets and liabilities are recognized based on anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases. For the years December 31, 2012 and 2011, there was no provision for income taxes, current or deferred.							With the advent of the Merger, Company management determined that VitaMed would become the sole focus of the Company and previous business performed by Therapeutics was discontinued.  Because of these events, deferred income taxes are determined by calculating the loss from operations of the Company from October 4, 2011 to December 31, 2011.  Deferred income taxes are determined using the liability method for the temporary differences between the financial reporting basis and income tax basis of the Company’s assets and liabilities.  Deferred income taxes are measured based on the tax rates expected to be in effect when the temporary differences are included in the Company’s tax return.  Deferred tax assets and liabilities are recognized based on anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases.  As of December 31, 2011, there is no provision for income taxes, current or deferred.
		At December 31, 2012 and 2011, we had a net operating loss carry forward of approximately $14,900,000 and $2,100,000 million, respectively, available to offset future taxable income through 2032.							At December 31, 2011, the Company had a net operating loss carry forward of approximately $2.1 million, available to offset future taxable income through 2031.  The Company established valuation allowances equal to the full amount of the deferred tax assets due to the uncertainty of the utilization of the operating losses in future periods.  The Company periodically assesses the likelihood that it will be able to recover its deferred tax assets.  The Company considers all available evidence, both positive and negative, including historical levels of income, expectations and risks associated with estimates of future taxable income.
		At December 31, 2012 and 2011, we had state net operating loss carryforwards of approximately $12,800,000 and $25,000, respectively, available to offset future losses through 2032. We established valuation allowances equal to the full amount of the deferred tax assets because of the uncertainty of the utilization of the operating losses in future periods. We periodically assess the likelihood that we will be able to recover the deferred tax assets. We consider all available evidence, both positive and negative, including historical levels of income, expectations and risks associated with estimates of future taxable income.							At December 31, 2011, the differences between the actual income tax benefit and the amount computed by applying the statutory federal tax rate (35%) to the loss before taxes are as follows:
		Our deferred tax asset and liability as presented in financial statements consist of the following:
			2012			2011			Expected income tax benefit at statutory rate	$	(4,519,678	)
		Deferred Income Tax Assets:							Non-deductible expenses:
		Net operating losses	$	5,920,861		$	748,404		Debt settlement		2,586,500
		Valuation allowance		(5,920,861	)		(748,404	)	VitaMed pre-merger loss		1,164,629
		Deferred Income Tax Assets, net	$	-0-		$	-0-		Other non-deductible expenses		22,912
									Change in valuation account		745,637
		Our provision for income taxes differs from applying the statutory U.S. federal income tax rate to the income before income taxes. The primary differences result from deducting certain expenses for financial statement purposes but for federal income tax purposes.							Income tax expense (benefit)	$	-0-
		A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:
			2012			2011
		Federal statutory tax rate		35	%		35	%
		State tax rate, net of federal tax benefit		5.5	%		-0-	%
		Adjustment in valuation allowances		(18.2	)%		(5.8	)%
		Permanent and other differences		(22.3	)%		(29.2	)%
		Provision (Benefit) for Income Taxes		-0-	%		-0-	%

RELATED_PARTIES

RELATED PARTIES	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Related Parties
RELATED PARTIES	NOTE 11 – RELATED PARTIES	NOTE 12 – RELATED PARTIES	NOTE K – RELATED PARTIES
	Loan Guaranty	Loan Guaranty	Loan Guaranty
	In March 2011, VitaMed entered into a Business Loan Agreement and Promissory Note for a $300,000 bank line of credit, or the Bank LOC, for which the bank required personal guarantees and cash collateral. Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers of VitaMed, and by Reich Family LP, an entity controlled by Mitchell Krassan, also an officer of VitaMed.  The Bank LOC accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012.  On March 19, 2012, the bank and VitaMed negotiated a one year extension to the Bank LOC and a subsequent 2-month extension until May 1, 2013.	In March 2011, VitaMed entered into a Business Loan Agreement and Promissory Note for a $300,000 bank line of credit (the “Bank LOC”) for which the bank required personal guarantees and cash collateral. Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers of VitaMed, and by Reich Family Limited Partnership, an entity controlled by Mitchell Krassan, also an officer of VitaMed. The Bank LOC accrued interest at the rate of 3.020% per annum based on a year of 360 days and was due on March 1, 2012. The bank and VitaMed negotiated a one year extension to the Bank LOC which was executed on March 19, 2012 (the “Bank LOC Extension”).	On March 7, 2011, VitaMed entered into a Business Loan Agreement and Promissory Note  for a $300,000 bank line of credit (the “Bank LOC”) for which the bank required a personal guarantee and cash collateral.  Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers of VitaMed, and by Reich Family Limited Partnership, an entity controlled by Mitchell Krassan, also an officer of VitaMed.  The Bank LOC accrued interest at the rate of 3.020% per annum based on a year of 360 days and was due on March 1, 2012.  The bank and VitaMed negotiated a one-year extension to the Bank LOC which was executed on March 19, 2012 (the “Bank LOC Extension”).  The Bank LOC Extension accrues interest at the rate of 2.35% and is due on March 1, 2013.  In consideration for the personal guarantees and cash collateral, VitaMed issued VitaMed Warrants for an aggregate of 499,998 Units (or Company Warrants for an aggregate of 613,713 shares pursuant to the Conversion Ratio).  The ten-year Warrants vest at the rate of an aggregate of 76,714 shares per calendar quarter end and have an exercise price of $0.2444 per share.  In the event that the bank loan is repaid prior to being fully vested, the Company Warrants will be reissued only for the number of shares vested through the date of repayment.  At March 31, 2012, an aggregate of 306,867 shares will be vested thereunder.
	In consideration for the personal guarantees and cash collateral, we issued warrants for an aggregate of 613,713 shares.  On November 13, 2012, we entered into an amendment with the bank to reduce the Bank LOC to $100,000, or the Amended Bank LOC. As part of the Amended Bank LOC, the personal guarantees and cash collateral for Mr. Finizio and Mr. Milligan were released.  In accordance with the terms of the warrants, the warrants previously granted to Mr. Finizio and Mr. Milligan were amended to reflect the amount vested prior to the date of the Amended Bank LOC (179,000 each).  At June 30, 2013, an aggregate of 562,571 warrants related to this loan guaranty were vested.	The Bank LOC Extension accrues interest at the rate of 2.35% and is due on March 1, 2013. In consideration for the personal guarantees and cash collateral, VitaMed issued VitaMed Warrants for an aggregate of 499,998 Units (or Company Warrants for an aggregate of 613,713 shares pursuant to the Conversion Ratio). The Company Warrants vest at the rate of an aggregate of 76,714 shares per calendar quarter end and have an exercise price of $0.2444 per share. In the event that the bank loan is repaid prior to being fully vested, the Company Warrants will be reissued only for the number of shares vested through the date of repayment. On November 13, 2012, the then outstanding balance of $299,220 was repaid in full and the Company and the bank amended the Business Loan Agreement and Promissory Note to reflect a $100,000 bank line of credit (the “Amended Bank LOC”). As part of the Amended Bank LOC, the personal guarantees and cash collateral were removed for Mr. Finizio and Mr. Milligan. In accordance with the terms of the Company Warrants, the Company Warrants previously granted to Mr. Finizio and Mr. Milligan have been amended to reflect the amount vested prior to the date of the Amended Bank LOC (179,000 each). At December 31, 2012, an aggregate of 562,571 Company Warrants were vested.	Loans from Affiliates
	In February 2013, we borrowed $100,000 under the Amended Bank LOC.  The Amended Bank LOC required a personal guarantee and cash collateral limited to $100,000 which was provided by Reich Family LP.   On April 25, 2013, we paid the principal and interest due under the Amended Bank LOC of $100,735. On May 1, 2013, the Amended Bank LOC expired and was not renewed. Accordingly, the personal guarantee was canceled and the cash collateral was returned to Reich Family LP	Loans from Affiliates	The VitaMed Promissory Notes for an aggregate of $500,000 (see NOTE I -- NOTES PAYABLE) included an aggregate of $200,000 being issued to certain officers and directors of the Company.  John Milligan, President and Director, and Dr. Brian Bernick, Director, were issued VitaMed Promissory Notes for $50,000 each.  Reich Family LP, an entity controlled by Mitchell Krassan, Executive Vice President, and Fourth Generation Equity Partners, LLC (“Fourth Generation”), an entity controlled by Nick Segal, a director of VitaMed at the time of the issuance, were  issued VitaMed Promissory Notes for $50,000 each.  The VitaMed Promissory Notes bear interest at the rate of four percent (4%) per annum.  On October 6, 2011, (i) principal and interest of approximately $50,696 under the Note to Reich Family LP was repaid, (ii) principal and interest of approximately $50,696 under the Note to Fourth Generation was converted into 133,411 shares of the Company’s Common Stock at $0.38 per share, and (iii) the due date for the VitaMed Promissory Notes to Mr. Milligan and Dr. Bernick was extended to March 1, 2012.  As mentioned hereinafter in FOOTNOTE O – SUBSEQUENT EVENTS, the VitaMed Promissory Notes to Mr. Milligan and Dr. Bernick were further extended by mutual agreement to April 14, 2012.
	Lock-Up Agreements	In June 2011, VitaMed issued Promissory Notes (the “VitaMed Promissory Notes”) in the aggregate principal amount of $500,000 of which $100,000 was sold to affiliates (the “Affiliate Notes”). In June 2012, the Affiliate Notes were extended to October 15, 2012 (one held by Mr. Milligan for $50,000 and one for $50,000 held by BF Investments, LLC (owned by Brian Bernick, a member of the board of directors of our company). On October 4, 2012 these VitaMed Promissory Notes were paid in full including $5,341 in accrued interest.	The 4% Promissory Notes issued in the aggregate of $100,000 (see NOTE I -- NOTES PAYABLE) included one issued to Robert Finizio, Chief Executive Officer and Director, and one issued to John Milligan, President and Director, in the amount of $50,000 each.
	As required by the terms of the merger agreement with VitaMed dated July 18, 2011, the Company entered into Lock-Up Agreements, or the Agreements, with stockholders covering the aggregate of 70,000,000 shares of our common stock issued pursuant to this merger or reserved for issuance pursuant to stock options and warrants. Each stockholder agreed that from the date of the Agreements until 18 months thereafter, or the Lock-Up Period, they would not make or cause any sale of our common stock.  After the completion of the Lock-Up Period, each stockholder agreed not to sell or dispose of more than 2.5% of their aggregate common stock or shares reserved for issuance under stock options and warrants per quarter over the following 12-month period, or the Dribble Out Period.  Upon the completion of the Dribble Out Period, the Agreements shall terminate.	In December 2011, we issued 4% promissory notes to Mr. Finizio and Mr. Milligan and for an aggregate of $100,000 ($50,000 each) with original due dates of March 1, 2012. These promissory notes were extended by mutual agreement to June 1, 2012. In June 2012, the VitaMed Promissory Note held by Mr. Finizio was paid in full, including $888 in accrued interest. Mr. Milligan’s VitaMed Promissory Note was extended to October 15, 2012. On October 4, 2012 this VitaMed Promissory Notes was paid in full including $1,519 in accrued interest.	Lock Up Agreements
	Purchases by Related Parties	Lock Up Agreements	As required by of the Merger Agreement, a Lock Up Agreement (“Agreement”) was entered into between the Company and security holders covering the aggregate of 70,000,000 shares of the Company’s Common Stock issued pursuant to the Merger or reserved for issuance pursuant to Company Options and Company Warrants.  Each security holder agreed that from the date of the Agreement until eighteen (18) months thereafter (the “Lock-Up Period”), they would not make or cause any sale of the Company’s securities.  After the completion of the Lock-Up Period, the security holder agreed not to sell or dispose of more than 2.5 percent (2.5%) of the aggregate Common Stock or shares reserved for issuance for Company Options and Company Warrants per quarter over the following twelve (12) month period (the “Dribble Out Period”).  Upon the completion of the Dribble Out Period, the Agreements shall terminate.
	During the six months ended June 30, 2013 and 2012, we sold our products to Dr. Brian Bernick, our Chief Medical Officer and director, in the amounts of $0 and $1,440, respectively, while $0 and $1,272 in receivables related thereto remained outstanding at both June 30, 2013 and December 31, 2012, respectively.	As required by of the Merger Agreement, a Lock Up Agreement (“Agreement”) was entered into between us and security holders covering the aggregate of 70,000,000 shares of our Common Stock issued pursuant to the Merger or reserved for issuance pursuant to Company Options and Company Warrants. Each security holder agreed that from the date of the Agreement until 18 months thereafter (the “Lock-Up Period”), they would not make or cause any sale of our securities. After the completion of the Lock-Up Period, the security holder agreed not to sell or dispose of more than 2.5% of the aggregate Common Stock or shares reserved for issuance for Company Options and Company Warrants per quarter over the following 12 month period (the “Dribble Out Period”). Upon the completion of the Dribble Out Period, the Agreements shall terminate.	Sales to Related Parties
	Agreements with Pernix Therapeutics, LLC	Purchases by Related Parties	During 2011 and 2010, the Company sold its products to Dr. Brian Bernick, a director of the Company, in the amounts of $20,669 and $25,269, respectively.  At December 31, 2011 and 2010, $0 and $79, respectively, remained outstanding.
	On February 29, 2012, Cooper C. Collins, President and largest stockholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on the Board.  The Company entered into a Stock Purchase Agreement with Pernix on October 4, 2011.  From time to time, we have entered into agreements with Pernix in the normal course of business primarily for the purchase of inventory.  During the six months ended June 30, 2013 and 2012, we made purchases of approximately $0 and $96,250, respectively, from Pernix.  At June 30, 2013 and December 31, 2012, there were outstanding amounts due to Pernix of approximately $0 and $308,000, respectively.	During 2012 and 2011, we sold our products to Dr. Brian Bernick, a director of our company, in the amounts of $2,632 and $20,669, respectively, while $1,272 and $0 of receivables related thereto remained outstanding at December 31, 2012 and 2011, respectively.	Agreements with Pernix Therapeutics, LLC
	Additionally, there were amounts due to us from Pernix for legal fee reimbursement in regards to the Aceto litigation described below in the amounts of $171,261 and $0 for the periods ending June 30, 2013 and December 31, 2012, respectively.	Agreements with Pernix Therapeutics, LLC	As previously mentioned the Company closed a Stock Purchase Agreement with Pernix on October 4, 2011.  From time to time, the Company has, and will continue to, enter into agreements with Pernix in the normal course of business, which agreements are, and will be negotiated in, arms-length transactions.  The President and largest shareholder of Pernix, Cooper C. Collins, was recently elected to serve on the Company’s Board of Directors.
		On February 29, 2012, Cooper C. Collins, President and largest shareholder of Pernix Therapeutics, LLC (“Pernix”), was elected to serve on our Board of Directors.  We closed a Stock Purchase Agreement with Pernix on October 5, 2011.  From time to time, we have entered and will continue to enter into agreements with Pernix in the normal course of business.  All such agreements are reviewed by independent directors or a committee consisting of independent directors.  During the years ended December 31, 2012 and 2011, we made purchases of approximately $404,000 and $19,000, respectively, from Pernix.  At December 31, 2012 and 2011, there were amounts due Pernix of approximately $308,000 and 19,000 outstanding, respectively.
		Warrants assigned to Related Party
		In June 2012, a 100,000 Company Warrant was assigned to the son of Chairman of our Board of Directors by a non-affiliated third party.

BUSINESS_CONCENTRATIONS

BUSINESS CONCENTRATIONS	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Business Concentrations
BUSINESS CONCENTRATIONS	NOTE 12 - BUSINESS CONCENTRATIONS	NOTE 13 - BUSINESS CONCENTRATIONS	NOTE L - BUSINESS CONCENTRATIONS
	We purchase our products from several suppliers with approximately 98% and 87% of our purchases were supplied from one vendor for the six months ended June 30, 2013 and 2012, respectively.	We purchase our products from several suppliers, with approximately 76% and 95% of our purchases from one supplier for the years ended December 31, 2012 and 2011, respectively.	The Company purchases its products from several suppliers with approximately 95% and 93% coming from one supplier for the years ended December 31, 2011 and 2010, respectively.
	We sell our prescription dietary supplement products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. Revenue generated from sales to two customers, Cardinal Health, Inc. and McKesson Corporation accounted for 62% and 36% of our recognized revenue for the six months ended June 30, 2013 and 2012, respectively.	We sell our prescription dietary supplement products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. For the year ended December 31, 2012, 28% of our recognized revenue and 98% of our deferred revenue was generated from sales to only three customers: AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation. We did not sell to these customers in prior years.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments And Contingencies
COMMITMENTS AND CONTINGENCIES	NOTE 13 – COMMITMENTS AND CONTINGENCIES	NOTE 14– COMMITMENTS AND CONTINGENCIES	NOTE M – COMMITMENTS AND CONTINGENCIES
	Office Lease	Operating Lease	The Company leases administrative and distribution facilities in Boca Raton, Florida pursuant to a forty-five month non-cancelable operating lease expiring in 2013.  The lease stipulates, among other things, base monthly rents of $5,443 plus the Company’s share of monthly estimated operating expenses of $3,500 and sales tax.  The lease contains one renewal option for an additional two-year period.
	We lease administrative office space in Boca Raton, Florida pursuant to a 63 month non-cancelable operating lease commencing on July 1, 2013 and expiring on September 30, 2018.  The lease stipulates, among other things, average base monthly rents of $28,442 (inclusive of estimated operating expenses) and sales tax, for a total future minimum payments over the life of the lease of $1,791,900.	We lease administrative and distribution facilities in Boca Raton, Florida pursuant to a 45 month non-cancelable operating lease expiring in 2013. The lease stipulates, among other things, base monthly rents ranging from $5,443 to $5,933 over the term of the lease plus our share of monthly estimated operating expenses of $3,500 and sales tax. The lease expires May 31, 2013 and we believe we will be able to extend the lease in a manner adequate to meet our current needs.	The rental expense related to this lease totaled $106,315 and $116,175 for the years ended December 31, 2011 and 2010.
	The rental expense related to our prior lease which expired June 30, 2013 totaled $60,168 and $56,918 for the six months ended June 30, 2013 and 2012, respectively.	The rental expense related to this lease totaled $106,315 and $122,752 for the years ended December 31, 2012 and 2011, respectively. Future minimum rental payments through May 31, 2013 total $29,667.	As of December 31, 2011, future minimum rental payments are as follows:
	Litigation	Employment Agreements	Years Ending December 31,
			2012	$	111,725
	We are party to various legal actions arising in the ordinary course of business, including actions related to our intellectual property. While it is not feasible to determine the actual outcome of these actions at this time, we do not believe that these matters, including those described below, will have a material adverse effect on our consolidated financial condition, results of operations, or cash flows.	On November 8, 2012, the Compensation Committee of our Board of Directors recommended that the Board of Directors approve employment agreements with our executive officers, namely: Chief Executive Officer (Robert G. Finizio), President (John C.K. Milligan, IV) and Chief Financial Officer (Daniel A. Cartwright) (each an “Executive; together the “Executives”). Our Board of Directors approved the Employment Agreements with an effective date of November 8, 2012. With the exception of compensation, the three-year employment agreements are substantially the same with the Executives receiving employee benefits, vacation and other perquisites as may be determined from time to time and an automatic renewal option for one additional year. Conditions of termination for all employment agreements call for (i) termination immediately upon death, (ii) termination upon a disability in which the Executive is unable to perform his duties for more than 180 total calendar days during any 12-month period, (iii) voluntary termination by the Executive upon a 14 calendar day prior notice, (iv) involuntary termination by our company without cause with 60-day notice or 90-day notice when termination is due to the non-extension of the employment term by our company, (v) termination for cause and (vi) termination for good reason wherein the Executive shall have 90 days from the date of notice to terminate his employment. In addition, if we are subject to a change in control, the Executive shall be entitled to receive severance benefits as outlined therein. The employment agreements contain standard provisions for confidentiality and noncompetition.	2013		56,601
			2014		-0-
	Aceto Corporation	Compensation for services rendered by Robert G. Finizio as Chief Executive Officer calls for: (i) a time-based ten-year stock option (the “Time-Based Option”) granted and issued on November 30, 2012 (“Date of Grant”) to purchase 900,000 shares of our Common Stock with the exercise price equal to the closing price of our Common Stock on the Date of Grant with the underlying shares vesting annually over three years on the anniversary of the employment date, (ii) the right to receive a performance-based ten-year stock option (the “Performance-Based Option”) in an amount to be determined, (iii) a base salary of not less than $355,100 per year and (iv) an annual short-term incentive compensation bonus of up to 35% of the base salary, at the discretion of our Board of Directors.	2015		-0-
			Thereafter		-0-
	On November 13, 2012, Aceto Corporation filed a lawsuit against TherapeuticsMD and Boca-Green in the United States District Court for the Southern District of Florida seeking to enjoin us from using the Quatrefolic product and trademarks, among other things. On July, 17, 2013, the Court dismissed Aceto Corporation’s Complaint with leave to file an Amended Complaint on or before August 5, 2013. Based on our assessment of the case which is in the discovery stage, we believe that the case is without merit and, as a result, should not have a material adverse effect on our consolidated financial condition, results of operations, or cash flows.	Compensation for services rendered by John C.K. Milligan, IV as President calls for: (i) a Time-Based Option granted and issued on the Date of Grant to purchase 800,000 shares of our Common Stock with the exercise price equal to the closing price of our Common Stock on the Date of Grant with the underlying shares vesting annually over three years on the anniversary of the employment date, (ii) the right to receive a Performance-Based Option in an amount to be determined, (iii) a base salary of not less than $288,100 per year and (iv) an annual short-term incentive compensation bonus of up to 30% of the base salary, at the discretion of our Board of Directors.	Total	$	168,326
	Avion Pharmaceuticals, LLC	Compensation for services rendered by Daniel A. Cartwright as Chief Financial Officer calls for: (i) a Time-Based Option granted and issued on the Date of Grant to purchase 700,000 shares of our Common Stock with the exercise price equal to the closing price of our Common Stock on the Date of Grant with the underlying shares vesting annually over three years on the anniversary of the employment date, (ii) the right to receive a Performance-Based Option in an amount to be determined, (iii) a base salary of not less than $257,100 per year and (iv) an annual short-term incentive compensation bonus of up to 30% of the base salary, at the discretion of our Board of Directors.	In December 2011, the Company paid approximately $245,000 to a non-affiliated third party for fees related to research and development of new products.  The Company believes that it could incur additional related fees up to $950,000 in 2012.
	On November 30, 2012, Avion Pharmaceuticals, LLC, filed a lawsuit against TherapeuticsMD and Boca- Green in the United States District Court for the Northern District of Georgia seeking to enjoin us from using the Prena1 name, among other things. Based on our assessment of the case which is in the discovery stage, we believe that the case is without merit and, as a result, should not have a material adverse effect on our consolidated financial condition, results of operations, or cash flows.	The employment agreements provide that as soon as reasonably practicable, we shall file a Form S-8 registration statement, subsequent to any S-1 or S-3 registration statement, to register the issuance of shares under the Time-Based Options.
	For additional information on these litigation matters, see our Annual Report on Form 10-K for the year ended December 31, 2012.	In addition, should we experience a change in control, the executives are entitled to receive severance benefits in conjunction with a qualifying termination or Change in Control (“CIC”) Severance Benefits. A qualifying termination includes the occurrence of any one or more of the following events on or after the date of the announcement of a transaction which would lead to a change in control and up to 12 months following the date of the change of control shall trigger the payment of CIC Severance Benefits: (a) an involuntary termination of the Executive’s employment by us for reasons other than cause, death or disability, and (b) the voluntary termination by the Executive for Good Reason as evidenced by a Notice of Termination delivered to the us by the Executive. CIC Severance Benefits include (i) an amount equal to 1.0 to 1.5 times the Executive’s annual Base Salary established for the fiscal year in which the termination occurs, (ii) an amount equal to 1,0 to 1.5 times the Executive’s Targeted Annual Bonus Award established for the fiscal year in which the termination occurs, (iii) an amount equal to the Executive’s unpaid Base Salary and accrued but unused vacation pay through the date of termination, (iv) all outstanding long-term incentive awards shall accelerate and become fully vested, (v) a continuation of the welfare benefits of health care, life and accidental death and dismemberment, and disability insurance coverage for 1.0 to 1.5 years after the termination. The payment of the CIC Severance Benefits mentioned herein shall be paid in cash to the Executive in a single lump sum within sixty (60) days of termination.
		Litigation
		We are party to various legal actions arising in the ordinary course of business, including actions related to our intellectual property. While it is not feasible to determine the actual outcome of these actions at this time, we do not believe that these matters, including those described below, will have a material adverse effect on our consolidated financial condition, results of operations, or cash flows.
		Aceto Corporation
		On November 13, 2012, Aceto Corporation filed a lawsuit against our company in the United States District Court for the Southern District of Florida. The lawsuit alleges, among other things, that we are improperly obtaining and using the Quatrefolic product and related trademarks that we have acquired pursuant to an allegedly invalid sublicense with Pernix Therapeutics, LLC, a subsidiary of Pernix Therapeutics Holdings, Inc., or Pernix. Cooper C. Collins, a member of our Board of Directors, is the President, Chief Executive Officer, and a director of Pernix. The lawsuit seeks to enjoin us from using the Quatrefolic products and trademarks, in addition to unspecified actual and punitive damages. We filed a motion to dismiss on January 2, 2013, as amended on February 27, 2013. Based on our initial assessment of the case which is in the pre-discovery stage, we believe that the case is without merit and, as a result, should not have a material adverse effect on our consolidated financial condition, results of operations, or cash flows.
		Avion Pharmaceuticals, LLC
		On November 30, 2012, Avion Pharmaceuticals, LLC (‘Avion”), filed a lawsuit against our company in the United States District Court for the Northern District of Georgia. The lawsuit alleges, among other things, unfair competition and trademark infringement against Avion’s “Prenate” trademarks based on the use of our Prena1 branded products which we launched in November 2012. The lawsuit seeks to enjoin us from using the Prena1 name, in addition to unspecified actual and punitive damages. We filed an answer and counterclaim on January 17, 2013, as amended on February 27, 2013. Based on our initial assessment of the case which is in the early discovery stage, we believe that the case is without merit and, as a result, should not have a material adverse effect on our consolidated financial condition, results of operations, or cash flows.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 15 – SUBSEQUENT EVENTS	NOTE O – SUBSEQUENT EVENTS
	Revolving Credit Note	Formation of New Subsidiary
	On January 31, 2013, we issued a Multiple Advance Revolving Credit Note (the “Note”) to Plato and Associates, LLC, a Missouri limited liability company (“Plato”). The Note allows us to draw down funding up to the $10 million maximum principal amount, at a stated interest rate of 6% per annum (the “Stated Interest Rate”). Plato may make advances to us from time to time under the Note at our request, which advances will be of a revolving nature and may be made, repaid, and made from time to time. Interest payments shall be due and payable on the tenth day following the end of each calendar quarter in which any interest is accrued and unpaid, commencing on April 10, 2013, and the principal balance outstanding under the Note, together with all accrued interest and other amounts payable under the Note, if any, will be due and payable on February 24, 2014. The default interest rate under the Note will be a per annum rate equal to the Stated Interest Rate plus eight percentage points (the “Default Interest Rate”), and the principal amount outstanding under the Note shall bear interest at the Default Interest Rate upon the occurrence of an event of default as specified in the Note, including, our nonpayment of amounts due under the Note or our failure to comply with any provision of the Note, among others.	On January 10, 2012, the Company formed a new wholly owned subsidiary, BocagreenMD, Inc., a Nevada corporation, for the purpose of selling certain of its products to select markets.
	As additional consideration for the Note, we issued Plato a warrant to purchase 1,250,000 shares of our Common Stock at an exercise price $3.20 per share (the “Warrant”). The Warrant will vest and become exercisable on October 31, 2013 and may be exercised any time after that date prior to the January 31, 2019 expiration date of the Warrant. These Warrants, with a fair value of approximately $1.7 million, were valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%. As of March 7, 2013 we had drawn $200,000 from this Note.	Issuance of Promissory Notes
	March 2013 Prospectus Supplement	Between January 2012 and February 10, 2012, the Company issued Promissory Notes for an aggregate of $700,000 (the “Notes”).  The Notes bore interest at a rate of six (6%) per annum and were due on March 1, 2012.  The Notes were repaid on February 24, 2012 through the issuance of Secured Promissory Notes as outlined below.
	On March 7, 2013 we filed a Prospectus Supplement for an underwritten public offering of our common stock with anticipated gross proceeds of $50 million. The securities being offered by us are pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the “SEC”) on January 25, 2013, which the SEC declared effective on February 5, 2013. We intend to use the proceeds of the offering for general corporate purposes, including funding our Phase 3 clinical trials for our proposed hormone therapy products. Jefferies LLC is acting as sole book-running manager for the offering, and Noble Financial Capital Markets is acting as co-manager for the offering.	Issuance of Secured Promissory Notes
		On February 24, 2012, TherapeuticsMD, Inc. (the “Company”) sold and issued Secured Promissory Notes (the “Notes”) to Steven G. Johnson (“Johnson”) and Plato & Associates, LLC (“Plato”) in the principal base amount of $1,358,014 and $1,357,110 respectively (the “Principal Base Amount(s)”) pursuant to the terms of that certain Note Purchase Agreement (the “Note Purchase Agreement”) of even date therewith.  As consideration for the Notes, Johnson and Plato surrendered certain promissory notes  previously issued by the Company in the aggregate amount of $858,014 and $857,110 respectively (which sums include principle and interest through February 24, 2011) (collectively known as the “Prior Notes”).  As a result of the foregoing the Company received an aggregate of $1,000,000 of new funding from Johnson and Plato.  On March 23, 2012, each of Johnson and Plato loaned the Company an additional $500,000 under the Notes for an aggregate of $1,000,000.
		The Principal Base Amount of each Note, plus any and all additional advances made to the Company thereafter (the “Aggregated Principal Amount”), together with accrued interest at the annual rate of six percent (6%), is due in one lump sum payment twenty-four (24) months from the date of issuance of the Notes (the “Maturity Date”).  As security for the Company’s obligations under the Note Purchase Agreement and the Notes, the Company entered into a Security Agreement of even date therewith and pledged all of its assets, tangible and intangible, as further described therein.
		As an inducement for the Purchasers to lend additional funds to the Company as outlined therein on Schedule I to the Note Purchase Agreement, and for the Purchaser’s leniency to, in essence, extend the maturity date of the Prior Notes for an additional twenty-four month period, the Purchasers, and/or assigns, received Company Warrant(s) to purchase an aggregate of 9,000,000 Shares.  The Company Warrant(s) shall terminate on the date that is five (5) years from the date of the issuance of the Notes and shall have an exercise price of $0.38 per share.  The Company is currently evaluating and quantifying the affect of the issuance of the Company Warrants on its financial statements.
		Extension and/or Payment of Promissory Notes
		As previously mentioned herein, on June 1, 2011, VitaMed Promissory Notes in the aggregate of $500,000.  The due date for three of the VitaMed Promissory Notes in the aggregate of $150,000 had previously been extended to March 1, 2012.  Two of the VitaMed Promissory Notes were further extended to April 14, 2012 and the other was further extended to June 1, 2012.
		In November and December, 2011, the Company sold six-percent Promissory Notes for an aggregate of $800,000 with due dates of March 1, 2012.  As mentioned hereinabove, these Notes were paid in full on February 24, 2011 through the issuance of Secured Promissory Notes to Johnson and Plato.
		In December 2011, the Company sold four-percent Promissory Notes for an aggregate of $100,000 with due dates of March 1, 2012.  These Notes were further extended by mutual agreement to April 14, 2012.
		As previously mentioned herein, the Bank LOC in the principle amount of $300,000 was extended until March 1, 2013.
		Approval of 2012 Stock Incentive Plan
		On February 23, 2012, the Company’s Board of Directors adopted the 2012 Stock Incentive Plan, a non-qualified plan not requiring approval by the Company’s shareholders (“2012 SOP”).  There are 10,000,000 shares authorized for issuance thereunder.  No shares have been issued under the 2012 SOP.
		Election of Additional Directors
		On February 29, 2012, the Company’s Board of Directors elected four additional individuals to serve as members of its Board of Directors, including: Samuel A. Greco, Cooper Collins, Robert V. LaPenta, Jr. and Nicholas Segal.
		Issuance of Company Options
		On February 27, 2012, the Company issued Company Options to Robert G. Finizio and John Milligan, officers and directors of the Company.  The ten-year Company Options are for 300,000 shares each and have an exercise price of $2.20 per share.  The Company Options vest in full on February 27, 2013.
		Approval of Committee Charters and Committee Appointments
		On February 29, 2012, the Company’s Board of Directors (i) approved charters for each of the Audit Committee, Compensation Committee and Corporate Governance Committee, (ii) appointed members to each committee and (iii) named a Chair of each committee.
		Members of the Audit Committee include Robert V. LaPenta, Jr., Samuel A. Greco and Nicholas Segal.  Mr. LaPenta, Jr. will serve as Chair.
		Members of the Compensation Committee include Cooper Collins, Robert G. Finizio and Nicholas Segal.  Mr. Collins will serve as Chair.
		Members of the Corporate Governance Committee include John C.K. Milligan, IV, Brian Bernick and Robert LaPenta, Jr.  Mr. Milligan will serve as Chair.
		Release of First Prescription Product
		On March 1, 2012, the Company launched its first prescription prenatal vitamin, vitaMedMD™ Plus Rx, a single-dose product containing one prenatal vitamin tablet and one life’s DHA™ capsule.
		Cancelation of Options
		Between January 1, 2012 and March 24, 2011, Company Options for an aggregate of 5,000 shares were canceled due to expiration of the Company Option or termination of the employee.

RESTATEMENT_OF_2010_AUDITED_FI

RESTATEMENT OF 2010 AUDITED FINANCIALS	6 Months Ended
	Jun. 30, 2013
Accounting Changes and Error Corrections [Abstract]
RESTATEMENT	NOTE N – RESTATEMENT OF 2010 AUDITED FINANCIALS
	Subsequent to the filing of the Company’s Current Report on Form 8-K, Amendment 3 filed on December 9, 2011, the Company determined that an error was made in certain assumptions used in the Black-Scholes calculation to determine the fair value of options issued from inception through December 31, 2010.
	For the year ended December 31, 2010, $363,750 was recorded as non-cash compensation on the audited financial statements of VitaMed.  The Company determined that the fair value should have been $177,601, an overstatement of $186,149.  The Company is restating sales, general and administration for the year ended December 31, 2010 to include the $186,149 reduction in non-cash compensation expense.
	For the period from inception through December 31, 2010, $559,917 was recorded as non-cash compensation on the audited financial statements of VitaMed, of which $196,167 pertains to the period from May 13, 2008 (“Inception”) through December 31, 2009.  The Company determined that the fair value should have been $283,530, of which $105,929 pertains to the period from Inception through December 31, 2009, an overstatement of $276,387, of which $90,238 pertains to the period from Inception through December 31, 2009.  The Company is restating accumulated deficit for the year ended December 31, 2010 to include the $276,387 reduction for the year ended December 31, 2010 and the $90,238 reduction for the period from Inception through December 31, 2009.
	The tables below summarize the impact of the restatements.
		As of
		31-Dec-10
		As Reported			As Restated
	Additional paid in capital	$	537,561		$	261,174
	Accumulated deficit	$	(4,356,100	)	$	(4,079,713	)
		For the Year Ended
		31-Dec-10
		As Reported			As Restated
	Sales, general and administration	$	3,650,959		$	3,464,810
	Total operating expense	$	3,739,144		$	3,552,994
	Operating loss	$	(3,053,613	)	$	(2,867,464	)
	Net loss	$	(3,053,613	)	$	(2,867,464	)

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended			12 Months Ended
	Jun. 30, 2013			Dec. 31, 2012				Dec. 31, 2011
Summary Of Significant Accounting Policies Policies
Principles of Consolidation				Principles of Consolidation				Principles of Consolidation
				The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, vitaMed and BocaGreen. All material intercompany balances and transactions have been eliminated in consolidation.				The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All material intercompany balances and transactions have been eliminated in consolidation.
Cash				Cash				Cash and Cash Equivalents
				We maintain cash at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced any losses related to these balances. All of our non-interest bearing cash balances were fully insured at December 31, 2012 and 2011 due to a temporary federal program in effect from December 31, 2010 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts.				Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. All of our non-interest bearing cash balances were fully insured at December 31, 2011 and 2010 due to a temporary federal program in effect from December 31, 2010 through December 31, 2012. Under the program, there is no limit to the amount of insurance for eligible accounts. Beginning 2013, insurance coverage will revert to $250,000 per depositor at each financial institution, and our non-interest bearing cash balances may again exceed federally insured limits. The Company had no interest-bearing amounts on deposit in excess of federally insured limits at December 31, 2011 and 2010.
				Beginning 2013, insurance coverage will revert to $250,000 per depositor at each financial institution, at which time our non-interest bearing cash balances may again exceed federally insured limits. We had no interest-bearing amounts on deposit in excess of federally insured limits at December 31, 2012 and 2011.
Trade Accounts Receivable and Allowance for Doubtful Accounts				Trade Accounts Receivable and Allowance for Doubtful Accounts				Trade Accounts Receivable and Allowance for Doubtful Accounts
				Trade accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide an allowance for doubtful accounts which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We consider trade accounts receivable past due more than 90 days to be delinquent. We write-off delinquent receivables to bad debt expense based on individual credit evaluations, results of collection efforts, and specific circumstances of the customer. Recoveries of accounts previously written off are recorded as reductions of bad debt expense when received. Historically, our bad debt expense has been limited because the majority of our trade receivables are paid via credit card. To the extent data we use to calculate these estimates does not accurately reflect bad debts; adjustments to these reserves may be required. At December 31, 2012 and 2011, we recorded an allowance for doubtful accounts of $42,048 and $1,500, respectively.				Trade accounts receivable are customer obligations due under normal trade terms. The Company reviews the accounts receivable for uncollectible accounts and credit card charge-backs and provides an allowance for doubtful accounts which is based upon a review of outstanding receivables, historical collection information and existing economic conditions. Trade accounts receivable past due more than 90 days are considered delinquent. Delinquent receivables are written off to bad debt expense based on individual credit evaluations, results of collection efforts, and specific circumstances of the customer. Recoveries of accounts previously written off are recorded as reductions of bad debt expense when received. Historically, our bad debt expense has been limited because the majority of our trade receivables are paid via credit card. Data we use to calculate these estimates does not accurately reflect bad debts; adjustments to these reserves may be required. At December 31, 2011 and 2010, the Company recorded an allowance for doubtful accounts of $1,500 and $0, respectively.
Inventories				Inventories				Inventories
				Inventories represent packaged nutritional products and supplements and raw materials which are valued at the lower of cost or market using the average cost method. The costs of manufacturing the prescription products associated with the deferred revenue (as discussed in Revenue Recognition) are recorded as deferred costs, which are included in inventory, until such time as the related deferred revenue is recognized.				Inventories represent packaged nutritional products and supplements which are valued at the lower of cost or market using the average cost method.
Fixed Assets				Fixed Assets				Fixed Assets
				Equipment-We state equipment at cost, net of accumulated depreciation. Maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs are charged to operating expense as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related assets, which range from three to seven years. Depreciation expense totaled $19,904 and $23,962 for the years ended December 31, 2012 and 2011, respectively.				Property and Equipment-Property and equipment is stated at cost, net of accumulated depreciation. Maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs are charged to operating expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from 3 to 7 years. Depreciation expense totaled $25,686 and $5,105 for the years ended December 31, 2011 and 2010, respectively.
				Leasehold Improvements-We state improvements at cost, net of accumulated depreciation. We compute depreciation using the straight-line method over the remaining term of the lease. Depreciation expense totaled $7,580 and 1,724 for the years ended December 31, 2012 and 2011, respectively.				Website-Costs incurred in the planning stage of a website are expensed, while costs incurred in the development stage are capitalized and amortized over the estimated three-year life of the asset. Amortization of website development costs totaled $29,159 and $17,678 for the years ended December 31, 2011 and 2010, respectively.
Intangible Assets				Intangible Assets				Intangible Assets
				Patent and Trademarks-We have adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 350 Intangible-Goodwill and Other (“ASC 350”). Capitalized patent costs, net of accumulated amortization, include legal costs incurred for a patent application. In accordance with ASC 350, once the patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. Intangible assets are reviewed annually for impairment or when events or circumstances indicate that their carrying amount may not be recoverable.				The Company has adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 350 Intangible-Goodwill and Other (“ASC 350”).
				There was no amortization expense related to patent costs for the years ended December 31, 2012 and 2011 as patents have not yet been granted.				Capitalized patent costs, net of accumulated amortization, include legal costs incurred for a patent application. In accordance with ASC 350, once the patent is granted, the Company will amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, the Company will write-off any capitalized patent costs at that time. Intangible assets are reviewed annually for impairment or when events or circumstances indicate that their carrying amount may not be recoverable. There was no amortization expense related to patent costs for the years ended December 31, 2011 and 2010 as patents have not yet been granted.
				Website Costs-We expense costs incurred in the planning stage of a website, while costs incurred in the development stage are capitalized and amortized over the estimated three year life of the asset. Amortization of website development costs totaled $28,776 and $29,159 for the years ended December 31, 2012 and 2011, respectively.
Impairment of Long-Lived Assets				Impairment of Long-Lived Assets				Impairment of Long-Lived Assets
				We review the carrying values of property and equipment and finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances include, but are not limited to, the following:				Carrying values of property and equipment and finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances include, but are not limited to:
					•	significant declines in an asset’s market price;
					•	significant deterioration in an asset’s physical condition;			·	Significant declines in an asset’s market price;
					•	significant changes in the nature or extent of an asset’s use or operation;			·	Significant deterioration in an asset’s physical condition;
					•	significant adverse changes in the business climate that could impact an asset’s value, including adverse actions or assessments by regulators;			·	Significant changes in the nature or extent of an asset’s use or operation;
					•	accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;			·	Significant adverse changes in the business climate that could impact an asset’s value, including adverse actions or assessments by regulators;
					•	current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset’s use; and			·	Accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;
					•	expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.			·	Current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset’s use; and
									·	Expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.
				If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group’s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. Assessments also consider changes in asset utilization, including the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then a loss is recorded for the difference between the assets’ fair value and respective carrying value. We determine the fair value of the assets using an “income approach” based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate; however, unanticipated events and changes in market conditions could affect such estimates, resulting in the need for an impairment charge in future periods.
								If impairment indicators are present, the Company determines whether an impairment loss should be recognized by testing the applicable asset or asset group’s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. The Company estimates the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compares that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. Assessments also consider changes in asset utilization, including the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then a loss is recorded for the difference between the assets’ fair value and respective carrying value. The fair value of the assets is determined using an “income approach” based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include: market size and growth, market share, projected selling prices, manufacturing cost and discount rate. The Company’s estimates are based upon its historical experience, its commercial relationships, market conditions and available external information about future trends. The Company believes its current assumptions and estimates are reasonable and appropriate; however, unanticipated events and changes in market conditions could affect such estimates, resulting in the need for an impairment charge in future periods.
Fair Value of Financial Instruments	Our financial instruments consist primarily of receivables, accounts payable, accrued expenses, and short-term debt. The carrying amount of accounts receivable, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such instruments and are considered Level 1 assets under the fair value hierarchy. Interest rates that are currently available to us for issuance of short and long-term debt with similar terms and remaining maturities are used to estimate the fair value of our short and long-term debt and would be considered Level 3 inputs under the fair value hierarchy.			Fair Value of Financial Instruments				Fair Value of Financial Instruments
	We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC 820 Fair Value Measurements and Disclosures. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).  Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:			Our financial instruments consist primarily of receivables, accounts payable, accrued expenses, and short-term debt. The carrying amount of receivables, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such instruments and are considered Level 1 assets under the fair value hierarchy. Interest rates that are currently available to us for issuance of short and long-term debt with similar terms and remaining maturities are used to estimate the fair value of our short and long-term debt and would be considered Level 3 inputs under the fair value hierarchy.				The Company’s financial instruments consist primarily of receivables, accounts payable, accrued expenses and short-term debt. The carrying amount of receivables, accounts payable and accrued expenses approximates its fair value because of the short-term maturity of such instruments. Interest rates that are currently available to the Company for issuance of short-term debt with similar terms and remaining maturities are used to estimate the fair value of the Company’s short-term debt.
		Level 1	unadjusted quoted prices in active markets for identical assets or liabilities;	We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).				The Company categorizes its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).
		Level 2	quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and	Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:				Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:
		Level 3	unobservable inputs for the asset or liability.		Level 1		unadjusted quoted prices in active markets for identical assets or liabilities;
									Level 1	Unadjusted quoted prices in active markets for identical assets or liabilities;
	At June 30, 2013 and December 31, 2012, we had no assets or liabilities that were valued at fair value on a recurring basis.				Level 2		quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and
									Level 2	Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and
					Level 3		unobservable inputs for the asset or liability.
									Level 3	Unobservable inputs for the asset or liability.
				At December 31, 2012 and 2011, we had no assets or liabilities that were valued at fair value on a recurring basis.
								At December 31, 2011 and 2010, the Company had no assets or liabilities that are valued at fair value on a recurring basis.
Income Taxes				Income Taxes				Income Taxes
				We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. In accordance with ASC 740, Income Taxes, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur. We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. As of December 31, 2012 and 2011, we had no tax positions relating to open tax returns that were considered to be uncertain.				Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. In accordance with ASC 740, Income Taxes, the Company recognizes the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. Recognized uncertain income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur. The Company recognizes both interest and penalties related to uncertain tax positions as part of the income tax provision. As of December 31, 2011 and 2010, the Company has no tax positions relating to open tax returns that were considered to be uncertain.
Stock Based Compensation				Stock Based Compensation				Stock Based Compensation
				In December 2004, the FASB issued ASC 718, Compensation – Stock Compensation (“ASC 718”). Under ASC 718 companies are required to measure the compensation costs of unit-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Unit-based compensation arrangements include unit options, restricted share plans, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. We use the Black-Scholes option pricing model that requires the input of highly complex and subjective variables including the expected life of options granted and our expected stock price volatility over a period equal to or greater than the expected life of the options.				In December 2004, the FASB issued ASC 718, Compensation – Stock Compensation (“ASC 718”). ASC 718 companies are required to measure the compensation costs of unit-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Unit-based compensation arrangements include unit options, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. The Company uses the Black-Scholes option pricing model which requires the input of highly complex and subjective variables including the expected life of options granted and the Company’s expected stock price volatility over a period equal to or greater than the expected life of the options.
				Equity instruments (“instruments”) issued to other than employees are recorded on the basis of the fair value of the instruments, as required by ASC 718. FASB ASC 505, Equity Based Payments to Non-Employees defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.				Equity instruments (“instruments”) issued to other than employees are recorded on the basis of the fair value of the instruments, as required by ASC 718. FASB ASC 505, Equity Based Payments to Non-Employees defines the measurement date and recognition period for such instruments. In general, the measurement date is when either a (a) performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in the ASC.
				We recognize compensation expense for all share-based payments granted based on the grant date fair value estimated in accordance with ASC 718-10, “Share Based Payments.” Compensation expense is generally recognized on a straight-line basis over the employee’s requisite service period.				The Company recognizes compensation expense for all share-based payments granted based on the grant date fair value estimated in accordance with ASC 718-10, “Share Based Payments.” Compensation expense is generally recognized on a straight-line basis over the employee’s requisite service period.
Debt Discounts				Debt Discounts				Debt Discounts
				Costs incurred with parties that are providing long-term financing, which include warrants issued with the underlying debt, are reflected as a debt discount based on the relative fair value of the debt and warrants to the total proceeds. These discounts are generally amortized over the life of the related debt using the effective interest rate method. In connection with debt issued during the years ended December 31, 2012 and 2011, we recorded debt discounts totaling $2,706,920 and $28,719, respectively. The aggregate balance of unamortized debt discount at December 31, 2012 and 2011 was $1,102,680 and $0, respectively. Amortization expense related to debt discounts totaled $1,604,240 and $28,719 for the years ended December 31, 2012 and 2011, respectively, and is included in amortization of debt discount on the accompanying consolidated financial statements.				Costs incurred with parties who are providing long-term financing, which include warrants issued with the underlying debt, are reflected as a debt discount based on the relative fair value of the debt and warrants to the total proceeds. These discounts are generally amortized over the life of the related debt using the effective interest rate method. In connection with debt issued during the years ended December 31, 2011 and 2010, the Company recorded debt discounts totaling $28,719 and $0, respectively. Amortization expense related to debt discounts totaled $28,719 and $0 for the years ended December 31, 2011 and 2010, respectively, and is included in interest expense on the accompanying consolidated financial statements. Debt discount was fully amortized at December 31, 2011.
Revenue Recognition				Revenue Recognition				Revenue Recognition
				We recognize revenue on arrangements in accordance with ASC 605, “Revenue Recognition”. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.				The Company recognizes revenue on arrangements in accordance with ASC 605, “Revenue Recognition” (“ASC 605”). Revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed and collectability is reasonably assured. The Company generates revenue by sales of products primarily to retail consumers. The Company’s policy is to recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. Outbound shipping and handling fees are included in sales and are billed upon shipment. Shipping expenses are included in cost of sales. The majority of the Company’s sales are paid with credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. We provide an unconditional thirty-day money-back return policy whereby we accept product returns from our retail, wholesale and eCommerce customers. Historically we have experienced returns (monitored on a daily basis) equal to approximately one percent of sales. Total returns were $20,726 and $13,734 for the years ended December 31, 2011 and 2010, respectively. We consider the potential returns to be de minimis and have not established an allowance for product returns at this time.
				Over The Counter Products
				We generate OTC revenue by sales of products primarily to retail consumers. Our policy is to recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. Outbound shipping and handling fees are included in sales and are billed upon shipment. Shipping expenses are included in cost of sales. The majority of our sales are paid with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers. We recognize our revenue from OTC sales net of returns, sales discounts, and eCommerce fees.
				For the years ended December 31, 2012 and 2011, we recorded an allowance for returns of $27,168 and $0, respectively. We estimate the allowance for returns based on historical return activity, which is reviewed, and adjusted if necessary, on a quarterly basis.
				Prescription Products
				We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of sales discounts and end-user rebates.
				We accept returns of unsalable product from customers within a return period of six months prior to and following product expiration. Our prescription products currently have a shelf-life of 24 months from date of manufacture. Given the limited history of prescriptions products, we currently cannot reliably estimate expected returns of the prescription products at the time of shipment. Accordingly, we defer recognition of revenue on prescription products until the right of return no longer exists, which occurs at the earlier of the time the prescription products are dispensed through patient prescriptions or expiration of the right of return. As a result of this policy, we had a deferred revenue balance of $1,144,752 and $0 at December 31, 2012 and 2011, respectively.
				We maintain various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The rebate program is designed to enable the end-user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end-user. We estimate the allowance for rebates based on industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. For the years ended December 31, 2012 and 2011, we recorded reduction to income for rebates of $34,255 and $0, respectively.
Shipping and Handling Costs				Shipping and Handling Costs				Shipping and Handling Costs
				We expense all shipping and handling costs as incurred. These costs are included in cost of sales on the accompanying consolidated financial statements.				The Company expenses all shipping and handling costs as incurred. These costs are included in cost of sales on the accompanying consolidated financial statements.
Advertising Costs				Advertising Costs				Advertising Costs
				We expense advertising costs when incurred. Advertising expenses totaled $65,944 and $19,408 during the years ended December 31, 2012 and 2011, respectively.				The Company expenses advertising costs when incurred. Advertising expenses totaled $19,408 and $25,698 during the years ended December 31, 2011 and 2010, respectively.
Research and Development Expenses	Research and development, or R&D, expenses include internal R&D activities, external contract research organization, or CRO, services and their clinical research sites, and other activities. Internal R&D activity expenses include laboratory supplies, salaries, benefits, and share-based compensation expenses.  CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting, and regulatory legal counsel.  Internal R&D activities and other activity expenses are charged to operations as incurred.  We make payments to the CRO’s based on agreed upon terms and may include payments in advance of a study starting date.  Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.  We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO.  Accrued CRO costs are subject to revisions as such studies progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.			Research and Development Expenses				Research and Development Expenses
				Research and development expenditures, which are expensed as incurred, totaled $4,492,362 and $107,241 during the years ended December 31, 2012 and 2011, respectively.				Research and development expenditures, which are expensed as incurred, totaled $107,241 and $65,402 during the years ended December 31, 2011 and 2010, respectively.
Earnings Per Share	We calculate earnings per share, or EPS, in accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure of two EPS amounts, basic and diluted. We compute basic EPS based on the weighted average number of shares of common stock outstanding during the period. We compute diluted EPS based on the weighted average number of shares of common stock outstanding plus all potentially dilutive common shares outstanding during the period. Such potentially dilutive common shares consist of stock options and warrants. Potentially dilutive common shares totaling 21,773,002 and 18,884,154 at June 30, 2013 and 2012, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to the net loss reported by us.			Earnings Per Share				Earnings Per Share
				We calculate earnings per share (“EPS”) in accordance with ASC 260, “Earnings Per Share,” which requires the computation and disclosure of two EPS amounts, basic and diluted. We compute basic EPS based on the weighted average number of shares of Common Stock outstanding during the period. We compute diluted EPS based on the weighted average number of shares of Common Stock outstanding plus all potentially dilutive common shares outstanding during the period. Such potential dilutive common shares consist of stock options and warrants. Potential common shares totaling 25,926,987 and 13,639,845 at December 31, 2012 and 2011, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to the net loss reported by us.				The Company calculates earnings per share (“EPS”) in accordance with ASC 260, “Earnings Per Share,” which requires the computation and disclosure of two EPS amounts, basic and diluted. Basic EPS is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted EPS is computed based on the weighted average number of common shares outstanding plus all potentially dilutive common shares outstanding during the period. Such potential dilutive common shares consist of stock options and warrants. Potential common shares totaling 96,618,626 and 165,752 (Reverse Split shares) at December 31, 2011 and 2010, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to the net loss reported by the Company.
Use of Estimates				Use of Estimates				Use of Estimates
				Our financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.				The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Recently Issued Accounting Pronouncements	On July 18, 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU provide guidance on the financial statements presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in this ASU do not require new recurring disclosures. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments in ASU No. 2013-11 are not expected to have an impact on our condensed consolidated financial statements.			Recently Issued Accounting Pronouncements				Recently Issued Accounting Pronouncements
				In July 2012, FASB issued Accounting Standards Update (“ASU”) No. 2012-02, “Testing Indefinite-Lived Intangible Assets for Impairment” (“ASU 2012-02”). ASU 2012-02 gives entities an option to first assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that the indefinite-lived intangible asset impaired. If based on its qualitative assessment an entity concludes that it is more likely than not that the fair value of an indefinite lived intangible asset is less than its carrying amount, quantitative impairment testing is required. However, if an entity concludes otherwise, quantitative impairment testing is not required. ASU 2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with early adoption permitted. ASU 2012-02 is not expected to have a material impact on our financial position or results of operations.				In December 2011, FASB issued Accounting Standards Update (“ASU”) 2011-11, Balance Sheet - Offsetting. This guidance requires disclosures about offsetting and related arrangements for recognized financial instruments and derivative instruments. The standard is effective for us as of January 1, 2013 and will not materially impact our financial statement disclosures.
				In December 2011, the FASB issued ASU No. 2011-11, “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities” (“ASU 2011-11”). ASU 2011-11 enhances current disclosures about financial instruments and derivative instruments that are either offset on the statement of financial position or subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset on the statement of financial position. Entities are required to provide both net and gross information for these assets and liabilities in order to facilitate comparability between financial statements prepared in conformity with U.S. GAAP and financial statements prepared on the basis of International Financial Reporting Standards (“IFRS”). ASU 2011-11 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. ASU 2011-11 is not expected to have a material impact on our financial position or results of operations.				In September 2011, the FASB issued ASU 2011-08, “Testing Goodwill for Impairment.” This guidance provides the option to evaluate prescribed qualitative factors to determine whether a calculated goodwill impairment test is necessary. The standard is effective for us as of January 1, 2012 and will not materially impact on our financial condition, results of operations, or financial statement disclosures.
				In September 2011, the FASB issued ASU No. 2011-08 Intangibles – Goodwill & Other (“ASU 2011-08”), which updates the guidance in Accounting Standards Codification (“ASC”) Topic 350, Intangibles – Goodwill & Other (“ACS Topic 350”). The amendments in ASU 2011-08 permit an entity to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test described in ASC Topic 350. The more-likely-than-not threshold is defined as having a likelihood of more than fifty percent. If, after assessing the totality of events or circumstances, an entity determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. The amendments in ASU 2011-08 include examples of events and circumstances that an entity should consider in evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. However, the examples are not intended to be all-inclusive and an entity may identify other relevant events and circumstances to consider in making the determination. The examples in this ASU 2011-08 supersede the previous examples under ASC Topic 350 of events and circumstances an entity should consider in determining whether it should test for impairment between annual tests, and also supersede the examples of events and circumstances that an entity having a reporting unit with a zero or negative carrying amount should consider in determining whether to perform the second step of the impairment test. Under the amendments in ASU 2011-08, an entity is no longer permitted to carry forward its detailed calculation of a reporting unit’s fair value from a prior year as previously permitted under ASC Topic 350. ASU 2011-08 is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. The adoption of ASU 2011-08 did not have a material impact on our financial position or results of operations.				In May 2011, FASB issued ASU 2011-05, Comprehensive Income: Presentation of Comprehensive Income, to allow an entity the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both choices, an entity is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. ASU 2011-05 eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders’ equity. The amendments do not change the guidance regarding the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. The amendments should be applied retrospectively and is effective for fiscal years and interim periods within those years beginning after December 15, 2011. Early adoption is permitted. The adoption is not expected to have a material impact on the Company’s results of operations, financial position or cash flows.
				In May 2011, the FASB issued ASU 2011-04 (“ASU 2011-04”), which updated the guidance in ASC Topic 820, Fair Value Measurement. The amendments in ASU 2011-04 generally represent clarifications of Topic 820, but also include some instances where a particular principle or requirement for measuring fair value or disclosing information about fair value measurements has changed. ASU 2011-04 results in common principles and requirements for measuring fair value and for disclosing information about fair value measurements in accordance with U.S. GAAP and IFRS. The amendments in ASU 2011-04 are to be applied prospectively. For public entities, the amendments are effective for interim and annual periods beginning after December 15, 2011. The adoption of ASU 2011-04 did not have a material impact on our financial position or results of operations.				In May 2011, the FASB issued ASU 2011-04, Fair Value Measurement: Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs. This ASU represents the converged guidance of the FASB and the IASB (the “Boards”) on fair value measurement, and results in common requirements for measuring fair value and for disclosing information about fair value measurements, including a consistent meaning of the term “fair value.” These amendments change some of the terminology used to describe many of the existing requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. The amendments should be applied prospectively, and they are effective during interim and annual periods beginning after December 15, 2011. Early application by public entities is not permitted. The adoption is not expected to have a material impact on the Company’s results of operations, financial position or cash flows.
				We do not believe there would have been a material effect on the accompanying financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.				Management does not believe there would be a material effect on the accompanying financial statements had any other recently issued but not yet effective accounting standards been adopted in the current period.
Reclassifications	Certain 2012 amounts have been reclassified to conform to current year presentation.			Reclassifications
				Certain 2011 amounts have been reclassified to conform to current year presentation.
Interim Financial Statements	Our accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles, or GAAP, for complete financial statements.  In our opinion, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission, or SEC.  The balance sheet at December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements.  The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period.  Actual results could differ from those estimates. Results of operations for interim periods are not necessarily indicative of results for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2012.

INVENTORY_Tables

INVENTORY (Tables)	6 Months Ended					12 Months Ended
	Jun. 30, 2013					Dec. 31, 2012
Inventory Tables
Schedule of Inventory	Inventory consists of the following:					Inventory consists of the following:
		June 30,		December 31,
		2013		2012			December 31,
	Finished product	$	1,100,486	$	1,124,739		2012		2011
	Raw material		291,035		380,000	Finished product	$	1,124,739	$	588,073
	Deferred costs		114,538		110,471	Raw material		380,000		-0-
	TOTAL INVENTORY	$	1,506,059	$	1,615,210	Deferred costs		110,471		-0-
						TOTAL INVENTORY	$	1,615,210	$	588,073

OTHER_CURRENT_ASSETS_Tables

OTHER CURRENT ASSETS (Tables)	6 Months Ended					12 Months Ended
	Jun. 30, 2013					Dec. 31, 2012					Dec. 31, 2011
Other Current Assets Tables
Schedule of Other Current Assets	Other current assets consist of the following:					Other current assets consist of the following:
		June 30,		December 31,
		2013		2012			December 31,
	Prepaid research and development costs	$	1,686,254	$	189,375		2012		2011
	Deferred financing costs		1,051,988		-0-	Prepaid consulting	$	432,216	$	95,962
	Prepaid consulting		541,936		432,216	Deposits with vendors		189,375		300,503
	Other receivables-related party (Note 12)		171,261		-0-	Prepaid insurance		127,403		52,611
	Prepaid insurance		125,266		127,403	Prepaid guaranty costs		2,944		46,984
	Other prepaid costs		30,578		-0-	TOTAL OTHER CURRENT ASSETS	$	751,938	$	496,060
	Prepaid guaranty costs		-0-		2,944
	TOTAL OTHER CURRENT ASSETS	$	3,607,283	$	751,938

FIXED_ASSETS_Tables

FIXED ASSETS (Tables)	6 Months Ended							12 Months Ended
	Jun. 30, 2013							Dec. 31, 2012							Dec. 31, 2011
Fixed Assets Tables
Schedule of Property, Plant and Equipment	Fixed assets consist of the following:							Fixed assets consist of the following:
		June 30,			December 31,
		2013			2012				December 31,
	Equipment	$	90,573		$	67,668			2012			2011
	Furniture and fixtures		46,625			46,625		Equipment	$	67,668		$	33,650
	Leasehold improvements		11,980			11,980		Furniture and fixtures		46,625			22,169
			149,178			126,273		Leasehold improvements		11,980			4,049
	Accumulated depreciation		(72,684	)		(60,600	)			126,273			59,868
	TOTAL FIXED ASSETS	$	76,494		$	65,673		Accumulated depreciation		(60,600	)		(33,116	)
								TOTAL FIXED ASSETS	$	65,673		$	26,752

OTHER_ASSETS_Tables

OTHER ASSETS (Tables)	6 Months Ended					12 Months Ended
	Jun. 30, 2013					Dec. 31, 2011
Other Assets Tables
Schedule of other assets	Prepaid expense consists of the following:
		June 30,		December 31,
		2013		2012
	Prepaid manufacturing costs	$	899,000	$	-0-
	Prepaid consulting expense		1,081,519		953,655
	TOTAL PREPAID EXPENSE	$	1,980,519	$	953,655

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	6 Months Ended					12 Months Ended
	Jun. 30, 2013					Dec. 31, 2012
Intangible Assets Tables
Schedule of Intangible assets	Intangible assets consist of the following:					Other assets consist of the following:
		June 30,		December 31,
		2013		2012			December 31,
	Patent costs	$	337,163	$	224,971		2012		2011
	Website costs, net of amortization of $83,668 and $77,159, respectively		8,075		14,584	Patent costs	$	224,971	$	18,870
	TOTAL INTANGIBLE ASSETS	$	345,238	$	239,555	Website costs, net of amortization of $77,159 and $48,383 for the years ended December 31, 2012 and 2011, respectively		14,584		43,361
						TOTAL INTANGIBLE ASSETS	$	239,555	$	62,231

OTHER_CURRENT_LIABILITIES_Tabl

OTHER CURRENT LIABILITIES (Tables)	6 Months Ended					12 Months Ended
	Jun. 30, 2013					Dec. 31, 2012					Dec. 31, 2011
Other Current Liabilities Tables
Schedule of Other Current Liabilities	Other current liabilities consist of the following:					Other current liabilities consist of the following:
		June 30,		December 31,
		2013		2012			December 31,
	Accrued offering costs	$	500,000	$	-0-		2012		2011
	Accrued payroll and commission costs		228,877		397,210	Accrued payroll	$	285,210	$	295,915
	Accrued vacation costs		263,851		114,899	Accrued vacation		114,899		68,438
	Accrued professional fees		120,250		90,000	Accrued commission		112,000		-0-
	Allowance for coupons and returns		86,540		53,002	Accrued legal and accounting expense		90,000		15,010
	Other accrued expenses		93,853		29,400	Allowance for coupons and returns		53,002		-0-
	Dividends payable(1)		41,359		41,359	Dividends payable(1)		41,359		41,359
	TOTAL OTHER CURRENT LIABILITIES	$	1,334,730	$	725,870	Other accrued expenses		29,400		45,025
	______________					TOTAL OTHER CURRENT LIABILITIES	$	725,870	$	465,747
	(1) In June 2008, the Company declared and paid a special dividend of $0.40 per share of common stock to all stockholders of record as of June 10, 2008.  This amount reflects unclaimed dividends by certain stockholders.

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended											12 Months Ended
	Jun. 30, 2013											Dec. 31, 2012											Dec. 31, 2011
Stockholders Equity Tables
Company Warrants Outstanding and Issued												During the year ended December 31, 2012, we issued the following:
													Number of Shares Under Company Warrants			Exercise Price			Exercise Term in Years		Fair Value
												Debt modification		5,685,300			$0.38			5	$	10,505,247
												Issued with debt		10,314,700			$0.38-$3.00			5		15,549,855
												Services		1,332,500			$2.40-$2.80			5		1,563,620
														17,332,500							$	27,618,722
												During the year ended December 31, 2011, we issued the following:
													Number of Shares Under Company Warrants			Exercise Price			Exercise Term in Years		Fair Value
												Loan guarantee		613,713		$	0.24			10	$	93,969
												Loan consideration		613,718		$	0.41			5		30,993
												Product consulting		1,045,485			$0.38-$0.41			10-May		189,942
												Services		784,711			$0.38-$1.50			10-May		159,363
														3,057,627							$	474,267
Schedule of Assumptions FV Warrants	The assumptions used in the Black-Scholes Model during the six months ended June 30, 2013 are set forth in the table below.											The weighted average fair value per share of Company Warrants granted and the assumptions used in the Black-Scholes Model during the years ended December 31, 2012 and 2011 are set forth in the table below.
		Six Months			Year Ended December 31, 2012								2012			2011
		Ended										Weighted average fair value	$	2.05		$	0.16
		30-Jun-13										Risk-free interest rate		0.72-1.04%			0.91-3.48%
	Risk-free interest rate		0.65-1.42	%		0.61-2.23	%					Volatility		44.64-44.81%			39.13-51.83%
	Volatility		33.35-45.76	%		40.77-46.01	%					Term (in years)		5			10-May
	Term (in years)		5-6.25			5-6.25						Dividend yield		0	%		0	%
	Dividend yield		0	%		0	%
Schedule of Stock Warrant Activity	A summary of our warrant activity and related information for 2013 follows:											A summary of our Common Stock purchase warrant activity and related information for the years ended December 31, 2012 and 2011 follows:
		Number of			Weighted Average			Weighted					Number of Shares Under Company Warrants			Weighted Average Exercise Price			Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
		Shares			Exercise			Average		Aggregate
		Under Company Warrants			Price			Remaining		Intrinsic		Balance at December 31, 2010		-0-
								Contractual		Value		Granted		3,057,627		$	0.36			7.9	$	3,483,691
								Life in Years				Exercised		-0-
	Balance at December 31, 2012		12,193,499		$	1.63			4.8	$	17,971,994	Expired		-0-
	Granted		2,100,000		$	2.72			7.3	$	867,000	Cancelled		-0-
	Exercised		-0-									Balance at December 31, 2011		3,057,627		$	0.36			7.9	$	3,483,691
	Expired		-0-									Granted		17,332,500		$	1.26			4.3	$	31,891,150
	Cancelled		-0-									Exercised		(8,145,486	)	$	0.38
	Balance at June 30, 2013		14,293,499		$	1.79			4.8	$	17,985,449	Expired		-0-
	Vested and Exercisable at June 30, 2013		12,149,559		$	1.67			4.3	$	16,540,175	Cancelled		(51,142	)	$	0.24
												Balance at December 31, 2012		12,193,499		$	1.63			4.8	$	17,971,994
												Vested and Exercisable at
												31-Dec-12		11,784,408		$	1.69			4.7	$	16,859,266
Stock Options	A summary of activity under the LTIP and 2012 SOP and related information follows:											A summary of activity under the 2009 and 2012 Plans and related information follows:
		Number of			Weighted			Weighted		Aggregate			Number of Shares Under Company Options			Weighted Average Exercise Price			Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
		Shares			Average			Average		Intrinsic
		Under			Exercise			Remaining		Value		Balance at December 31, 2010		-0-
		Company			Price			Contractual				Granted(1)		10,682,218		$	0.16			7.6	$	14,188,484
		Option						Life in Years				Exercised		(92,057	)	$	0.19
	Balance at December 31, 2012		13,733,488		$	1.16			7.7	$	26,804,117	Expired		-0-
	Granted		1,583,677		$	2.79			9.9	$	365,845	Cancelled		-0-
	Exercised		(61,372	)								Balance at December 31, 2011		10,590,161		$	0.16			7.6	$	14,067,649
	Expired		-0-									Granted		5,121,250		$	2.8			9.7	$	1,737,530
	Cancelled		(600,000	)								Exercised		(1,931,788	)	$	0.13
	Balance at June 30, 2013		14,655,793		$	1.08			7.8	$	26,038,328	Expired		-0-
	Vested and Exercisable at June 30, 2013		9,623,443		$	0.6			6.5	$	23,208,051	Cancelled		(46,135	)
												Balance at December 31, 2012		13,733,488		$	1.16			7.7	$	26,804,117
												Vested and Exercisable at December 31, 2012		8,370,408		$	0.38			6.7	$	22,811,422
Schedule of Assumptions FV Options												The assumptions used in the Black-Scholes Model during the years ended December 31, 2012 and 2011 and are set forth in the table below.
													2012			2011
												Risk-free interest rate		0.61-2.23%			0.91-2.54%
												Volatility		40.77-46.01%			37.92-40.48%
												Expected life (in years)		5-6.25			5.5-6.25
												Dividend yield		0	%		0	%

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2012							Dec. 31, 2011
Income Taxes Tables
Deferred tax assets and liabilities	Our deferred tax asset and liability as presented in financial statements consist of the following:
		2012			2011
	Deferred Income Tax Assets:
	Net operating losses	$	5,920,861		$	748,404
	Valuation allowance		(5,920,861	)		(748,404	)
	Deferred Income Tax Assets, net	$	-0-		$	-0-
Schedule of Tax Rate Reconciliation	A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:
		2012			2011
	Federal statutory tax rate		35	%		35	%
	State tax rate, net of federal tax benefit		5.5	%		-0-	%
	Adjustment in valuation allowances		(18.2	)%		(5.8	)%
	Permanent and other differences		(22.3	)%		(29.2	)%
	Provision (Benefit) for Income Taxes		-0-	%		-0-	%

COMMITMENT_AND_CONTINGENCIES_T

COMMITMENT AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2011
Business Combinations [Abstract]
Schedule of future minimum rental payments

RESTATEMENT_OF_2010_AUDITED_FI1

RESTATEMENT OF 2010 AUDITED FINANCIALS (Tables)	6 Months Ended
	Jun. 30, 2013
Accounting Changes and Error Corrections [Abstract]
Schedule of the impact of the restatements		As of
		31-Dec-10
		As Reported			As Restated
	Additional paid in capital	$	537,561		$	261,174
	Accumulated deficit	$	(4,356,100	)	$	(4,079,713	)
		For the Year Ended
		31-Dec-10
		As Reported			As Restated
	Sales, general and administration	$	3,650,959		$	3,464,810
	Total operating expense	$	3,739,144		$	3,552,994
	Operating loss	$	(3,053,613	)	$	(2,867,464	)
	Net loss	$	(3,053,613	)	$	(2,867,464	)

THE_COMPANY_Details_Narrative

THE COMPANY (Details Narrative)	0 Months Ended
	Oct. 02, 2011	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Oct. 03, 2011	Jul. 29, 2011	Jul. 28, 2011	Dec. 31, 2010
Merger agreeement description with VitaMed	Completed the following required corporate actions: a reverse split of the Company's 16,575,209 issued and outstanding shares of Common Stock on a ratio of 1 for 100 (the Reverse Split). As a result of the Reverse Split, each share of Common Stock outstanding on July 28, 2011 (the Record Date), without any action on the part of the holder thereof, became one one-hundredth of a share of Common Stock. The Reverse Split decreased the number of outstanding shares of the Company's Common Stock by approximately 99% resulting in 165,856 shares outstanding after the Reverse Split. The effectuation of the Reverse Split did not result in a change in the relative equity position or voting power of the shareholders of the Company; an increase of our authorized shares of Common Stock to 250,000,000; a change in the name of the Company to TherapeuticsMD, Inc.; and an amendment to the Company's Long Term Incentive Compensation Plan to increase the authorized shares for issuance thereunder to 25,000,000.
Reverse split description	1 for 100
Reverse stock split	0.01
Common stock, shares outstanding		131,212,706	99,784,982	82,978,804	58,573,187	165,856	16,575,209	55,487,321
Common stock, shares authorized		250,000,000	250,000,000	250,000,000		250,000,000		250,000,000
Shares authorized under Incentive Plan						25,000,000
Shares exchanged, on a pro rata basis with VitaMed	70,000,000
Shares issued in exchange for Units					58,407,331
Former members of VitaMed ownership percentage in common stock					99.00%
Company Options
Shares reserved for issuance in merger agreement					10,119,796
Company Warrants
Shares reserved for issuance in merger agreement					1,472,916

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Allowance for doubtful accounts	$100,385		$100,385		$42,408	$1,500	$0
Depreciation expense			12,084	15,141	27,484	25,686	22,783
Amortization of intangible assets			6,509	13,972	28,776	29,159
Debt discounts					2,706,920	28,719
Debt discount on notes payable					1,102,680	0
Amortization expense related to debt discount					1,604,240	28,719	0
Sales returns					27,168	20,726	13,734
Deferred Revenue	1,219,072		1,219,072		1,144,752
Rebate Expense					34,255
Advertising expenses					65,944	19,408	25,698
Research and development expenditures	1,747,084	833,342	3,312,285	1,245,303	4,492,362	107,241	65,402
Anti-dilutive shares excluded from earnings per share calculation					25,926,987	13,639,845
Reverse Split Shares
Anti-dilutive shares excluded from earnings per share calculation					96,618,626	165,752
Equipment
Depreciation expense					19,904	23,962	5,105
Leasehold Improvements
Depreciation expense					7,580	1,724
Website
Amortization of intangible assets							$17,678

GOING_CONCERN_Details_Narrativ

GOING CONCERN (Details Narrative) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 07, 2013	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Going Concern Details Narrative
Operating loss		($5,616,994)	($3,974,582)	($10,559,885)	($6,842,603)	($16,148,423)	($5,427,218)	($2,867,464)
Net cash flows used in operating activities				-10,684,753	-5,649,439	-12,737,326	-4,966,596	-2,843,788
Accumulated deficit		-64,498,612		-64,498,612		-52,113,313	-16,993,078	-4,079,713
Gross expected proceeds from underwritten public offering of common stock	$50,000,000			$45,400,000

INVENTORY_Details

INVENTORY (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Inventory
Finished Product	$1,100,486	$1,124,739	$588,073
Raw Material	291,035	380,000
Deferred Costs	114,538	110,471
Inventory	$1,506,059	$1,615,210	$588,073	$618,069

OTHER_CURRENT_ASSETS_Details

OTHER CURRENT ASSETS (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Other Current Assets
Prepaid consulting	$541,936	$432,216	$95,962	$0
Deposits with Vendors	1,686,254	189,375	300,503	0
Prepaid insurance	125,266	127,403	52,611	6,292
Prepaid guaranty costs		2,944	46,984	0
Deferred financing costs	1,051,988
Other receivables - related party	171,261
Other prepaid costs	30,578
Other current assets	$3,607,283	$751,938	$496,060	$6,292

FIXED_ASSETS_Details_Narrative

FIXED ASSETS (Details Narrative) (USD $)	6 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Fixed Assets Details Narrative
Depreciation Expense	$12,084	$15,141	$27,484	$25,686	$22,783

FIXED_ASSETS_Details

FIXED ASSETS (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Property and equipment, Gross	$149,178	$126,273	$59,868	$122,847
Accumulated depreciation	-72,684	-60,600	-33,116	-26,655
Property and equipment, net	76,494	65,673	26,752	96,192
Equipment
Property and equipment, Gross	90,573	67,668	33,650	30,837
Furniture and Fixtures
Property and equipment, Gross	46,625	46,625	22,169	26,219
Leasehold Improvements
Property and equipment, Gross	11,980	11,980	4,049
Website
Property and equipment, Gross				$65,791

OTHER_ASSETS_Details

OTHER ASSETS (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Other Assets
Prepaid manufacturing costs	$899,000
Prepaid consulting expense	1,081,519	953,655	71,689	0
Prepaid guaranty costs			8,826	0
Prepaid expense	$1,980,519	$953,655	$80,515	$0

INTANGIBLE_ASSETS_Details_Narr

INTANGIBLE ASSETS (Details Narrative) (USD $)	6 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Intangible Assets Details Narrative
Amortization of intangible assets	$6,509	$13,972	$28,776	$29,159

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Intangible assets	$345,238	$239,555	$62,231	$10,000
Patent costs
Intangible assets	337,163	224,971	18,870
Website costs
Accumulated amortization	83,668	77,159	48,383
Intangible assets	$8,075	$14,584	$43,361

OTHER_CURRENT_LIABILITIES_Deta

OTHER CURRENT LIABILITIES (Details Narrative) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Other Current Liabilities Details Narrative
Dividends Payable, amount per share	$0.40	$0.40

OTHER_CURRENT_LIABILITIES_Deta1

OTHER CURRENT LIABILITIES (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012		Dec. 31, 2011		Dec. 31, 2010
Other Current Liabilities
Accrued offering costs	$500,000
Accrued payroll	228,877	285,210		295,915		0
Accrued vacation	263,851	114,899		68,438		24,208
Accrued commision		112,000
Accrued legal and accounting expense	120,250	90,000		15,010
Allowance for coupons and returns	86,540	53,002
Dividends payable	41,359	41,359	[1]	41,359	[1]	0
Other accrued expenses	93,853	29,400		45,025		90,998
Other current liabilities	$1,334,730	$725,870		$465,747		$115,206
[1]	In June 2008, we declared and paid a special dividend of $0.40 per share of common stock to all shareholders of record as of June 10, 2008. This amount reflects moneys remaining unclaimed by certain shareholders.

NOTES_PAYABLE_Details_Narrativ

NOTES PAYABLE (Details Narrative) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended								12 Months Ended							0 Months Ended			12 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Oct. 18, 2011	Apr. 18, 2011	Dec. 31, 2010	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012
								February 24 Debt Issuance	June 19 Debt Issuance	March 1 2011 Debt Issuance	November and December 2011 Debt Issuance	November and December 2011 Debt Issuance	VitaMed Promissory Note June 2011	VitaMed Promissory Note June 2011	First United Line of Credit	First United Line of Credit	VitaMed Promissory Notes September October 2011	December 2011 Debt Issuance	December 2011 Debt Issuance	Promissory Notes issued for consulting services	Promissory Notes issued for consulting services	Promissory Notes issued for consulting services	Promissory Note Individual	Promissory Note Individual	Promissory Note Entity	Promissory Note Entity
																							February 24 Debt Issuance	June 19 Debt Issuance	February 24 Debt Issuance	June 19 Debt Issuance
Debt Interest rate					6.00%					20.00%	6.00%	6.00%	6.00%	6.00%			4.00%				6.00%		6.00%	6.00%	6.00%	6.00%
Promissory notes sold in January and February 2012					$900,000
Promissory notes sold in August and September 2012					1,600,000
Promissory notes sold in September 2012					200,000
Promissory notes, principal					3,102,000								500,000	500,000			534,160				210,000	210,000	1,358,014	2,347,128	1,357,110	2,344,719
Warrants Issued														613,718			1,415,136						4,500,000		4,500,000
New Funding								1,000,000		2,000,000
Notes surrendered								1,700,000		2,691,847													1,347,128		1,344,719
Accrued Interest forfeited								15,124
Warrants Issued - Note Modification								5,685,300	7,000,000
Warrants Issued - new Funding								3,314,700		7,000,000
Fair Value of Prior Notes Extinguished								1,517,741
Debt Discount from February 24, 2012 note								197,383
Loss on extinguishment of debt				-10,307,864	-10,307,864	-7,390,000		10,307,864
FV Warrants - treated as Debt Discount								859,647		1,649,890
Interest Expense								859,647					33,204	21,453	7,366	5,650		6,344	2,390
Additional Funding - March-May2012								3,000,000
Shares issued in exercise of warrants					3,102,000	17,250		3,102,000
Shares issued in exercise of warrants, shares					8,145,486	92,057		8,145,486
Interest Rate of June 19, 2012 notes									6.00%	6.00%
Amortization of debt discount					1,604,240	28,719	0	859,647	547,210
Notes payable, net of debt discount of $1,102,680 and $0, respectively					3,589,167							800,000
Debt discount on notes payable					1,102,680	0		859,647	1,102,680				28,719
VitaMed Senior Secured Promissory Notes Interest Rate													6.00%	6.00%
Value of debt converted to shares					1,054,647	849,137							1,054,647	1,054,647						7,600,000
Shares issued in exchange for debt, shares					2,775,415	21,681,958							2,775,415	2,775,415						20,000,000
Conversion Price Per share					$0.38								$0.38	$0.38
Beneficial Conversion Feature		-6,716,504		-6,716,504	-6,716,504
First United line of credit, maximum					300,000
First United line of credit, Personal Guarantees					100,000
First United line of credit, Personal Guarantees Warrants Issued					613,713
First United line of credit, Interest Rate					3.02%
First United line of credit, extension Interest Rate					2.35%
First United line of credit, Outstanding Principal					299,220
Notes Paydown July 2011					200,000
Notes extension					300,000
Notes Paydown October 2011					50,000					170,152
Notes conversion, value													100,000	100,000
Notes conversion Common Stock													266,822	266,822
Interest Accrued - VitaMed Promissory Notes paid in full					2,160
Promissory notes extended through October 15, 2012 - Milligan					50,000
Promissory notes extended through October 15, 2012 - BF Investments					50,000
Promissory Notes Issued December 2011						100,000
Promissory Notes Issued December 2011, value of each note						50,000
Promissory Notes Issued December 2011 outstanding balance					50,000
Interest Accrued and paid in full - Promissory Notes Issued December 2011					888
Notes payable, related parties						$200,000

NOTES_PAYABLE_Details_Narrativ1

NOTES PAYABLE (Details Narrative1) (USD $)	6 Months Ended		12 Months Ended		0 Months Ended	1 Months Ended		0 Months Ended	1 Months Ended		0 Months Ended		0 Months Ended		0 Months Ended		0 Months Ended		3 Months Ended			0 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Apr. 25, 2013	Feb. 28, 2013	Mar. 31, 2011	Jan. 31, 2013	Mar. 31, 2013	Feb. 28, 2013	Feb. 24, 2012	Feb. 28, 2012	Jun. 19, 2012	Feb. 24, 2012	Jun. 19, 2012	Feb. 24, 2012	Jun. 19, 2012	Feb. 24, 2012	31-May-12	Jun. 19, 2012	Jun. 19, 2012	Mar. 21, 2013	Jun. 19, 2012	Mar. 31, 2013
					First United Bank Line of Credit	First United Bank Line of Credit	First United Bank Line of Credit	Plato and Associates Note	Plato and Associates Note	Plato and Associates Note	Promissory Notes	Promissory Notes	Promissory Note Individual - February 2012 Notes Issuance	Promissory Note Individual - February 2012 Notes Issuance	Promissory Note Entity - February 2012 Notes Issuance	Promissory Note Entity - February 2012 Notes Issuance	Promissory Notes - February 2012 Notes Issuance	Promissory Notes - February 2012 Notes Issuance	Promissory Notes - February 2012 Notes Issuance	Promissory Note Individual - June 2012 Notes Issuance	Promissory Note Entity - June 2012 Notes Issuance	Promissory Notes - June 2012 Notes Issuance	Promissory Notes - June 2012 Notes Issuance	Promissory Notes - June 2012 Notes Issuance
Debt Interest rate			6.00%				3.02%	6.00%				6.00%	6.00%		6.00%
Promissory notes, principal			$3,102,000					$10,000,000				$900,000		$1,358,014		$1,357,110				$2,347,128	$2,344,179
Proceeds from revolving credit note									200,000	200,000
Repayment of revolving credit note									401,085
Warrants Issued in conjunction with debt								1,250,000										9,000,000					7,000,000
Exercise Price per share of warrants issued								3.2										0.38
Proceeds from notes and loans payable		6,900,000	8,700,000	2,684,160		100,000	300,000
Collateral for line of credit						100,000	100,000
Repayment of line of credit					100,735
New Funding																		1,000,000	3,000,000				2,000,000
Notes surrendered											1,700,000		1,347,128		1,344,719		2,691,847
Accrued Interest forfeited																		15,124
Value of debt converted via warrant conversion			1,054,657	8,239,137													3,102,000
Number of shares issued in warrant conversion (as related to debt)			2,775,415	21,681,958													8,145,486
Repayment of notes payable	-4,691,847	-50,780	-1,850,000	-200,000																		4,882,019
Accrued Interest				$28,321																				$21,595

STOCKHOLDERS_EQUITY_Details_Na

STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	0 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended						4 Months Ended					0 Months Ended	12 Months Ended				12 Months Ended		12 Months Ended														9 Months Ended	27 Months Ended	3 Months Ended	12 Months Ended					12 Months Ended				0 Months Ended	12 Months Ended													0 Months Ended	12 Months Ended
	Mar. 07, 2013	Oct. 02, 2011	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Oct. 03, 2011	Jul. 29, 2011	Jul. 28, 2011	31-May-11	Jun. 30, 2013	Dec. 31, 2012	Jun. 30, 2013	Dec. 31, 2012	Feb. 27, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2011	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	Oct. 03, 2011	Dec. 31, 2010	Dec. 31, 2011	Dec. 31, 2012		Dec. 31, 2011		Dec. 31, 2010	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Oct. 05, 2011	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	Apr. 12, 2013	Dec. 31, 2012	Dec. 31, 2011
													VitaMed	2009 Long Term Incentive Compensation Plan	2009 Long Term Incentive Compensation Plan	2012 Stock Incentive Plan	2012 Stock Incentive Plan	Company Officer	Dr. Bernick, Director	Company Warrants	Company Warrants	Company Warrants	Company Warrants	Company Warrants	Company Warrants	Company Warrants	Company Warrants	Company Warrants	Company Warrants	Company Warrants	Company Warrants	Company Warrants	Company Warrants	Company Warrants	Warrants Issued in March 2012	Warrants Issued in May 2012	Warrants Issued in June 2012	VitaMed Warrants	VitaMed Stock Options	VitaMed Stock Options	Company Options	Company Options		Company Options		Company Options	Company Options	Company Options	Company Options	Company Options	Stock Purchase Agreement with Pernix Therapeutics	February 24 Debt Issuance	June 19 Debt Issuance	June 19 Debt Issuance	June 19 Debt Issuance	March 2011 Line of Credit	VitaMed Promissory Note June 2011	VitaMed Promissory Note June 2011	VitaMed Promissory Note June 2011	VitaMed Promissory Note June 2011	VitaMed Promissory Note June 2011	VitaMed Promissory Note June 2011	Company Warrants	Company Warrants	Underwriters	Lang	Lang
																							Services	Services	Services - VitaMed Contract	Services - VitaMed Contract	Services Provided in October 2011	Services Provided in December 2011	Lower Range	Lower Range	Lower Range	Upper Range	Upper Range	Upper Range	Services	Services	Services	Services - VitaMed Contract									Lower Range	Lower Range	Upper Range	Upper Range				Warrants Tranche 2	Warrants Tranche 1	Company Warrants			Company Warrants	VitaMed Warrants	VitaMed Warrants	VitaMed Warrants	Services	Services		Weighted Average Exercise Price	Weighted Average Exercise Price
																															Services			Services																											Lower Range	Upper Range	Company Officer	Company Officer		Services Provided in October 2011	Services Provided in October 2011
Common stock, shares outstanding			131,212,706		131,212,706		99,784,982	82,978,804	55,487,321	58,573,187	165,856	16,575,209
Shares issued for exercise of options					$6,251		$191,000												$17,250
Shares issued for exercise of options, shares					-61,372		1,931,788												92,057																							-1,931,788		-92,057
Noncash options exercised shares forfeited in lieu of cash							26,428
Noncash options exercised net options received							240,395
Shares issued in exercise of warrants							3,102,000	17,250																																												3,102,000
Shares issued in exercise of warrants, shares							8,145,486	92,057																																												8,145,486
Value of debt converted to shares							1,054,647	849,137																																																	1,054,647	1,054,647
Shares issued in exchange for debt, shares							2,775,415	21,681,958																																																	2,775,415	2,775,415
Conversion Price Per share							$0.38																																																		$0.38	$0.38
Shares issued in private placement							7,895,485	1,707,000	3,170,643																																										1,000,000
Shares issued in private placement, shares					29,411,765		3,953,489	5,551,589																																											2,631,579														1,954,587
Cash fees paid to private placement agent							552,500
Legal fees paid for investors in private placement							52,016
Price per share of common stock issued in private placement							$2.15
Aggregate purchase price of common stock sold in private placement							8,500,001						707,000
Stock Purchase Price			$1.70		$1.70																																														$0.38
Reverse split description		1 for 100
Warrants outstanding							12,193,499	3,057,627												12,193,499		14,293,499
Weighted average contractual life																				4 years 9 months 18 days	8 years 8 months 15 days	4 years 9 months 18 days
Exercise Price																				$1.63	$0.36	$1.79							$0.24			$3									$0.16	$1.16		$0.16			$2.20	$0.10	$3.40	$1.22
Unamortized costs warrants																				93,000	349,000	3,995,000
Warrants Issued																																																								613,713		613,718	613,718	500,000
Warrants Issued - Note Modification																																																				5,685,300	7,000,000	1,000,000	6,000,000
Warrants Issued - new Funding																																																				3,314,700				0.2444
Exercise Price per share of warrants issued																																																				0.38		3	2
Fair Value Modification Warrants Issued February 2012																																																				10,505,247
FV Warrants Issued - new Funding																																																				6,124,873
Valuation Method																				Black-Scholes	Black-Scholes														Black-Scholes Method	Black-Scholes Method	Black-Scholes Method															Black-Scholes Method	Black-Scholes Method
Expected term																				5 years	7 years 10 months 24 days		5 years				5 years	10 years		5 years	5 years		10 years	10 years	5 years	5 years	5 years	5 years									5 years	5 years 6 months	6 years 3 months	6 years 3 months		5 years	5 years			10 years				5 years				5 years			10 years
Expected Volatility																											41.04%	51.83%	44.64%	39.13%		44.81%	51.83%		44.81%	44.71%	44.78%	39.44%									40.77%	37.92%	46.01%	40.48%		44.50%	44.64%			47.89%					39.13%	39.15%		45.94%			45.94%
Risk-free interest rate																											1.08%	0.91%	0.72%	0.91%		1.04%	3.48%		1.04%	0.74%	0.72%	1.56%									0.61%	0.91%	2.23%	2.54%		0.89%	0.75%			3.48%					1.38%	1.65%		2.23%			2.23%
Expected dividend yield																				0.00%							0.00%	0.00%		0.00%					0.00%	0.00%	0.00%	0.00%				0.00%		0.00%								0.00%	0.00%			0.00%				0.00%				0.00%			0.00%
Debt discount on notes payable							1,102,680	0																																												859,647	1,102,680				28,719			30,993
Amortization of debt discount							1,604,240	28,719	0																																											859,647	547,210
Warrants Fair Value																				27,618,722	474,267		1,563,620	159,363			25,980	338								1,532,228		12,548															9,424,982			86,139								133,045
Fair value on grant date																																																					1,649,890
Warrants issued for consulting services																										245,485	184,211	500							31,000	1,300,000	1,500	200,000																										600,000			800,000
Awards issued for services, professional fees recognized																									6,936	5,612		15							29,736	218,045	1,656																										36,284	7,158		88,696	17,010
Prepaid Consulting Expense, Short Term																												323								360,528																														71,688	160,384
Prepaid Consulting Expense, Long Term			1,980,519		1,980,519		953,655	80,515	0																											953,655
Warrants vesting terms																																																								Awards vest 76,714 shares per calendar quarter end							vests over a 44-month period beginning on November 21, 2011 (or 13,36 shares for months 1-43 and 13,652 shares for month 44)	vests over a 44-month period beginning on November 21, 2011 (or 13,36 shares for months 1-43 and 13,652 shares for month 44)
Repayment of bank line of credit					-500,000		-300,000
Warrants vested																																																								562,571
Loan guaranty costs				-11,745	-2,944	-23,490	-45,036	-38,159
Warrant cost to be recognized																																																															89,603
Shares authorized under incentive plan											25,000,000			25,000,000	25,000,000	10,000,000	10,000,000
Shares issued under incentive plans														12,934,725	11,508,488	1,625,000	2,225,000																								10,590,161	13,733,488		10,590,161
Awards Granted																		300,000																					762,235	9,357,561	562,422	5,121,250	[1]	10,682,218	[1]
VitaMed options cancelled																																								16,000
VitaMed Options																																							621,000	7,639,722
Weighted average grant date fair value of options granted							$1.16	$0.16																																		$0.19		$0.09
Share based compensation expense					1,179,912	529,129	1,868,345	190,513	177,601																																	1,832,062		183,355
Allocatede share-based compensation expense							180,087	177,601
Unrecognized estimated compensation expense			3,695,420		3,695,420		4,391,000	244,000	206,000
Period for recognition of remaining unrecognized compensation expense					1 year 5 months 26 days		1 year 9 months 18 days	3 years 4 months
Price per share for private placement shares that may be purchased by underwriter			$1.58		$1.58
Net proceeds from private placement offering (not including shares purchased by underwriters)	50,000,000				45,400,000
Options to purchase shares granted to underwriter					4,411,765
Proceeds from sale of common stock, net					48,512,460		7,895,485	1,000,000																																																									3,100,000
Issuance of units for cash							$8,500,001						$707,000
Issuance of units for cash (units)													2,892,630
[1]	This includes: (i) VitaMed Options granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units of which 16,000 were canceled prior to conversion (or Company Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and October 3, 2011 for an aggregate of 621,000 Units (or Company Options for 762,235 shares per the Conversion Ratio) and (iii) Company Options granted between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options were reflected in the replacement Company Options including the number of shares vested.

STOCKHOLDERS_EQUITY_Details_Na1

STOCKHOLDERS' EQUITY (Details Narrative 1) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended			0 Months Ended		0 Months Ended			1 Months Ended	0 Months Ended		1 Months Ended			0 Months Ended				6 Months Ended	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Jan. 31, 2013	Jun. 30, 2013	Mar. 21, 2013	Jun. 19, 2012	Feb. 24, 2012	Mar. 31, 2012	Jun. 30, 2013	10-May-13	31-May-13	Jun. 30, 2013	Jun. 30, 2013	Jun. 19, 2012	Feb. 24, 2012	Jun. 19, 2012	Feb. 24, 2012	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
								Plato and Associates Note	Plato and Associates Note	Promissory Notes - June 2012 Notes Issuance	Promissory Notes - June 2012 Notes Issuance	Promissory Notes - February 2012 Notes Issuance	Company Warrants	Company Warrants	Company Warrants	Company Warrants	Company Warrants	Company Warrants	Warrants Tranche 1	Warrants Tranche 1	Warrants Tranche 2	Warrants Tranche 2	Company Warrants	Company Warrants	Company Warrants
														Sancilio & Company	Sancilio & Company	Sancilio & Company	Lower Range	Upper Range	Promissory Notes - June 2012 Notes Issuance	Promissory Notes - February 2012 Notes Issuance	Promissory Notes - June 2012 Notes Issuance	Promissory Notes - February 2012 Notes Issuance
Warrants:
Warrants outstanding					12,193,499	3,057,627																	14,293,499	12,193,499
Warrant Exercise Price																	0.24	3.2					1.79
Warrants Issued in conjunction with debt								1,250,000			7,000,000	9,000,000							6,000,000		1,000,000
Exercise Price per share of warrants issued								3.2				0.38							2	0.38	3	0.38
Warrants Fair Value								$1,711,956			$9,424,982			$462,196	$405,066					$10,505,247		$6,124,873		$27,618,722	$474,267
Expected term								6 years			5 years	5 years	5 years	5 years	5 years
Volatility rate								44.29%			44.64%	44.50%	44.81%	45.84%	45.89%
Risk-free rate								0.88%			0.75%	0.89%	1.04%	1.41%	1.12%
Dividend yield								0.00%			0.00%	0.00%	0.00%	0.00%	0.00%
Deferred Financing Costs									1,051,988
Financing costs	395,981		659,968								1,649,890
Amortization of debt discount					1,604,240	28,719	0			885,709		859,647
Warrants Issued - Note Modification																				5,685,300
Warrants Issued - new Funding																						3,314,700
Warrants forfeited																833,000								-51,142
Warrants granted													31,000			850,000							2,100,000	17,332,500	3,057,627
Warrants vested in period														283,333	283,333
Consulting expense recognized for warrants issued for services													29,736		405,066
Warrants recorded to prepaid expense - short term														154,068
Warrants recorded to prepaid expense - long term	1,980,519		1,980,519		953,655	80,515	0							308,128
Unvested warrants														283,334
Unamortized costs warrants																							$3,995,000	$93,000	$349,000

STOCKHOLDERS_EQUITY_Details_Na2

STOCKHOLDERS' EQUITY (Details Narrative 2) (USD $)

6 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

6 Months Ended

6 Months Ended

0 Months Ended

0 Months Ended

Jun. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Jul. 29, 2011

Dec. 31, 2010

2-May-13

2-May-13

2-May-13

Dec. 31, 2011

Feb. 27, 2012

10-May-13

Mar. 29, 2013

6-May-13

Mar. 29, 2013

Mar. 29, 2013

Mar. 29, 2013

Jun. 21, 2013

10-May-13

6-May-13

Mar. 29, 2013

Jun. 29, 2012

Jun. 30, 2013

Dec. 31, 2012

Jun. 30, 2013

Apr. 16, 2012

Jun. 21, 2013

Jun. 21, 2013

Jun. 21, 2013

Jun. 29, 2012

Jun. 29, 2012

Mar. 29, 2013

Mar. 29, 2013

Jun. 29, 2012

Jun. 29, 2012

Apr. 16, 2012

Apr. 16, 2012

Jun. 30, 2013

Dec. 31, 2012

Jun. 30, 2013

Dec. 31, 2012

Chairman of the Board

Committee Chairs

Dr. Bernick, Director

Dr. Bernick, Director

Dr. Bernick, Director

Vesting annually over a 4 year period on anniversary of issuance

Vesting annually over a 4 year period on anniversary of issuance

Vesting monthly over an 12 month period

Vesting monthly over an 12 month period

Vesting monthly over an 13 month period

Vesting monthly over an 7 month period

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

Stock Options

2009 Long Term Incentive Compensation Plan

2009 Long Term Incentive Compensation Plan

2012 Stock Incentive Plan

2012 Stock Incentive Plan

Robert Finizio, Chief Executive Officer

Dr. Bernick, Director

Vesting annually over a 3 year period on anniversary of issuance

Vesting monthly over an 18 month period

Vesting monthly over a 3 year period

Vesting annually over a 4 year period on anniversary of issuance

Vesting monthly over an 12 month period

Lower Range

Upper Range

Vesting annually over a 2 year period on anniversary of issuance

Vesting monthly fromDecember 31 2012

Committee Chairs

Dr. Bernick, Director

Stock Options:

Shares authorized under incentive plan

25,000,000

25,000,000

25,000,000

10,000,000

10,000,000

Shares issued under incentive plans

14,655,793

13,733,488

12,934,725

11,508,488

1,625,000

2,225,000

Shares issued for exercise of options, shares

61,372

-1,931,788

-92,057

61,372

Shares issued for exercise of options, value

$6,251

$191,000

$17,250

Options Granted

300,000

632,500

100,000

96,068

180,109

250,000

1,583,677

150,000

75,000

350,000

Weighted Average Exercise Price of options

$2.98

$2.71

$2.96

$2.80

$1.08

$1.16

$2.55

$1.70

$2.70

$2.55

$2.55

Term of options granted

10 years

10 years

10 years

10 years

10 years

10 years

9 years 10 months 24 days

10 years

10 years

10 years

Options vested in period

50,000

500

96,068

12,500

92,109

43,750

50,000

31,250

50,000

232,500

100,000

300,000

7,500

2,500

115,000

75,000

Stock Options Authorized to the Board of Directors and Key Executives

575,000

225,000

75,000

50,000

Options forfeited

-600,000

600,000

Unrecognized estimated stock compensation expense

$3,695,420

$4,391,000

$244,000

$206,000

Period for recognition of remaining unrecognized compensation expense

1 year 5 months 26 days

1 year 9 months 18 days

3 years 4 months

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (Company Warrants, USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Warrants Granted, number	2,100,000	17,332,500	3,057,627
Awards Granted, exercise price	$2.72	$1.26	$0.39
Awards Granted, term		5 years	7 years 10 months 24 days
Warrants Fair Value		$27,618,722	$474,267
Lower Range
Awards Granted, term			5 years
Upper Range
Awards Granted, term			10 years
Debt Modification
Warrants Granted, number		5,685,300
Awards Granted, exercise price		$0.38
Awards Granted, term		5 years
Warrants Fair Value		10,505,247
Issued with Debt
Warrants Granted, number		10,314,700
Awards Granted, term		5 years
Warrants Fair Value		15,549,855
Issued with Debt | Lower Range
Awards Granted, exercise price		$0.38
Issued with Debt | Upper Range
Awards Granted, exercise price		$3
Services
Warrants Granted, number		1,332,500	784,711
Awards Granted, term		5 years
Warrants Fair Value		1,563,620	159,363
Services | Lower Range
Awards Granted, exercise price		$2.40	$0.38
Awards Granted, term			5 years
Services | Upper Range
Awards Granted, exercise price		$2.80	$1.50
Awards Granted, term			10 years
Loan Guarantee
Warrants Granted, number			613,713
Awards Granted, exercise price			$0.24
Awards Granted, term			10 years
Warrants Fair Value			93,969
Loan Consideration
Warrants Granted, number			613,718
Awards Granted, exercise price			$0.41
Awards Granted, term			5 years
Warrants Fair Value			30,993
Product Consulting
Warrants Granted, number			1,045,485
Warrants Fair Value			$189,942
Product Consulting | Lower Range
Awards Granted, exercise price			$0.38
Awards Granted, term			5 years
Product Consulting | Upper Range
Awards Granted, exercise price			$0.41
Awards Granted, term			10 years

STOCKHOLDERS_EQUITY_Details_1

STOCKHOLDERS' EQUITY (Details 1) (Company Warrants, USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Valuation Method	Black-Scholes	Black-Scholes
Weighted average fair value	$2.05	$0.36
Expected term	5 years	7 years 10 months 24 days
Expected dividend yield	0.00%
Lower Range
Risk-free interest rate	0.72%	0.91%
Expected Volatility	44.64%	39.13%
Expected term		5 years
Expected dividend yield		0.00%
Upper Range
Risk-free interest rate	1.04%	3.48%
Expected Volatility	44.81%	51.83%
Expected term		10 years

STOCKHOLDERS_EQUITY_Details_2

STOCKHOLDERS' EQUITY (Details 2) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Weighted Average Remaining Contractual Life
Granted	10 years
Company Warrants
Number Warrants
Balance Beginning	12,193,499	3,057,627
Warrants Granted	2,100,000	17,332,500	3,057,627
Exercised		-8,145,486
Expired
Cancelled		-51,142
Balance ending	14,293,499	12,193,499	3,057,627
Vested and exercisable	12,149,559	11,784,408	2,254,758
Weighted Average Exercise Price
Balance Beginning	$1.63	$0.36
Warrants Granted	$2.72	$1.26	$0.39
Exercised		$0.38
Cancelled		$0.24
Exercise Price	$1.79	$1.63	$0.36
Vested and exercisable	$1.67	$1.69	$0.37
Weighted Average Remaining Contractual Life
Weighted average contractual life	4 years 9 months 18 days	8 years 8 months 15 days
Granted	7 years 8 months 12 days	5 years	8 years 8 months 15 days
Weighted average contractual life	4 years 9 months 18 days	4 years 9 months 18 days	8 years 8 months 15 days
Vested and exercisable	4 years 8 months 12 days	4 years 8 months 12 days	5 years 7 months 15 days
Aggregate Intrinsic Value
Warrants outstanding, beginning	$17,971,994	$3,483,691
Warrants granted	867,000	31,891,150	3,483,691
Warrants outstanding, ending	17,985,449	17,971,994	3,483,691
Vested and Exercisable	$16,540,175	$16,859,266	$2,361,339

STOCKHOLDERS_EQUITY_Details_3

STOCKHOLDERS' EQUITY (Details 3) (USD $)	3 Months Ended	6 Months Ended	12 Months Ended	0 Months Ended					6 Months Ended	3 Months Ended	12 Months Ended
	Mar. 24, 2012	Jun. 30, 2013	Dec. 31, 2012	Jun. 21, 2013	10-May-13	6-May-13	Mar. 29, 2013	Jun. 29, 2012	Jun. 30, 2013	Dec. 31, 2011	Dec. 31, 2012		Dec. 31, 2011
				Stock Options	Stock Options	Stock Options	Stock Options	Stock Options	Stock Options	Company Options	Company Options		Company Options
Balance Beginning									13,733,488		10,590,161
Awards Granted				632,500	100,000	96,068	180,109	250,000	1,583,677	562,422	5,121,250	[1]	10,682,218	[1]
Options Exercised		-61,372	1,931,788						-61,372		-1,931,788		-92,057
Expired	5,000
Cancelled									-600,000		-46,135
Balance ending									14,655,793	10,590,161	13,733,488		10,590,161
Vested and exercisable									9,623,443	6,581,049	8,370,408		6,581,049
Exercise Price									$1.16		$0.16
Granted									$2.79		$2.80		$0.16
Exercised											$0.13		$0.19
Cancelled
Exercise Price				$2.98	$2.71	$2.96		$2.80	$1.08	$0.16	$1.16		$0.16
Vested and exercisable									$0.60	$0.13	$0.38		$0.13
Weighted Average Remaining Contractual Life
Balance Beginning									7 years 8 months 12 days		7 years 7 months 6 days
Granted		10 years		10 years	10 years	10 years	10 years	10 years	9 years 10 months 24 days		9 years 8 months 12 days		7 years 7 months 6 days
Balance ending									7 years 9 months 18 days	7 years 7 months 6 days	7 years 8 months 12 days		7 years 7 months 6 days
Vested and exercisable									6 years 6 months		6 years 8 months 12 days		7 years 6 months
Balance Beginning									$26,804,117		$14,067,649
Granted									$365,845		$1,737,530		$14,188,484
Balance ending									26,038,328	14,067,649	26,804,117		14,067,649
Vested and exercisable									$23,208,051	$9,038,719	$22,811,422		$9,038,719
[1]	This includes: (i) VitaMed Options granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units of which 16,000 were canceled prior to conversion (or Company Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and October 3, 2011 for an aggregate of 621,000 Units (or Company Options for 762,235 shares per the Conversion Ratio) and (iii) Company Options granted between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options were reflected in the replacement Company Options including the number of shares vested.

STOCKHOLDERS_EQUITY_Details_4

STOCKHOLDERS' EQUITY (Details 4)	6 Months Ended			12 Months Ended
	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011
	Stock Options	Stock Options	Stock Options	Company Options	Company Options	Company Options	Company Options	Company Options	Company Options
		Lower Range	Upper Range			Lower Range	Lower Range	Upper Range	Upper Range
Risk-free interest rate		0.65%	1.42%			0.61%	0.91%	2.23%	2.54%
Expected Volatility		33.35%	45.76%			40.77%	37.92%	46.01%	40.48%
Expected term		5 years	6 years 3 months			5 years	5 years 6 months	6 years 3 months	6 years 3 months
Expected dividend yield	0.00%			0.00%	0.00%

INCOME_TAXES_Details_Narrative

INCOME TAXES (Details Narrative) (USD $)	Dec. 31, 2012	Dec. 31, 2011
Income Taxes Details Narrative
Federal net operating loss carryforwards	$14,900,000	$2,100,000
State Net Operating Loss Carryforwards	$12,800,000	$25,000

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	Dec. 31, 2012	Dec. 31, 2011
Deferred Income Tax Assets:
Net operating losses	$5,920,861	$748,404
Valuation allowance	-5,920,861	-748,404
Deferred Income Tax Assets, net

INCOME_TAXES_Details_1

INCOME TAXES (Details 1) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Income Taxes Details 1
Federal statutory tax rate					35.00%	35.00%
State tax rate, net of federal tax benefit					5.50%	0.00%
Adjustment in valuation allowances					-18.20%	-5.80%
Permanent and other differences					-22.30%	-29.20%
Provision (Benefit) for Income Taxes					0.00%	0.00%
Expected income tax benefit at statutory rate						($4,519,678)
Non-deductible expenses:
Debt settlement						2,586,500
VitaMed pre-merger loss						1,164,629
Other non-deductible expenses						22,912
Change in valuation account						745,637
Income tax expense (benefit)

RELATED_PARTIES_Details_Narrat

RELATED PARTIES (Details Narrative) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended			6 Months Ended				12 Months Ended						0 Months Ended	1 Months Ended
	Oct. 02, 2011	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012	Nov. 13, 2012	Feb. 28, 2013	Mar. 31, 2011	Jun. 30, 2013
									Dr. Bernick, Director	Dr. Bernick, Director	Pernix Therapeutics	Pernix Therapeutics	Pernix Therapeutics	Pernix Therapeutics	Dr. Bernick, Director	Dr. Bernick, Director	Dr. Bernick, Director	Board of Directors Chairman	First United Bank Line of Credit	First United Bank Line of Credit	First United Bank Line of Credit	First United Bank Line of Credit
Proceeds from notes and loans payable					$6,900,000	$8,700,000	$2,684,160													$100,000	$300,000
Collateral for line of credit																				100,000	100,000
Debt Interest rate						6.00%															3.02%
First United line of credit, Personal Guarantees Warrants Issued						613,713															613,713
Warrants amended, warrants vested prior to the amendment																			358,000
Warrants vested																						562,571
Shares exchanged, on a pro rata basis with VitaMed	70,000,000
Revenues									0	1,440					2,632	20,669	25,269
Related Party Receivable									0						1,272	0	79
Purchases		463,606	372,370	843,952	708,494	1,348,113	947,112	556,390			0	96,250	404,000	19,000
Related Party Accounts Payable											0		308,000	19,000
Legal Fee reimbursement due from related parties											$171,261				$0
Warrants Assigned																		100,000

BUSINESS_CONCENTRATIONS_Detail

BUSINESS CONCENTRATIONS (Details Narrative)	6 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Supplier Concentration Risk
Concentration Risk	98.00%	87.00%	76.00%	95.00%	93.00%
Customer Revenue Concentration Risk
Concentration Risk	62.00%	36.00%	28.00%
Customer Deferred Revenue Concentration Risk
Concentration Risk			98.00%

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended			1 Months Ended	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2011	Dec. 31, 2012
								Research and Development Arrangement	Research and Development Arrangement
Non-cancelable operating lease term	63		63		45
Monthly Base rent of leases				$28,442	$5,443	$5,443	$5,443
Share of monthly operating expenses					3,500	3,500	3,500
Rental Expense			56,918	60,168	122,752	106,315	116,175
Future minimum lease payments	1,791,900		1,791,900		29,667	168,326
Compensation agreement for Robert Finzio					Compensation for services rendered by Robert G. Finizio as Chief Executive Officer calls for: (i) a time-based ten-year stock option (the"Time-Based Option") granted and issued on November 30, 2012 ("Date of Grant") to purchase 900,000 shares of our Common Stock with the exercise price equal to the closing price of our Common Stock on the Date of Grant with the underlying shares vesting annually over three years on the anniversary of the employment date, (ii) the right to receive a performance-based ten-year stock option (the"Performance-Based Option") in an amount to be determined, (iii) a base salary of not less than $355,100 per year and (iv) an annual short-term incentive compensation bonus of up to 35% of the base salary, at the discretion of our Board of Directors.
Compensation agreement for John CK Milligan, IV					Compensation for services rendered by John C.K. Milligan, IV as President calls for: (i) a Time-Based Option granted and issued on the Date of Grant to purchase 800,000 shares of our Common Stock with the exercise price equal to the closing price of our Common Stock on the Date of Grant with the underlying shares vesting annually over three years on the anniversary of the employment date, (ii) the right to receive a Performance-Based Option in an amount to be determined, (iii) a base salary of not less than $288,100 per year and (iv) an annual short-term incentive compensation bonus of up to 30% of the base salary, at the discretion of our Board of Directors.
Compensation agreement for Daniel A. Cartwright					Compensation for services rendered by Daniel A. Cartwright as Chief Financial Officer calls for: (i) a Time-Based Option granted and issued on the Date of Grant to purchase 700,000 shares of our Common Stock with the exercise price equal to the closing price of our Common Stock on the Date of Grant with the underlying shares vesting annually over three years on the anniversary of the employment date, (ii) the right to receive a Performance-Based Option in an amount to be determined, (iii) a base salary of not less than $257,100 per year and (iv) an annual short-term incentive compensation bonus of up to 30% of the base salary, at the discretion of our Board of Directors.
Research and development fees paid to non-affiliates	1,747,084	833,342	3,312,285	1,245,303	4,492,362	107,241	65,402	245,000
Research and development commitment to non-affiliates									$950,000

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments And Contingencies Details
31-Dec-12			$111,725
31-Dec-13			56,601
31-Dec-14			0
31-Dec-15			0
Thereafter			0
Total	$1,791,900	$29,667	$168,326

SUBSEQUENT_EVENTS_Details_Narr

SUBSEQUENT EVENTS (Details Narrative) (USD $)	0 Months Ended	3 Months Ended	6 Months Ended		12 Months Ended		0 Months Ended
	Mar. 07, 2013	Mar. 24, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Feb. 27, 2012	Jan. 31, 2013
							Company Officer	Plato and Associates Note
Promissory notes, principal					$3,102,000			$10,000,000
Debt Interest rate					6.00%			6.00%
Warrants Issued								1,250,000
Exercise Price per share of warrants issued								3.2
Warrants Fair Value								1,700,000
Expected term								6 years
Expected Volatility								44.29%
Risk-free interest rate								0.88%
Expected dividend yield								0.00%
Proceeds from notes and loans payable				6,900,000	8,700,000	2,684,160		200,000
Gross expected proceeds from underwritten public offering of common stock	$50,000,000		$45,400,000
Options Granted							300,000
Term of options granted							10 years
Exercise price of options							$2.20
Options cancelled		5,000

RESTATEMENT_OF_2010_AUDITED_FI2

RESTATEMENT OF 2010 AUDITED FINANCIALS (Details Narrative) (USD $)	12 Months Ended	20 Months Ended	32 Months Ended
	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2010
Options issued as compensation	$177,601
VitaMed
Options issued as compensation		105,929	283,530
VitaMed | As Reported
Options issued as compensation	363,750	196,197	559,917
VitaMed | Restatement Adjustment
Options issued as compensation	$186,149	$90,238	$276,387

RESTATEMENT_OF_2010_AUDITED_FI3

RESTATEMENT OF 2010 AUDITED FINANCIALS (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Additional paid in capital							$261,174
Accumulated deficit	-64,498,612		-64,498,612		-52,113,313	-16,993,078	-4,079,713
Sales, general, and administration	5,476,553	3,573,485	10,003,135	6,400,535	14,069,701	6,406,197	3,464,810
Total operating expense	7,234,273	4,421,362	13,334,013	7,674,951	18,618,323	6,568,283	3,552,995
Operating loss	-5,616,994	-3,974,582	-10,559,885	-6,842,603	-16,148,423	-5,427,218	-2,867,464
Net loss	-6,009,646	-11,850,038	-12,385,299	-25,139,641	-35,120,235	-12,913,365	-2,867,464
As Reported
Additional paid in capital							537,561
Accumulated deficit							-4,356,100
Sales, general, and administration							3,650,959
Total operating expense							3,739,144
Operating loss							-3,053,613
Net loss							($3,053,613)